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“A crystal is like a class of children arranged for drill, but standing at ease, so that while the class as a 
whole has regularity both in time and space, each individual child is a little fidgety!” 
~ Dame Kathleen Lonsdale in Crystals and X-Rays (1948). 22 
 
All the work of the crystallographers serves only to demonstrate that there is only variety everywhere 
where they suppose uniformity ... that in nature there is nothing absolute, nothing perfectly regular. 
~ Comte Georges-Louis Leclerc de Buffon in Histoire Naturelle des Minéraux (1786). 3, 433 
 
 “One can ask: “If I crystallize a virus to obtain a crystal consisting of the molecules that make up the 
virus, are those molecules lifeless or not?” … The properties of living organisms are those of aggregates 
of molecules. It’s very difficult to draw a line between molecules that are lifeless and molecules that are 
not lifeless.”                                                                                                                                          .   
~ Linus Pauling in BioScience (1986). 36, 738. 
 
 “I shall never forget the sight. The vessel of crystallization was three quarters full of slightly muddy 
water—that is, dilute water-glass—and from the sandy bottom there strove upwards a grotesque little 
landscape of variously colored growths: a confused vegetation of blue, green, and brown shoots which 
reminded one of algae, mushrooms, attached polyps, also moss, then mussels, fruit pods, little trees or 
twigs from trees, here, and there of limbs. It was the most remarkable sight I ever saw, and remarkable 
not so much for its profoundly melancholy nature. For when Father Leverkühn asked us what we thought 
of it and we timidly answered him that they might be plants: “No,” he replied, “they are not, they only act 
that way. But do not think the less of them. Precisely because they do, because they try as hard as they 
can, they are worthy of all respect.” It turned out that these growths were entirely unorganic in their 
origin; they existed by virtue of chemicals from the apothecary's shop.” 
~ Thomas Mann in “Doktor Faustus” (1948). 19 
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ABSTRACT 
Isoniazid is the primary drug used for the treatment of tuberculosis. Covalent modifications to 
the amine group of isoniazid are currently under investigation and such modifications have been 
shown to render the drug effective against multiple-drug-resistant strains of Mycobacterium 
tuberculosis. 
In this thesis, crystal and co-crystal engineering was applied to synthesize crystals and co-
crystals of covalently modified isoniazid. Isoniazid was modified by bulky modifiers, namely 
benzophenone and benzophenone derivatives, and crystallized in the absence and presence of co-
formers. A series of co-crystals of modified isoniazid was prepared and their supramolecular 
structures were studied. All co-crystals were synthesized with salicylic acid and control over the 
dimensionality of packing was achieved. It was found that the benzophenone modifiers sterically 
masked the amide functional groups from participating in any intermolecular interactions. This 
steric masking is predictable and consistent and provides a general method whereby an amide 
functional group can be sterically blocked from intermolecular interactions. 
The effects of reaction and crystallization conditions on the supramolecular structure of isoniazid 
are also reported. Several pairs of co-crystals of modified isoniazid were synthesized under 
different crystallization conditions. Change in reflux time of the reagents resulted in 
stoichiometric variation in the resulting co-crystals. The addition of excess reagents as an 
additive resulted in polymorphism. Addition or absence of an acid catalyst either promoted or 
prevented solvate formation. The addition of either one or two methyl groups to the 
benzophenone aromatic rings did not substantially alter the packing patterns of the crystal 
structures.  
As the presence of co-formers may either enhance or inhibit the bioavailability of pharmaceutical 
drugs, the covalent modification of isoniazid was repeated in the absence of co-formers. The 
covalent modification without co-formers presented several synthetic difficulties and use of new 
catalysts and the development of new synthetic strategies such as refluxing in high-pressure glass 
vials were developed. A full structural study on the covalently modified isoniazid crystals is 
reported. 
v 
 
Side reactions of benzophenone were observed during the crystallization of isoniazid derivatives. 
These resulted in the formation of benzophenone azine crystals. The origin and mechanism of 
the formation of these benzophenone azine crystals were determined to occur via a two-step 
photodimerization process. The benzophenone azine crystals were found to be held together 
through weak interactions and a structural study of the packing of these crystals was reported. 
4-Aminoantipyrine is a pharmaceutical drug previously used as an antipyretic and is considered a 
prophylactic against oxidative stress. Two of its derivatives, aminoantipyrine and 4-(N,N-
dimethyl)-aminoantipyrine, have been used as analgesic and anti-inflammatory drugs since the 
late 19
th
 century. Their concurrent use with aspirin is particularly beneficial as they have been 
shown to prevent or attenuate the anti-platelet effects of aspirin. However, their use has been 
discontinued due to side effects and this discontinuation warrants further studies of methods to 
possibly increase the bioavailability and alter the physical properties of the drug, including via 
covalent modification and co-crystallization. To date, all reported attempts at co-crystallizing 
this drug have failed. 
In this study, co-crystal design strategies were developed to synthesize the first co-crystal of 4-
aminoantipyrine, and the methods leading up to the successful supramolecular synthesis of 4-
aminoantipyrine with co-formers are detailed. The synthesis of two novel salts of 4-
aminoantipyrine and two co-crystals of covalently modified 4-aminoantipyrine are also reported. 
A series of crystals of covalently modified 4-aminoantipyrine were also synthesized and a full 
structural study of these crystals is presented.  
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STRUCTURE AND OUTPUTS OF THE THESIS 
 
There are two styles of writing in this thesis. The introductory chapter (Chapter 1), the literature 
review (Chapter 2), the experimental methods (Chapter 3) and the conclusion (Chapter 9) are 
written in a uniform style.  
The central chapters consist of six publications that have either been published, submitted, or 
prepared for submission in well known accredited peer-reviewed crystallographic journals. In 
two of the papers, the reviewers’ comments are being attended to at request of the editor before 
final resubmission to the journal. These central chapters represent the author’s contribution to 
knowledge in the field of research and form the heart of the thesis. The advantage of presenting 
the six publications as chapters is that the most important findings, descriptions and conclusions 
from a large amount of work done during this PhD have been concisely presented. Each chapter 
is presented in the format required for submission by Crystal Growth and Design (the primary 
journal to which the papers have been submitted) and may vary from the format found in the 
introductory chapters. 
Each publication presented in this thesis is preceded by a summary in which the journal name, 
publication status and a synopsis of the work is described. 
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Chapter 1:  Introduction and Aims 
 
1.1 Overview 
 
Crystal and co-crystal structures cannot be easily predicted from molecular structures. Small 
changes in crystallization conditions can have unpredictable results on the supramolecular 
packing and structure of a crystal or co-crystal. The field of crystal and co-crystal engineering 
has arisen in an attempt to understand the processes of supramolecular synthesis and to develop 
design strategies to elucidate predictable and exploitable mechanisms for crystallization and co-
crystallization processes. These processes are particularly important to the pharmaceutical 
industry, as supramolecular structures such as salts and co-crystals often improve the 
bioavailability of active pharmaceutical ingredients (APIs). The work presented in this thesis is a 
contribution to the development of co-crystal design strategies and to the understanding of co-
crystal and crystal structures of isoniazid, 4-aminoantipyrine, benzophenone and their 
derivatives. 
 
  
2 
 
1.2 Co-crystals, salts and solvates 
 
For many years, the definition of a co-crystal has been debated and until recently, there has been 
no clear consensus. In 1985, Kitaigorodskii broadly defined a co-crystal as “a mixed crystal that 
contains two different molecules” (Kitaigorodskii, 1984). Desiraju expressed concern that the 
term “co-crystal” (also written as “cocrystal”) was being used too loosely and stressed the need 
for consensus on several crystallographic terms for which the meaning is ambiguous. Although 
he supported the use of the term “co-crystal” which had gained much popularity by 2003, he 
warned that terms which are “scientifically suspect” such as “pseudopolymorph” should be 
properly debated and discarded if necessary (Desiraju, 2003).  
Aakeröy later expanded the definition of co-crystals to include only reactants that are solids at 
room temperature, but excluded hydrates, solvates and clathrates (Aakeröy and Salmon, 2005). 
In contrast, Zawarotko et al. proposed a broader definition in the context of pharmaceutical co-
crystals and defined pharmaceutical co-crystals as “co-crystals that are formed between a 
molecular or ionic API and a co-former that is solid under ambient conditions” (Almarsson and 
Zaworotko, 2004). This definition clearly includes several classes of supramolecular solids, 
including salts, hydrates, solvates and clathrates, and lessens the ambiguity of the definition. 
More recently, Aitipamula et al. proposed a definition for co-crystals of APIs and defined co-
crystals as “solids that are crystalline single phase materials composed of two or more different 
molecular and/or ionic compounds generally in a stoichiometric ratio which are neither solvates 
nor simple salts” (Aitipamula et al., 2012). In their comprehensive discussion on 
crystallographic nomenclature, they also provided clear definitions for classifications of several 
other solid forms of APIs such as polymorphs and salts. Polymorphs were defined as different 
crystalline forms of the same substance, including hydrates and solvates. Salts were defined as  
“Any of numerous compounds that result from replacement or part or all of the acid hydrogen of 
an acid by a metal or a radical acting like a metal; an ionic or electrovalent crystalline solid.” 
Aitipamula concluded that co-crystals should be broadly defined and should be grouped with 
salts, but conceded that separating salts and co-crystals into several “classes” required further 
thought and debate. A schematic diagram showing the several solid forms proposed by 
Aitipamula is shown in Figure 1.1.  
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Figure 1.1:  Solid forms of APIs. An adaption of a schematic diagram proposed by Aitipamula 
et al. showing the several solid forms of active pharmaceutical ingredients (APIs). Diagram 
adapted from Cryst. Growth Des. (2012). 12, 2147−2152 
 
Recently, in 2016, inspired by Aitipamula’s comments on the need for the development of 
“classes” of supramolecular solids, Grothe et al. proposed a classification system for 
multicomponent crystals comprised of three classes, namely co-crystals, salts and solvates, 
having seven sub-classes (Grothe et al., 2016). According to Grothe: 
1)  A co-crystal contains only co-formers 
2)  A co-crystal solvate contains two or more co-formers and one or more solvents, but no 
ions. This would include hydrates, with water as a solvent. 
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3) A co-crystal salt has one or more co-formers, two or more ions, but no solvent 
molecules. 
4) A co-crystal salt solvate has one or more solvents, two or more ions, and one or more 
conformers. 
5) A salt contains only ions. 
6) A salt solvate contains ions, solvent molecules, but no co-formers. 
7)  A solvate contains exactly one co-former, with one or more solvent molecules, but no 
ions. 
 
A schematic diagram published by Grothe that allows for the easy visualization of his 
classification system is shown in Figure 1.2. 
 
Figure 1.2: The classification system published by Grothe et al. showing the three classes of 
solids (co-crystals, salts and solvates), and their seven subclasses. Diagram taken directly from 
Cryst. Growth Des. (2016). 16, 3237−3243. 
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While the differences between the sub-classes may often seem trivial, Vishweshwar points out  
that the differences between salts, co-crystals, solvates and hydrates can have a profound effect 
on the stability, physical properties and bioavailability of the APIs, and these distinctions are 
therefore critical to the pharmaceutical industry (Vishweshwar et al., 2006). 
 
1.3 Knowledge-based co-crystal design and synthon theory 
 
Wood et al. summarized the advancement of knowledge-based approaches to supramolecular 
synthesis in his paper “Knowledge-based approaches to co-crystal design” (Wood et al., 2014). 
He described the development of synthon theory from the studies of Margeret Etter to the use of 
modern search engines in the form of the Cambridge Structural Database (CSD) and Conquest 
(Groom and Allen, 2014). 
Etter proposed three general rules that applied to hydrogen bonding. First, she hypothesized that 
all “good” proton donors and acceptors are used in hydrogen bonding. Secondly, that six-
membered intramolecular hydrogen bonded rings are favoured over intermolecular interactions. 
And finally, she hypothesized that once all intramolecular hydrogen bonds had formed, then the 
remaining donors and acceptors would form intermolecular hydrogen bonds (Etter, 1990). She 
also described a hierarchy where particular donors, such as carboxylic acids and amides, are 
favoured with acceptors such as acid and amide carbonyl groups and sulfoxides. She noted that, 
in general, the “best donors” are usually paired with the “best acceptors”. An example of a 
modified isoniazid co-crystal where Etter’s rules are applied is shown in Figure 1.3.  
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Figure 1.3: Hydrogen bonding in a modified isoniazid co-crystal. The three hydrogen bond 
acceptors, O2, O3 and O5, are involved in intramolecular bonding to form six membered rings 
rather than forming intermolecular bonds.  The remaining acceptor, N2, is then involved in 
intermolecular bonding. O1 would generally form hydrogen bonds, but here it is sterically 
blocked from intermolecular interactions, as discussed in Chapter 4.2. 
 
The term “supramolecular synthon” was first coined by Desiraju who described supramolecular 
synthons as structural units within supramolecular structures that can be assembled by known or 
conceivable intermolecular interactions and that such synthons should be robust enough to apply 
to different hydrogen bonding networks (Desiraju, 1995). Supramolecular synthons may involve 
two identical functional groups (homosynthons) or different functional groups (heterosynthons). 
Zawarotko and Aakeröy later developed a usable “knowledge-based” workflow describing how 
synthon theory can be utilized in co-crystal design strategies (Almarsson and Zaworotko, 2004; 
Aakeröy and Salmon, 2005; Aakeröy et al., 2001, Aakeröy, 1997; Vishweshwar et al., 2005; 
Cheney et al., 2011). The flowchart, published by Wood, is shown in Figure 1.4 (Wood et al., 
2014). 
A search for robust synthons is possible on the CSD, where hydrogen bonding of various 
functional groups can be analyzed and the statistical data for known synthons can be determined. 
For example, analysis of CSD data shows that the probability of hydrogen bond formation 
between a carboxylic acid and a pyridyl ring is 91% (Nangia, 2009). Aakeröy et al. reported a 
study which included a search of co-crystals containing the acetaminopyridine and carboxylic 
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acid functional groups, and in all 28 of the compounds, the crystals were constructed via the 
carboxylic acid – pyridine heterosynthon. He also reported that in amide-based moieties faced 
with several C═O or ―OH hydrogen bond acceptors, after the formation of the robust acid – 
pyridine synthon, the remaining N―H donor shows a preference for the amide C═O over the 
acid C═O (Aakeröy et al., 2007).  This information is extremely useful in choosing a suitable co-
former for the assembly of a co-crystal.  
 
 
Figure 1.4: The flowchart for knowledge-based supramolecular assembly. Diagram taken 
directly from CrystEngComm. (2014). 16, 5839-5848. 
 
1.4 Pharmaceutical co-crystals 
 
Co-crystals have become of great importance to the pharmaceutical industry in the last five 
years, and co-crystal engineering is rapidly becoming one of the most active fields of research 
within the industry. It is well known in the pharmaceutical industry that changing the structure 
and composition of an active pharmaceutical ingredient has a significant influence on the 
physical properties, and therefore, the bioavailability of the drug (Aakeröy and Beatty, 2001).  
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Poor solubility of APIs is a primary challenge facing the pharmaceutical industry (Qiao et al., 
2011). Low solubility generally results in poor bioavailability, which may cause dosage 
complications, unforeseen pharmacological effects and the administration of higher doses of the 
affected drugs, with increased side effects. Sanphui and Nangia reported that over two thirds of 
all recently discovered drugs that are in the development phase experience solubility problems. 
They also remarked that salts and co-crystals present an immediate solution to the solubility 
problem due to their high solubility, stability and ease of synthesis (Sanphui and Nangia, 2014). 
As with salts, co-crystals often have higher stability and solubility than their pure pharmaceutical 
ingredients. With regards to isoniazid, Sarcevica et al. observed that the solubility of isoniazid 
that has been co-crystallized with a dicarboxylic acid approximates the solubility of the 
dicarboxylic acid, although they conceded that the thermodynamic stability and crystal structure 
of the co-crystal also play a role in the solubility of co-crystals (Sarcevica et al., 2013). 
Sarcevica’s research group has done considerable research into co-crystals of isoniazid, and have 
recognised that co-formers of isoniazid, for example trans-cinnamic acid, act synergistically with 
isoniazid and that co-crystallization with such co-formers may enhance multidrug resistant 
treatment (Sarcevica et al., 2013). 
Shan and Zawarotko have presented several case studies that clearly demonstrate how the 
solubility, stability and bioavailability of API crystal forms can be enhanced through crystal 
engineering (Shan and Zaworotko, 2008). In addition to the improvement in bioavailability, co-
crystals can be used to deliver pharmaceutical drugs that are not acidic or basic enough to form a 
salt, as well as other applications such as the isolation and purification of APIs, where 
homochiral co-crystallization can be used to separate enantiomers (Palovics et al., 2012). 
However, crystal and co-crystal structures cannot be easily predicted from molecular structures. 
Very little is yet known about how or when co-crystals will form, and the synthesis of specific 
desired co-crystals of APIs is difficult (Lemmerer et al., 2011). Crystal structures are not related 
to molecular structures in simple ways. The way in which a molecule crystallizes depends on the 
nature and position of every functional group in the molecule or molecules (Desiraju, 2013). 
Without the systematic and modular study of functional groups, crystal and co-crystal structures 
must be determined empirically. For example, paracetamol, when crystallized from acetone will 
always form a stable monoclinic crystal structure. When crystallized from methanol, the crystals 
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will have a metastable orthorhombic layer structure (Boldyreva, 2003). The two polymorphs of 
paracetamol are shown in Figure 1.5.  
Some recent work has been conducted using computational methods. These methods are based 
on searching for the most thermodynamically stable crystal structure. Although these methods do 
provide predictions of crystal structures, many structures may be very close in energy, providing 
unreliable predictions. Furthermore, there may be no routes to nucleating and growing such 
structures. (Price, 2014) 
In summary, no tried and tested method exists to ensure successful synthesis of co-crystals. As 
mentioned in Section 1.3, synthon theory has been recently developed in an attempt to predict 
the statistical probability of hydrogen bonding, but there is a dire shortage of data regarding 
intermolecular forces and hydrogen bonds between different functional groups, and synthon 
theory is certainly far from well developed. 
 
Figure 1.5: Two polymorphs of paracetamol. Diagram taken directly from J. Mol. Struct. (2003). 
647, 159–179. 
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1.5 Covalent Assisted Supramolecular Synthesis  
 
1.5.1 Covalent assisted supramolecular synthesis and “masking” of functional groups 
 
Covalent assisted supramolecular synthesis can be defined as the covalent modification of one 
part of a molecule with the purpose of gaining control over some aspect of the supramolecular 
synthesis of another part of the molecule, for example, the altering of the hydrogen bonding 
characteristics of a functional group, together with the co-crystallization of the modified 
molecule with a co-former (Lemmerer et al., 2011). 
To illustrate, consider the isoniazid molecule shown in Figure 1.6. Isoniazid typically has five 
potential hydrogen bonding sites, shown by the dotted lines. The amide group, shown as B in the 
diagram, is frequently involved in intermolecular interactions. To block these intermolecular 
interactions, the two hydrogen atoms shown as A could be replaced by two more bulky ligands, 
for example, methyl groups or aromatic rings. This covalent modification sterically blocks any 
adjacent molecule from approaching B. The amide functional group, B, is then said to be 
sterically “masked” from any intermolecular interactions (Lemmerer et al., 2011). This co-
crystal engineering technique of sterically modifying one part of a molecule to control the 
supramolecular assembly of another part of the molecule is referred to as “covalent assisted 
supramolecular synthesis”. 
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Figure 1.6: A molecule of isoniazid. Covalently modifying the terminal nitrogen atom, A, by 
replacing the two hydrogen atoms with more bulky groups has an effect on the intermolecular 
interactions of the amide group, B. 
 
1.5.2 Benzophenone and its derivatives as covalent modifiers 
 
While the covalent modification of isoniazid has been studied, there is no detailed or systematic 
study of the effect of bulky groups in particular on the supramolecular synthesis of isoniazid. 
The need for such data prompted an in-depth study of bulky groups and their effects in the 
covalent assistance of isoniazid, and a series of benzophenone and its derivatives were chosen 
for this study.  Benzophenone and its derivatives are not pharmaceutically active, but were 
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chosen primarily for their steric effects when modifying isoniazid. Benzophenone and its 
derivatives are “Generally Regarded as Safe (GRAS)” substances and are thus suitable for use in 
API studies in this respect (Burdock et al., 1991; Elder, 1983) . 
While experimenting on the covalent modification of isoniazid, a variety of crystals were often 
found to be formed simultaneously during crystallization. In addition to the desired modified 
isoniazid moiety, crystals were also harvested that were found to be benzophenone azines 
(Figure 1.7). This prompted further investigation into the behaviour of the benzophenone 
derivatives, and this study was thus extended to investigate the formation of crystals of side-
products of benzophenone and its derivatives produced during the covalent modification of 
isoniazid, in order to obtain a comprehensive and complete knowledge of all processes involved 
during the covalent assisted supramolecular synthesis of isoniazid with these bulky groups. The 
eight benzophenone derivatives that were used in this study are shown in Table 1.1. 
 
O
   
N
N
 
   (a)       (b) 
Figure 1.7: (a) Benzophenone and (b) benzophenone azine. 
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Table 1.1: The eight benzophenone derivatives used in this study. 
 
O
 
Benzophenone 
 
O
 
4-Methylbenzophenone 
 
O
 
4,4’-Dimethylbenzophenone 
 
O
OH 
4-Hydroxybenzophenone 
 
OOH OH
 
2,2’-Dihydroxybenzophenone 
 
O
NH2 
4-Aminobenzophenone 
 
O
NH2H2N  
4,4’-Diaminobenzophenone 
 
O
N
 
4-(Dimethylamino)benzophenone 
 
 
 
 
 
 
14 
 
1.6 Isoniazid and its derivatives 
 
Isoniazid (isonicotinic acid hydrazide) is the front-line chemotherapeutic drug used in the 
treatment of tuberculosis in South Africa. However, Mycobacterium tuberculosis is becoming 
increasingly resistant to isoniazid, and it has become urgent that drugs which are effective 
against resistant strains of the bacteria are developed. It has been reported that the covalent 
modification of isoniazid is an effective way to enhance the efficacy of the drug against these 
resistant strains (Suarez et al., 2009; Hearn et al., 2009). Isoniazid is a pro-drug, and must be 
activated by the bacterial catalase-peroxidase enzyme called KatG in Mycobacterium 
tuberculosis. KatG attaches to the isonicotinic acyl group with the reduced form of nicotinic 
adenine dinucleotide (NADH) to form an active complex. However, N-arylaminoacetyl 
transferases (a different class of enzyme), rapidly acetylate the amino position of isoniazid, 
preventing the reaction with NADH. This decreases the efficacy of isoniazid, resulting in drug 
resistance (Suarez et al., 2009; Hearn et al., 2009). 
However, if the isoniazid is reacted with an aldehyde or ketone group, the NH2 functional group 
is replaced with an imine group (Figure 1.8), and the modified isoniazid becomes structurally 
blocked from the effects of the N-arylaminoacetyl transferases, resulting in a drug which may be 
effective against drug-resistant tuberculosis strains (Suarez et al., 2009; Hearn et al., 2009). 
 
N
H
NO
NH2
N
H
NO
N
R2
R1
 
   (a)        (b) 
Figure 1.8: (a) The structure of isoniazid and (b) covalently modified isoniazid.  
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In addition to such covalent modification, the bioavailability of the modified isoniazid may be 
further enhanced by co-crystallizing it with a co-former, as discussed in Section 1.4. From a 
crystal engineering point of view, the pyridine ring of isoniazid is an excellent hydrogen bond 
acceptor to the carboxylic acid group, as well as to other functional groups. The hydrazide group 
of isoniazid also has potential to hydrogen bond through its oxygen and nitrogen atoms, and has 
three hydrogen atoms which can act as donors. Thus, from a synthon perspective, isoniazid is an 
ideal choice for studies of co-crystal formation and crystal engineering (Mashhadi et al., 2014). 
In 2010, Grobelny et al. stated that “Without any doubt there is a need for novel therapeutic 
agents and/or combinations based on drug substances already available for the treatment of 
TB.” (Grobelny et al., 2011). 
The covalent modification of isoniazid with a ketone or aldehyde occurs via an acid-catalyzed 
condensation reaction. The reaction starts with a nucleophilic attack on the carbonyl group by the 
amine nitrogen to form an unstable carbinolamine moiety, followed by acid catalyzed 
dehydration to form an imine (Xavier and Srividhya, 2014). This resulting imine will be referred 
to throughout this thesis as “modified isoniazid”. The mechanism of covalent modification is 
shown in Figure 1.9. 
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Figure 1.9: The mechanism for the acid catalyzed covalent modification of isoniazid to form an 
imine (modified isoniazid).  
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1.7 4-Aminoantipyrine and its derivatives 
 
4-Aminoantipyrine (4AAP) is an API with powerful antipyretic (fever reducing) properties 
(Acheson, 1960), and is considered a prophylactic against oxidative stress (Teng et al., 2011a). 
Two of its derivatives, aminoantipyrine and 4-(N,N-dimethyl)-aminoantipyrine, have been used 
as analgesic and anti-inflammatory drugs since the late 19
th
 century. Their concurrent use with 
aspirin is particularly beneficial as they have been shown to prevent or attenuate the anti-platelet 
effects of aspirin (Hohlfeld et al., 2008). However, despite the many documented therapeutic 
benefits, these pyrazolones have been associated with agranulocytosis, an acute condition 
involving a severe lowered white blood cell count, and their use has been largely discontinued 
(Teng et al., 2011b). This has sparked several attempts to synthesize salts and co-crystals of 
4AAP (Huo, 2009), as well as a drive to produce covalently modified derivatives of 4AAP 
(Deshmukh et al., 2015). Deshmukh commented that due to the significant benefits of 4AAP 
derivatives, and their interactions with DNA, the precise nature and structures of these Schiff 
bases is of “remarkable importance” (Deshmukh et al., 2015). The desired modification of 
4AAP to prepare pharmaceutically significant derivatives is by the covalent addition of adducts 
to the 4-amino functional group shown in Figure 1.10. 
N
N
H2N
O
    
N
N
N
O
R1
R2  
Figure 1.10: Structure of 4-aminoantipyrine (4AAP) and its derivatives. The desired 
modification of 4AAP is by the covalent addition of adducts (R1 and/or R2) to the 4-amino 
functional group. 
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In addition to its pharmaceutical interest, 4AAP is an interesting candidate for crystal 
engineering due to its high reactivity with ketones and aldehydes and its subsequent reluctance to 
form molecular salts or co-crystals. It reacts readily with ketones and aldehydes at room 
temperature, and its reactive properties have made it useful as a nitrogen scavenger species 
against hydroxyl radicals (Santos et al., 2010). To date, 251 derivatives of 4AAP have been 
reported in the CSD (version 5.39) where the modifying adduct has attached to the amino 
nitrogen atom. Yet, despite the drive to synthesize salts and co-crystals of pharmaceuticals such 
as 4AAP, only five molecular salts of 4AAP have been reported, of which two are simple salts 
with halide counter-ions (Table 1.2). No co-crystal or complex of 4AAP in which all species are 
neutral has ever been reported. The scarcity of salts of 4AAP and the complete absence of any 
co-crystals of the species are in part due to the fact that it reacts covalently with many of its 
potential co-former rather than co-crystallizing on a supramolecular basis. 
Therefore, it is clear that a co-crystal design strategy for the supramolecular synthesis of co-
crystals (and salts) of 4AAP should be developed. There is also a need to prepare covalently 
modified derivatives of 4AAP, and for a study of their molecular and supramolecular structures. 
Table 1.2:  Reported salts of 4-aminoantipyrine 
Salt CSD Reference Code Reference 
aminoantipyrine-4-aminium 
chloride 
HUKTIS (Chitradevi et al., 2015) 
aminoantipyrine-4-aminium 
bromide monohydrate 
PAXSOY (Yang et al., 2012)  
aminoantipyrine-4-aminium 
thiourea chloride 
EVOLIL (Murtaza et al., 2011) 
aminoantipyrine-4-aminium 
2,2’-dithiobenzoate 
PUGHEF, PUGHEF01 (Huo et al., 2009) 
(Fazil et al., 2012) 
aminoantipyrine-4-aminium 
salicylate 
DUHYOV (Chitradevi et al., 2009) 
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1.8 Carboxylic acids as co-formers 
 
The carboxylic acid – pyridine (COOH···Npyr) heterosynthon is well known, and is shown in the 
example in Figure 1.11. Statistically, from analysis of CSD structures, the probability of 
hydrogen bond formation between a carboxylic acid and a pyridyl ring is 91% (Nangia, 2009). In 
particular, many successful attempts at co-crystallization of isoniazid with benzoic acids have 
been reported in which this heterosynthon has been used. A comprehensive list of all carboxylic 
acid co-formers of unmodifed isoniazid reported on the CSD (version 5.39) to date (February 
2018), including their references and CSD reference codes, are listed in Table 1.3.  
 
 
Figure 1.11: The robust COOH···Npyr heterosynthon between isoniazid and 2-hydroxybenzoic 
acid. 
 
Table 1.3: All reported carboxylic acid co-formers of unmodified isoniazid on the CSD (version 
5.39) with their corresponding CSD reference codes and literature references. 
Year Co-former CSD Reference Code Reference 
2008 2,2'-dithiodibenzoic acid BIZMAZ (Meng et al., 2008) 
2010 malonic  acid 
succinic acid 
glutaric acid 
adipic acid 
pimelic acid 
4-hydroxybenzoic acid 
2,4-dihydroxybenzoic acid 
FADGEY 
FADGIC, FADGIC02 
FADGOI 
FADGUO 
FADHAV 
FADHEZ 
FADHID 
(Lemmerer et al., 2010) 
 
2011 4-aminosalicylic acid URUDER,  
URUDER01-URUDER10 
(Grobelny et al., 2011) 
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2012 salicylic acid 
2-chloro-4-nitrobenzoic acid 
LATKUO 
LATLEZ 
(Lemmerer, 2012) 
2012 fumaric acid LATTAD (Cherukuvada et al., 2012) 
2013 3-(4-hydroxyphenyl)acrylic acid PEHFUF (Ravikumar et al., 2013) 
2013 4-hydroxybenzoic acid 
 
nicotinamide / succinic acid 
(ternary co-crystal) 
Nicotinamide / fumaric acid 
(ternary co-crystal) 
BICQUB, BICQUB01, 
LATTAD01, LATTAD02 
BICQUA 
 
BICQEL 
 
(Aitipamula et al., 2013) 
2013 benzoic acid 
sebacic acid 
trans-cinammic acid 
 
suberic acid 
SETRIU 
SETROA 
SETSAN 
SETSAN01, SETSAN02 
SETRUG 
(Sarcevica et al., 2013) 
2014 3,4,5-Trihydroxybenzoic acid LODHOD, LODHOD01 (Kaur et al., 2014) 
2014 2,3-dihydroxybenzoic acid 
3,5-dihydroxybenzoic acid 
3-hydroxybenzoic acid 
3,4,5-Trihydroxybenzoic acid 
BOMBOW 
BOMBUC 
BOMCAJ 
LODHOD02 
(Mashhadi et al., 2014) 
2014 ferulic acid 
vanillic acid 
caffeic acid 
FOSFIE 
FOSFUQ, FOSFUQ01 
FOSMIL, FOSMIL01 
(Swapna et al., 2014) 
2016 adipic acid FADGUO01 (Sarcevica et al., 2016) 
2016 3,4-dihydroxybenzoic acid EJOYEV (Mashhadi et al., 2016) 
2017 benzene-1,2,4,5-tetracarboxylic 
acid 
VEGHOH (Cunha et al., 2017) 
2018 4-cyanobenzoic acid  
4-aminobenzoic acid  
4-nitrobenzoic acid  
ACUDAG 
ACUDEK, ACUDEK01 
ACUDIO 
(Diniz et al., 2018) 
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When considering a suitable co-former for the synthesis of 4-aminoantipyrine, it was noted that 
Hemamalini et al. successfully co-crystallized various aminobenzoic acids (in particular, 2-
aminobenzoic acid) with a series of aminopyridines (excluding 4AAP). This study showed that 
the carboxylic acid functional group on 2-aminobenzoic acid is potentially capable of forming a 
robust heterosynthon with either the amine or with the carbonyl functional groups of molecules 
with the aminopyridine backbone (Hemamalini et al., 2014). Based on Hemamalini’s study, 2-
aminobenzoic acid may therefore be considered a potentially good choice as a possible 
heterosynthon for co-crystals of 4AAP. Furthermore, the molecular packing modes of carboxylic 
acids have been extensively studied and documented and the most important homo- and 
heterosynthons have been described in detail by Leiserowitz (Leiserowitz, 1976), and the use of 
carboxylic acids as the co-former of choice with isoniazid and 4AAP can thus be considered a 
knowledge based approach to co-crystal engineering.  
Carboxylic acids were therefore chosen to be the co-formers for all co-crystal syntheses in this 
study. Benzoic acids were chosen as co-formers to co-crystallize with modified isoniazid, and a 
range of carboxylic acids were investigated as possible co-formers for the supramolecular 
synthesis of multicomponent crystals of 4AAP. 
 
1.9 Dimensionality of packing 
 
A crystal or co-crystal will pack as a 3-dimensional (3D) hydrogen bonded network, a 2-
dimensional (2D) sheet, a 1-dimensional (1D) chain or tape (also referred to as a ribbon), or as 
zero-dimensional (0D) entities, depending largely on the number of hydrogen bonding sites 
between the co-crystallizing molecules. 3D hydrogen bonded networks are infinite three 
dimensional supramolecular structures which are connected by three or more hydrogen bonds, 
whereas 2D sheets are infinite two-dimensional structures. A 1D chain is an infinite one-
dimensional structure where molecules are connected by a single hydrogen bond, whereas a 1D 
tape (or ribbon) refers to infinite one-dimensional structures connected by two or more hydrogen 
bonds, where these hydrogen bonds are essentially co-planar (Burrows, 2004). Examples of each 
type of packing dimensionality are shown in Figure 1.12. 
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  (a)        (b)  
    
      (c) 
 
   (d)     (e) 
Figure 1.12: Examples of dimensionality of packing. (a) Co-crystals with 0D packing 
dimensionality. (b) A 1D chain. (c) A 1D tape (or ribbon). (d) A 2D sheet. (e) A 3D network. 
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1.11 Aims and objectives of this study 
 
The aims of this study were to contribute to the development of crystal and co-crystal design 
strategies and to the understanding of crystal and co-crystal structures of isoniazid, 4-
aminoantipyrine, benzophenone and their derivatives.  
Crystal design involves the synthesis of crystal structures with desired properties, based on an 
understanding of, and use of intermolecular interactions. Co-crystal design involves a study of 
the processes of supramolecular synthesis and to develop design strategies to elucidate 
predictable and exploitable mechanisms for co-crystallization processes.  
In particular, the specific objectives of this study were to: 
 Prepare co-crystals of covalently modified isoniazid using bulky modifiers (namely 
benzophenone and derivatives of benzophenone) and examine how these bulky modifiers 
and crystallization conditions affect the supramolecular structure of the co-crystals. 
(Chapter 4) 
  
 Crystallize and perform a structural study of isoniazid that has been covalently modified 
with benzophenone and its derivatives. 
(Chapter 5) 
 
 Examine the formation of the crystalline benzophenone azine side-products formed 
during the covalent modification and co-crystallization of isoniazid.  
(Chapter 6) 
 
 Develop a design strategy for the supramolecular synthesis of 4-aminoantipyrine. 
(Chapter 7) 
 
 Crystallize and perform a structural study of covalently modified 4-aminoantipyrine.  
(Chapter 8)  
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Chapter 2:  Literature 
 
2.1 The crystal structure of isoniazid 
 
The crystal structure of isoniazid was first published in the Journal of the American Chemical 
Society by H. Jensen in 1954. Crystals of isoniazid were described as well developed needles 
extended along the c-axis. The unit cell was found to be orthorhombic with dimensions a = 
11.33_Å, b = 14.74 Å, c = 3.84 Å and a P212121 space group (Jensen, 1954). The crystal 
structure of isoniazid (Figure 2.1a) shows four hydrogen bonding interactions of isoniazid, via 
the pyridine nitrogen atom (hydrogen bond acceptor), the amino hydrogen atom (donor), the 
amino nitrogen atom (acceptor) and the hydrazide hydrogen atom (donor). Both NH2 hydrogens 
are involved in hydrogen bonding. The single crystal structure of isoniazid does not show any 
hydrogen bonding interactions of the carbonyl oxygen atom, but it has been demonstrated via 
shifts observed in a vibrational spectroscopy study that there is, in fact, hydrogen bonding of the 
carbonyl oxygen atom (Akalin and Akyuz, 2007). Examining the short contacts in the crystal 
structure suggests a weak bifurcated C―H···O interaction between the carbonyl oxygen atom 
and two hydrogen atoms of an adjacent pyridine ring (Figure 2.1b). 
       
         (a)       (b) 
Figure 2.1: The crystal structure and hydrogen bonding of isoniazid (CSD ref: INICAC1). The 
hydrogen bonding observed in the crystal structure is shown in (a), while (b) shows short 
contacts between the carbonyl oxygen atom and two hydrogen atoms of the pyridyl ring. 
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2.2 Co-crystal engineering of isoniazid 
2.2.1 The co-crystallization of isoniazid and modified isoniazid 
 
Since the realization that co-crystallization of APIs may lead to changes in their physicochemical 
properties, there has been a plethora of advances in this field. However, the investigation of co-
crystals of the anti-tuberculosis drug isoniazid has only gained serious attention since 2010. In 
that year, Lemmerer, Bernstein and Kahlenberg made use of the “knowledge-based” approach 
synthon theory to synthesize seven co-crystals of isoniazid with mono and dicarboxylic acids. It 
was observed that the primary intermolecular interaction present in all seven co-crystals was the 
carboxylic acid – pyridine (COOH···Npyr) heterosynthon (Lemmerer et al., 2010). In the same 
year, Grobelny et al. synthesized two drug-drug co-crystals of isoniazid, having pyrazinamide 
and 4-aminosalicylic acid as co-formers. They confirmed that the same heterosynthon observed 
by Lemmerer was present in both co-crystals. They also noted that in 4-aminosalicylic acid, 
there are two distinct symmetry independent carboxylic acid – pyridine heterosynthons. The 
extent of proton transfer is dependent on the temperature, and although the first heterosynthon 
clearly has the characteristics of a co-crystal, the second may be more indicative of a salt, as 
shown in Figure 2.2. Inspection of the H–O lengths reveals that the H-atom is largely in the 
same position at different temperatures in pair I, but there is evidence for proton migration in 
pair II, with more salt-like character present at lower temperatures. At 100K, the OH···Npyr bond 
length is 1.30Å, but this lengthens to 1.56 Å at 240K. (Grobelny et al., 2011) 
 
Figure 2.2: The two distinct carboxylic acid – pyridine heterosynthons observed in the 
supramolecular synthesis of isoniazid with 4-aminosalicylic acid. One of these heterosynthons 
has the characteristics of a co-crystal and the other of a salt. Diagram taken directly from 
CrystEngComm. (2011). 13, 4358–4364. 
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In 2011, Sevukarajan et al. synthesized a co-crystal of isoniazid with L(+) tartaric acid and 
published an extensive study on the physical and biological properties of the co-crystal. They 
observed that the micrometritic properties (relating to the surface area and particle size of the 
drugs) was improved though co-crystallization, but that with this particular co-former, solubility 
decreased and the anti-tubercular activity decreased as compared with pure isoniazid. This was 
determined by comparing the in vitro antitubercular activity of pure isoniazid against M. 
tuberculosis with that of the co-crystal using a Microplate Alamar Blue assay. The compounds 
show activity up to 12.5 μg/ml for pure isoniazid and 25 μg/ml for the L(+) tartaric 
acid/isoniazid co-crystal. This indicates that the co-crystal has less antitubercular activity than 
the pure drug. (Sevukarajan et al., 2011). 
In 2013, Aitipamula et al. reported the co-crystallization of isoniazid with succinic acid, fumaric 
acid, 4-hydroxybenzoic acid (pHBA) and nicotinamide. Co-crystallization of isoniazid with 
pHBA yielded two polymorphs of the hydrated co-crystal (Figures 2.3 and 2.4). Co-
crystallization with fumaric acid likewise produced a novel polymorph. A ternary co-crystal of 
isoniazid, nicotinamide and succinic acid was also reported (Figure 2.5). Once again, all co-
crystals present were hydrogen bonded through the carboxylic acid – pyridine heterosynthon. In 
contrast to the observation of Sevukarajan, Aitipamula reported that in the ternary co-crystal, the 
solubility was increased compared with pure isoniazid. However, other co-crystals displayed 
decreased solubility (Aitipamula et al., 2013). Before this publication, there had been no reported 
polymorphs of co-crystals of isoniazid, or of any hydrates of isoniazid co-crystals.  
 
Figure 2.3: First reported hydrate of a co-crystal of Isoniazid. (CSD ref: BICQUB01) 
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    Polymorph Form I          Polymorph Form II 
       (a)          (b) 
Figure 2.4: First reported polymorphs of a co-crystal of isoniazid, using 4-aminobenzoic acid as 
the co-former. (CSD ref: (a) BIQQUB01 and (b) BICQUB) 
 
 
Figure 2.5: First reported ternary co-crystal of Isoniazid, using nicotinamide and fumaric acid as 
co-formers. Diagram taken directly from CrystEngComm, 2013, 15, 5877–5887. 
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In the same year, Sarcevica et al. reported a series of isoniazid co-crystals with various 
carboxylic acids. However, the contribution of Sarcevica et al. to the understanding of the co-
crystallization of isoniazid will be discussed in detail in Section 2.2.4.2 where work done on 
polymorphism of isoniazid co-crystals is detailed. 
In 2014, Mashhadi et al. reported the synthesis of 1:1 co-crystals of isoniazid with four anti-
oxidant hydroxybenzoic acids, namely 3-hydroxybenzoic acid, 2,3-dihydroxybenzoic acid, 3,5-
dihydroxybenzoic acid and 3,4,5-trihydroxybenzoic acid (gallic acid). A notable deviation from 
the previously reported isoniazid co-crystals was the absence of the carboxylic acid – pyridine 
heterosynthon with the 3,5-dihydroxybenzoic acid co-former. While the other three co-formers 
displayed the usual synthon, 3,5-dihydroxybenzoic acid was hydrogen bonded to isoniazid via a 
phenol – pyridine heterosynthon (Mashhadi et al., 2014). (Figure 2.6) 
   
 
Figure 2.6: Four co-crystals of isoniazid with anti-oxidant hydroxybenzoic acids synthesized by 
Mashhadi et al. Note that the co-crystal of isoniazid with the 3,5-dihydroxybenzoic acid co-
former is unusual because it forms via the phenol – pyridine synthon rather than the usual 
carboxylic acid – pyridine synthon . Diagram taken directly from J. Mol. Struct. (2014) 7, 446-
452. 
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Swapna et al. has noted that isoniazid undergoes degradation in fixed-dose combination (FDC) 
drugs, and has reported co-crystals of isoniazid with vanillic acid, ferulic acid, caffeic acid and 
resorcinol. The main goal of their work was to produce stable forms of isoniazid. Their work on 
solid forms of isoniazid with these co-formers was also the first report on preparing co-crystals 
of isoniazid using liquid-assisted grinding (LAG) (Swapna et al., 2014). 
The synthesized co-crystals of isoniazid and vanillic acid were dimorphic. Likewise, those of 
isoniazid and ferulic acid were also dimorphic, and those with caffeic acid were trimorphic. The 
co-crystal of isoniazid and resorcinol was the only co-crystal in their report that did not exhibit 
polymorphism. 
The co-crystals were tested for stability and were found to be stable at ambient temperature and 
humidity for up to one year. At the higher temperature of 40°C and 75% relative humidity, all 
forms except the isoniazid-resorcinol co-crystal were stable for at least six months. The 
isoniazid-resorcinol co-crystal started degrading after one month. 
Swapna et al. concluded that one of the forms of each of the isoniazid-ferulic acid and isoniazid- 
vanillic acid co-crystals (Figure 2.7), as well as one of the forms of isoniazid caffeic acid co-
crystal may thus be suitable co-crystals for a stable isoniazid solid form (Swapna et al., 2014). 
Figure 2.7: The isoniazid vanillic acid co-crystal prepared by Swapna et al. showing the sheet 
structure and the N―H···O and O―H···N heterosynthons. Diagram taken directly from Cryst. 
Growth, Des. 2014, 14, 5991–6005. 
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Of further interest in their study, Swapna et al. reported a screening study of all heterosynthons 
found in co-crystals of isoniazid to date. As expected, the carboxylic acid – pyridine 
heterosynthon was the predominant synthon in co-crystals of isoniazid, but seven other homo- 
and heterosynthons have been reported in isoniazid co-crystal structures and are shown in Figure 
2.8 (Swapna et al., 2014). 
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Figure 2.8: The eight hetero- and homosynthons found in isoniazid co-crystals.  
 
In 2016, co-crystals of two Schiff bases of isoniazid modified with acetone were reported by 
Oruganti et al., having 2,5-dihydroxybenzoic acid and 3-aminobenzoic acid as the co-formers. 
They also report that attempts to synthesize co-crystals of the same modified Schiff base with 
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2,6-dihydroxybenzoic acid and with phthalic acid failed and suggest that the failure of these to 
co-crystallize could be due to the steric effects of the hydroxy and carboxylic acid groups in the 
2-position being too close to the carboxylic acid in the 1-position. (Figure 2.9) Oruganti 
suggests that the steric hindrance blocks the formation of the robust carboxylic acid – pyridine 
heterosynthon typically observed in co-crystals of isoniazid (Oruganti et al., 2016). It should be 
noted, however, that they did succeed in preparing salts of unmodified isoniazid with 2,6-
dihydroxybenzoate and with o-phthalate. 
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Figure 2.9: A summary of the attempted synthesis of co-crystals by Oruganti et al. Success was 
achieved with the modified isoniazid molecule shown on the left and the two co-formers 
indicated, whereas failure was reported for the two co-crystals with substituents on the 2- and 6-
positions, which Oruganti attributed to steric effects. 
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2.2.2 Covalent assisted supramolecular synthesis 
 
A series of papers have been written on covalent assisted supramolecular synthesis. Covalent 
assisted supramolecular synthesis can be defined as the covalent modification of a molecule with 
the purpose of gaining control over some aspect of the supramolecular synthesis, for example, 
the altering the hydrogen bonding characteristics of a functional group or control over 
dimensionality of the packing, together with the co-crystallization of the modified molecule with 
a co-former. 
In Lemmerer et al. (2010) isoniazid was co-crystallized with 4-hydroxybenzoic acid and 2,4-
dihydroxybenzoic acid, and with several dicarboxylic acids, including malonic, glutaric, 
succinic, and pimelic acids. It was then demonstrated that the covalent modification of isoniazid 
with acetone and 2-butanone did not affect the supramolecular synthesis of isoniazid co-crystals, 
as the essential functional groups, pyridine and carboxylic acid, were not affected by the 
modification. In their experiment, acetone was added to the crystallizing solution, and the two 
amino hydrogen atoms were replaced by the acetone in a Schiff base reaction to form an imine. 
(Figure 2.10) 
 
Figure 2.10: A schematic diagram showing the one-pot covalent assisted supramolecular 
synthesis of the modification of isoniazid with acetone and 2-butanone and simultaneous co-
crystallization with 3-hydroxybenzoic acid. Diagram taken directly from CrystEngComm, 2010, 
12, 2856-2864.  
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Lemmerer, Bernstein and Kahlenberg subsequently carried out a series of covalently assisted 
supramolecular reactions where nine modified co-crystals were prepared (Lemmerer et al., 
2011). An interesting aspect of this paper was that both the covalent modification and 
supramolecular synthesis were done in a one-pot reaction. Lemmerer points out that this one-pot 
technique is unusual, and that most examples of crystals where an API has been modified and 
co-crystallized require two distinct steps – first, the modification of the API, and then the 
supramolecular synthesis in an additional step. Specifically, Lemmerer demonstrated that the 
hydrogen bonding functionality can be carried out in situ by simply adding ketones to the 
crystallizing solution. Lemmerer also demonstrated that, as isoniazid will invariably hydrogen 
bond through the carboxylic acid – pyridine heterosynthon, the same heterosynthon is involved 
in the intermolecular hydrogen bonding of covalently modified isoniazid (Lemmerer et al., 
2011). 
A further series of covalently assisted co-crystallizations have also been reported (Lemmerer, 
2012) showing the potential medical importance of covalent assisted molecular synthesis and 
showed how the physical properties of co-crystals could be manipulated through this technique, 
which could potentially allow for the biological activity of APIs to be improved and modified. 
Lemmerer provides a detailed explanation of how the structures and hydrogen bonding patterns 
changed due to the modification of the hydrogen bonding functionality and by the use of 
different crystal co-formers. 
 
2.2.3 “Masking” of functional groups / masked synthons 
 
Recently, there has been interest in the controlled “masking” of functional groups. This is a 
concept in which hydrogen bonding sites can be blocked from their regular intermolecular 
interactions by predictable means. The concept of “masked” synthons in co-crystal engineering 
was developed concurrently by MacGillivray et al. (Sander et al., 2013) where interjected water 
molecules were used to inhibit hydrogen bonding between the co-crystal components, and by 
Lemmerer (Lemmerer et al., 2011), who found that it was possible to block hydrogen bonding 
functionality by sterically blocking the site via covalent modification of an adjacent site. 
34 
 
2.2.3.1 Masking of functional groups by interjected water molecules 
 
In 2009, Bhatt et al. demonstrated that control over robust heterosynthons can be achieved by 
interjecting solvent molecules between the API and co-former (Bhatt et al., 2009). They 
classified their modification as a “moderate synthon success.” In cases where interjected solvent 
molecules (for example, water) completely blocked the formation of synthons, this was classified 
as “masked synthons”. This is illustrated in Figure 2.11, which has been adapted from 
MacGillivray’s paper on ‘Masked synthons’ in crystal engineering (Sander et al., 2013). In the 
example shown in the figure, the regular COOH···Npyr / COOH···OHphenol synthon is shown, and 
is classified as “synthon success.” When one part of the synthon is masked by the interjection of 
a water molecule, it was classified as “moderate synthon success”. Finally, complete 
modification of the synthon by the interjection of two water molecules was called a “masked 
synthon” (Sander et al., 2013). MacGillivray et al. confirmed the proof of concept by preparing 
hydrated co-crystals of acetaminophen and trans-1,2-bis(4-pyridyl)ethylene where water 
molecules were interjected between the synthons. The result was a complete lack of hydrogen 
bonding between the molecules. Instead, the molecules were connected to each other by water 
bridges, consisting of one or two water molecules. They demonstrated that depending on the 
stoichiometry, either moderate synthon success or complete masking could be achieved by the 
interjection of water molecules. 
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Figure 2.11: MacGillivray’s “masking” of synthons by interjected water molecules. Adapted 
from CrystEngComm. 2013, 15, 4816-4822. 
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2.2.3.2 Masking of functional groups through covalent modification of adjacent groups 
 
Lemmerer’s approach to masking was somewhat different in that he observed that masking of 
hydrogen bonding functionality could be achieved by the steric interference obtained by the 
covalent modification of a different functional group to that where masking is required. He 
demonstrated that the covalent modification of isoniazid with acetone and 2-butanone did not 
affect the supramolecular synthesis of isoniazid co-crystals, as the essential functional groups, 
pyridine and carboxylic acid, were not affected by the modification (Lemmerer et al., 2010). 
Lemmerer also demonstrated that the modifiers bonded to the isoniazid could give a measure of 
control of the outcome of the supramolecular synthesis depending on the identity and steric size 
of the modifier used. It was shown that the steric size itself can be used to shield or to ‘‘mask’’ 
the remaining hydrogen bonding functionality of isoniazid in such a way that common hydrogen 
bonds and intermolecular interactions are prevented from taking place as shown in Figure 2.12 
(Lemmerer et al., 2011). 
 
 
Figure 2.12: Diagram adapted from CrystEngComm. (2011). 13, 5692–5708. Lemmerer shows 
that by masking two of the hydrogen bonding sites by covalent modification with acetone, the 
dimensionality of packing can be altered, from 2D sheets to 1D ribbons, for example. 
 
As an example of steric control over intermolecular interactions, when the NH2 functional group 
on the hydrazide moiety of isoniazid was covalently modified by the addition of a benzophenone 
modifier to form a Schiff base, the amide hydrogen donor and nitrogen acceptor atoms of 
isoniazid are completely inaccessible to intermolecular interactions with neighbouring isoniazid 
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or 3-hydroxybenzoic acids co-formers due to the steric effects of the bulky benzophenone 
modifier (Lemmerer et al., 2011). (Figure 2.13) 
 
 
Figure 2.13: Diagram adapted from CrystEngComm. (2011). 13, 5692–5708. Lemmerer 
demonstrated that when isoniazid is covalently modified with benzophenone, the amide 
hydrogen donor and nitrogen acceptor atoms are completely inaccessible to intermolecular 
interactions with neighbouring isoniazid or 3-hydroxybenzoic acids co-formers due to the steric 
effects of the bulky benzophenone modifier. 
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2.2.4 Effect of crystallization conditions on supramolecular synthesis 
 
Changing crystallization and reaction conditions often has a profound effect on the resulting 
supramolecular structure of salts and co-crystals. However, to date, there are no tried and tested 
rules to dictate what products will be formed by changing variables such as the solvent, 
temperature, or ratio of products during synthesis, amongst others. Much of the available data in 
this regard is empirical, and there is still a great need for more data. Statistical analysis of 
hydrogen bonding synthons and other variables can be extracted from the CSD, and the more 
data that is available, the more robust the information gained from statistical analysis becomes. 
A recent example of empirical work looking at the influence of crystallization conditions on the 
synthesis of 4-aminosalicylic acid and of various forms of multicomponent crystals has been 
very recently published (André et al., 2017). Andre’ et al. highlighted how making changes such 
as changing of evaporating conditions, grinding of reagents (LAG) rather than the use of 
solvents, and choice of synthon results in different forms of the supramolecular products (André 
et al., 2017). 
 
2.2.4.1 Stoichiometric variation 
 
Stoichiometric variation in co-crystals can be influenced by the different synthons available to  
the molecules to be co-crystallized. In isoniazid, which has five potential hydrogen bonding 
sites, changing crystallization or reaction conditions is known to result in stoichiometric 
variation, as isoniazid hydrogen bonds readily through its pyridine and its hydrazide functional 
groups.  Chiya et al. showed that it was possible to create stoichiometric variation in salts of 
isoniazid with 2-butynoic acid by varying the stoichiometric ratio of isoniazid to 2-butynoic acid 
during the synthesis process (Chiya and Lemmerer, 2012). A 1:1 ratio of isoniazid to this co-
former resulted in a 1:1 salt of these two molecules (Figure 2.14a), the salt having been formed 
by proton transfer from 2-butynoic acid to the pyridine nitrogen atom of isoniazid. However, a 
1:4 ratio of isoniazid to the 2-butynoic acid co-former resulted in a 1:2 salt of these two 
molecules (Figure 2.14b). 
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      (a) 
 
       (b) 
Figure 2.14: Salts of  isoniazid and 2-butynoic acid. 
(a) The 1:1 salt (4-(hydrazinylcarbonyl)pyridinium)·(but-2-yn-1-olate) (CSD ref: VAXROD) 
(b) The 1:2 salt (4-(hydrazinylcarbonyl)pyridinium)·(but-2-yn-1-olate)2 (CSD ref: VAXRUJ)  
 
2.2.4.2 Polymorphism 
 
Just as changing the ratio of supramolecular reagents in isoniazid co-crystals and salts can result 
in stoichiometric variation, so it has also been reported that the use of different solvents may 
result in polymorphism. Sarcevica et al. have done considerable research in the field of isoniazid 
co-crystals. Sarcevica has recognised that co-formers of isoniazid, for example trans-cinnamic 
acid, act synergistically with isoniazid and that co-crystallization with such co-formers may 
enhance multidrug resistant treatment (Sarcevica et al., 2013). They have reported three co-
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crystals of isoniazid with cinnamic acid, as well as polymorphism in isoniazid/suberic acid, 
where the experimental method was changed to make use of a different solvent. A 1:1 ratio of 
isoniazid : cinnamic acid, crystallized from a 2:1 mixture of ethanol : acetonitrile afforded two 
polymorphs (Sarcevica et al., 2013). However, a 1:1 ratio of isoniazid : cinamic acid, crystallized 
from a 1:1 mixture of ethyl acetate : acetonitrile resulted in a third polymorph (Sarcevica et al., 
2014). All three polymorphs exhibit the same hydrogen bonding patterns in their asymmetric 
units, but differ in their packing arrangements. The hydrogen bonding in the asymmetric units is 
via the COOH···Npyr and COOH···NHamide  heterosynthons. Details of these polymorphs and 
their unit cell dimensions can be found in Table 2.1. The asymmetric unit and three packing 
arrangements are shown in Figure 2.15. 
 
Table 2.1. The three polymorphs of isoniazid with cinammic acid. 
Polymorph 
CSD 
Refererence 
Code 
Unit Cell Dimensions 
Space 
Group 
Form I SETSAN 
a = 7.4573Å 
b = 9.5154Å 
c = 10.1737Å 
α = 96.904° 
β = 103.264° 
γ = 101.946° 
V = 676.699Å
3
 P1 
Form II SETSAN01 
a = 14.9124Å 
b = 3.7468Å 
c = 24.3089Å 
α = 90° 
β = 90° 
γ = 90° 
V =1348.18Å
3
 P21/c 
Form III SETSAN02 
a = 6.4872Å 
b = 8.1478Å 
c = 13.5603Å 
α = 95.1691° 
β = 101.111° 
γ = 98.6376° 
V = 690.082Å
3
 P1 
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   (a)     (b) 
 
  
   (c)       (d) 
Figure 2.15: Polymorphs of isoniazid and cinnamic acid 
(a) The asymmetric unit of all three polymorphs exhibit the same hydrogen bonding pattern. 
(b) Packing arrangement of Form I (CSD ref: SETSAN)  
(c) Packing arrangement of Form II (CSD ref: SETSAN01) 
(d) Packing arrangement of Form III (CSD ref: SETSAN02) 
  
Sarcevica et al. similarly showed that polymorphs of isoniazid and suberic acid could be 
prepared from a 1:1 ratio of isoniazid and suberic acid, and crystallized from a 2:1 mixture of 
ethanol : acetonitrile, and from a 1:1 mixture of acetonitrile : methyl tert-butyl ether respectively. 
(Sarcevica et al., 2013). The first polymorph (CSD Ref: SETRUG) was synthesized using the 
42 
 
slow evaporation method. The second polymorph was synthesized using liquid assisted grinding 
(LAG) on a Retsch mill using 0.2 mL of the solvent. Single crystals were obtained with seed 
addition (seed crystals were obtained from LAG experiments). However, the second polymorph 
could only be identified from powder diffraction patterns as the poor quality of the crystals did 
not allow crystal structure determination. 
 
2.2.4.3 Impurities and additives 
 
It is well known that the presence of even tiny amounts of impurities in a crystallization solution 
may affect the nucleation, growth and dissolution properties of a crystal (Weissbuch et al., 
2001). In fact, it has been reported that the presence of additives during a crystallization process 
will invariably affect the morphology and crystal structure during crystallization (Meir and 
Leslie, 2015; Addadi et al., 1981). In certain instances, it may be desirable to add impurities or 
additives to a crystallization solution in order to induce changes in supramolecular structure, for 
example, stoichiometric variation or polymorphism. An example of the addition of “tailor-made” 
additives has been reported where control over the optical activity of crystallization was 
achieved by the induced preferential crystallization through the use of additives (Addadi et al., 
1981). Typically, a crystallizing solution contains a 1:1 stoichiometry of the API and co-former, 
and varying this ratio may result in changes in supramolecular structure and the formation of 
new co-crystals (Chiya and Lemmerer, 2012). These changes may be understood if one considers 
an excess of one or the supramolecular agents to be an additive. In other words, it may be useful 
in certain specific situations or experiments to consider anything other than a 1:1 ratio of 
supramolecular reagents as additives in order to induce changes in the desired products. 
 
2.3 Crystal engineering of isoniazid 
2.3.1 Covalent modification of isoniazid 
 
As described in Section 1.6, the covalent modification of isoniazid by the replacement of NH2 
hydrogen atoms with modifiers is the primary focus in the synthesis of medicines that target 
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drug-resistant strains of tuberculosis, as this covalent modification prevents the enzymes of the 
TB bacteria from rendering the drug ineffective (Hearn et al., 2009). Hearn et al. prepared a 
series of Schiff bases of isoniazid and compared the biological activity of isoniazid and modified 
isoniazid on mice. Hearn demonstrated that the NH2 functional group of isoniazid is subject to 
deactivating acetylation by a class of enzymes known as N-arylaminoacetyl transferases (NATs). 
He explained that this deactivation is the reason for the resistance of the tuberculosis bacteria 
against isoniazid. However, if the isoniazid drug is modified by the covalent modification of the 
amine group to form Schiff bases (before entering the body) (Figure 2.16b), the enzymatic 
deactivation process no longer works to deactivate the drug and the resulting modified isoniazid 
can be effective for the treatment of  multi-drug resistant strains of the bacteria. Hearn et al. 
prepared 43 Schiff bases of isoniazid and found that all of them exhibited at least some activity 
against M. Tuberculosis in vitro. Four of the modified isoniazid derivatives, compounds 3, 36, 38 
and 46 in Figure 2.17, were tested in vivo in mice and displayed considerable activity against 
multidrug-resistant strains of M. Tuberculosis. A complete list of the modifiers used by Hearn as 
well as the experimental results of his primary in vitro screening of his compounds are detailed 
in Figure 2.17. Where the Schiff bases were crystallized, the drugs were reported to be pure. In 
his conclusion Hearn noted that “Schiff bases [of isoniazid (INH)] may serve as discovery tools 
in probing INH-based treatment modalities, particularly for those patients chronically 
underdosed in conventional INH therapy.” (Hearn et al., 2009). 
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       (a)         (b) 
Figure 2.16: (a) Isoniazid. (b) The general structure of the Schiff bases prepared and tested by 
Hearn et al. 
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Figure 2.17. The R-groups used for the covalent modification of isoniazid and the experimental 
results reported by Hearn et al. in his study of the effects of the covalent modification of isonazid 
on antitubercular activity. Figure taken directly from Eur. J. Med. Chem. (2009). 44, 4169-4178. 
Other early work on the covalent modification of isoniazid was by the covalent modification of 
isoniazid with two halogenated aromatic modifiers (Silva et al., 2006). (Figure 2.18)  
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Figure 2.18: The two modified isoniazid molecules prepared by Silva et al. using halogenated 
aromatics as modifiers. 
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In 2012, Coelho et al. prepared a series of 23 N-acylhydrazones derived from isoniazid and 
determined the biological activity of those modified isoniazid derivatives. Thirteen of the 
modified isoniazid products showed a more than 10-fold higher biological activity against katG-
resistant strains of M. tuberculosis (Coelho et al., 2012). 
 
 
Figure 2.19: Taken directly from Infect. Dis. Rep., 2012, 4(1):e13. The figure shows the design 
concept of the acylhydrazones prepared by Coelho et al. 
 
Very recently, Ferraresci-Curotto et al. reported a series where isoniazid was modified to 
produce isoniazid hydrazones using four halogenated aldehydes, namely vanillin, 5-
bromovanillin, 5-chlorosalicylaldehyde and 5-bromosalicylaldehyde (Figure 2.20). The four 
modified isoniazid products were found to be isomorphic. The molecules in the packing of the 
hydrazones were bonded to each other via OH···Npyr hydrogen bonds, resulting in 2-dimensional 
planar polymeric structures (Ferraresi-Curotto et al., 2017). 
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Figure 2.20: Part (a) shows the four modifiers used by Ferraresi-Curotto et al. to prepare a series 
of isoniazid hydrazones, and (b) is the general structure of the series. 
 
2.4 Photodimerization of benzophenones 
2.4.1 Previous synthetic methods for benzophenone azines 
 
While experimenting on the covalent modification of isoniazid, benzophenone azine was found 
to occasionally crystallize together with the modified isoniazid crystals and co-crystals. The 
formation of the benzophenone azine that occurred was studied and will be described in Chapter 
6. The study also resulted in the development of a new method of synthesizing benzophenone 
azines. The literature described in this section therefore details the previously reported methods 
of benzophenone azine synthesis. 
Ketone azides are frequently used in synthetic chemistry as starting materials for the synthesis of 
basic aromatic rings (Kost and Grandberg, 1959; Carty, 1972; Wuts and Greene, 2006), as well 
as for ligands in metal complex catalysis (Verner and Potacek, 2006). The synthesis of 
benzophenone azine was first proposed by Lauer and Dyer in 1942 (Lauer and Dyer, 1942). 
(Figure 2.21) They reported benzophenone azine as one of several products of the oxidation of 
benzophenone oxime. The method of synthesis required inert conditions and several synthetic 
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steps, as well as oxidation with the highly toxic potassium ferricyanide. During the synthesis, a 
mixture of benzophenone, benzophenone azine and the benzophenone oxime ester 
(C6H5)2C═N−O−N═C(C6H5)2 were formed, and manual separation was required. In addition to 
benzophenone azine, a mix of the product from the other reaction was observed. The presence of 
benzophenone azine was supported by molecular weight determinations (Lauer and Dyer, 1942). 
N
N
N
N2 (g)
HO
O
N
O
N
+ + +
Benzophenone oxime Benzophenone azine
Benzophenone o-diphenylmethyleneamino oximeBenzophenoneNitrogen gas  
 
Figure 2.21: Lauer and Dyer’s method of synthesis of benzophenone azine from benzophenone 
oxime showing also the many side products produced from their method of synthesis 
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In 1995, Saha et al. (Saha et al., 1995) synthesized benzophenone azine via the reaction of the 
iron-containing Lewis acid complex [ɳ5-(C5H5)Fe(CO)2(THF)]
+
[BF4]
-
 and provided evidence of 
an iron carbine intermediate. Inert conditions were required for the synthesis and benzophenone 
azine was found to be one of two components in a product mixture, along with 
tetraphenylethylene, with benzophenone having a 39% yield after separation. The crystal and 
molecular structure was determined and was used to confirm that the azine, rather than the 
azitine product was afforded. In their paper, the first crystal structure of benzophenone azine was 
reported (CSD ref: ZOSLUO) and the monoclinic unit cell dimensions were determined to be a = 
16.303(3) Å, b = 5.4864(2) Å, c = 21.973(5) Å, β = 85.52(2)°, V = 1959.4(8) Å³. It was reported 
that the asymmetric unit contained two half a molecules of benzophenone azine, but they 
determined that despite the high crystallographic symmetry, the two halves of the molecule were 
not related by symmetry. Rather, the molecule possesses a C2 symmetry, with the molecular C2 
axis coincident with the crystallographic twofold axis (Saha et al., 1995). 
 
2.4.2 Weak hydrogen bonds in benzophenone azines:  C−H···O and C−H···π  
 
A particularly interesting feature of the crystals that will be described in Chapter 6, relating to a 
new method of synthesis of benzophenone azines, is the abundance of the weak C−H···O and 
C−H···π hydrogen bonding patterns in their packing. Desiraju has described C−H···π 
interactions as being “supportive” interactions and mentions that although C−H···π interactions 
are fairly ubiquitous, they are “very weak and merely exist in a structure that is wholly 
determined by other interactions” (Desiraju, 2005). He also asks the question of whether it is 
possible to engineer crystal structures consisting of only weak interactions. Desiraju mentions 
that historically, these weak hydrogen bonds were dismissed as having little impact on crystal 
structure, but stresses that today, an understanding of these interactions is considered crucial with 
regards to the elucidation of crystal structures, as well as for knowledge-based crystal design 
processes. Kuduva et al. remarks that there is a distinct awareness between weak and strong 
hydrogen bonds, but that the differences between the weak and strong types of bonds are more a 
matter of degree rather than a fundamental difference in the types of reaction (Kuduva et al., 
2001).  
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2.4.3 Stereochemistry of benzophenone azines 
 
Structural isomerism exists in benzophenone azines and the spectroscopic resolution of their 
configurations are not trivial. Benzophenone azines that have two non-equivalent substituents 
can exist as three stereoisomers, namely EE, EZ or ZZ (Figure 2.22). Afonin et al. has, however 
reported that the 
13
C NMR shielding constant of the Cipso atom is stereospecific. Should it be 
necessary for the stereochemistry of benzophenones to be known unambiguously, a complete 
configurational assignment has been published by Afonin which can be used as a reference 
(Afonin et al., 2012). 
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R1
R1
R2
R2
N
N
R1
R2
R2
R1
EE EZ ZZ  
Figure 2.22: The three stereoisomers of benzophenone azines. This E/Z stereochemistry applies 
if R1 has a lower priority than R2. 
 
2.5 The crystal structure of 4-aminoantipyrine 
 
The crystal structure of 4-aminoantipyrine has been reported by Li et al. (Li et al., 2013) and by 
Mnguni et al. (Mnguni and Lemmerer, 2015). (Figure 2.23) The unit cell was found to be 
hexagonal with dimensions a = 7.4519 Å, b = 7.4519 Å, c = 31.8705 Å (V =1532.69 Å
3
) and a 
P61 space group. The crystal structure has an intermolecular N−H···O heterosynthon involving 
the amino group hydrogen atom donor and the carbonyl oxygen atom hydrogen bond acceptor. 
This forms an infinite chain with graph set notation C(5) (Etter et al., 1990). There is a sixfold 
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screw axis that defines the chain, and a symmetrically pleasing helical form results down the 
crystallographic c-axis (Figure 2.23d). There are also two C−H···π interactions involving the 
methyl group hydrogen atoms and the phenyl ring. The dimensionality of the packing is a three-
dimensional (3D) network (Li et al., 2013).  
        
N
N
O
H2N                      
  (a)      (b) 
               
(c) 
 
         (d) 
Figure 2.23: (a) Structure diagram, (b) asymmetric unit and (c) hydrogen bonding of 4-
aminoantipyrine. (CSD ref: LOYXEE)  and (d) the helical packing of the 4AAP. Part (d) of 
Figure 2.23 is taken directly from Acta Cryst. (2015). C71, 103–109 
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2.6 Co-Crystal and crystal engineering of 4-aminoantipyrine 
 
2.6.1 Salts of 4-aminoantipyrine 
 
To date, 251 derivatives of 4-aminoantipyrine have been reported in the CSD (version 5.39), 
where the modifying adduct has attached to the amino nitrogen atom. However, there are no 
reported co-crystals of 4AAP. Only five molecular salts of 4AAP have been reported in 
literature, summarized in Figure 2.24 and Figure 2.25, with CSD reference codes and literature 
references shown in Table 2.2. Two of these are simple salts with halide counter-ions. The 
exocyclic nitrogen atom of 4AAP is readily protonated and forms a chloride salt in the presence 
of hydrochloric acid and a bromide salt when refluxed in an aqueous dibromomethane solution 
(Figure 2.24b and 2.24c).  
 
Table 2.2: Reported salts of 4-aminoantipyrine 
Salt CSD Reference Code Reference 
aminoantipyrine-4-aminium 
chloride 
HUKTIS (Chitradevi et al., 2015) 
aminoantipyrine-4-aminium 
bromide monohydrate 
PAXSOY (Yang et al., 2012)  
aminoantipyrine-4-aminium 
thiourea chloride 
EVOLIL (Murtaza et al., 2011) 
aminoantipyrine-4-aminium 
2,2’-dithiobenzoate 
PUGHEF, PUGHEF01 (Huo et al., 2009) 
(Fazil et al., 2012) 
aminoantipyrine-4-aminium 
salicylate 
DUHYOV (Chitradevi et al., 2009) 
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Figure 2.24: The structure of 4AAP and its reported simple salts with their CSD reference 
codes: 
(a) 4-aminoantipyrine (SIKBAR), (LOYXEE) 
(b) aminoantipyrine-4-aminium chloride (HUKTIS) 
(c) aminoantipyrine-4-aminium bromide monohydrate (PAXSOY) 
 
 
Figure 2.25: Molecular salts of 4AAP reported in literature with their CSD reference codes: 
(a) aminoantipyrine-4-aminium thiourea chloride (EVOLIL) 
(b) aminoantipyrine-4-aminium 2,2’-dithiodibenzoate (PUGHEF), (PUGHEF01) 
(c) aminoantipyrine-4-aminium salicylate (DUHYOV) 
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The chloride salt of 4AAP reported by Chitradevi forms the same hydrogen bonding as does pure 
4AAP described in Section 2.5 but has an additional N−H···Cl hydrogen bond to a halogen. This 
forms a dimeric  2
2 10  ring around the inversion center of the unit cell (Chitradevi et al., 2015). 
(Figure 2.26) As expected, the bromide salt hydrogen bonds through the same synthons as the 
chloride salt with the additional water molecule being hydrogen bonded to the methyl group and 
the bromine ion (Yang et al., 2012). (Figure 2.27) 
 
Figure 2.26: The crystal structure of the 4-aminiumantipyrine chloride salt reported by 
Chitradevi. Diagram taken directly from J. Mol. Struct., 2015, 1099, 58-67. 
 
Figure 2.27: Hydrogen bonding of the bromide salt of 4-aminiumantipyrine reported by Yang et 
al.. (CSD ref: PAXSOY) 
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Murtaza et al. prepared a three-component salt (Figure 2.25(a)) by acidifying the 4AAP with an 
aqueous solution of hydrochloric acid, and then refluxing with ethanol (Murtaza et al., 2011). It 
was reported that the three components form a two-dimensional structure parallel to (001) via a 
network of  N−H···Cl, N−H···S, N−H···O, and C−H···S hydrogen bonds (Figure 2.28). 
 
Figure 2.28: Hydrogen bonding of the bromide salt of 4-aminiumantipyrine reported by Murtaza 
et al. (CSD ref: EVOLIL) 
 
A molecular salt of 4AAP and 2,2’-dithiobenzoic acid was synthesized first by Huo and then 
Fazil et al (Huo, 2009, Fazil et al., 2012). and was crystallized from ethanol and from a 50% 
ethanol/water mixture respectively (Figure 2.25(b)). Huo commented that the components were 
selected as building blocks for creating a co-crystal, but proton transfer was observed in the 
ethanol medium. In the molecular salt, a carboxylic acid group is deprotonated and the exocyclic 
amino atom is protonated. N−H···O and O−H···O intermolecular hydrogen bonds connect the 
ions into 1D chains along the b-axis (Figure 2.29). 
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Figure 2.29: Hydrogen bonding of the molecular salt of 4AAP and 2,2’-dithiobenzoic acid 
reported by Huo and by Fazil et al. (CSD ref: PUGHEF01) 
Finally, a salt of 4AAP with salicylic acid was prepared in aqueous solution by Chitradevi et al. 
Chitradevi et al., 2009). Ionic interaction exists between the carboxylate anion and the aminium 
cation, forming a  2
2 10  ring motif. As expected by Etter’s rules, an S(6) intramolecular 
O−H···O hydrogen bond was also found in the crystal structure (Figure 2.30). 
 
Figure 2.30: Hydrogen bonding of the molecular salt of 4AAP and salicylic acid reported by 
Chitradevi et al. (CSD ref: DUHYOV) 
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2.6.2 Salt or co-crystal? The effect of pKa 
 
The effect of pKa on co-crystal formation has recently come into the spotlight. Childs et al. states 
that the absolute separation of the pKa values of a molecule and its potential co-former plays a 
critical role in determining whether the supramolecular synthesis of two such molecules will 
result in a salt or in a co-crystal (Childs et al., 2007). It is generally accepted that in 
supramolecular synthesis two molecules will form a salt if the pKa separation (where ∆pKa = 
pKa(protonated base) – pKa(acid)) of the acid and base is greater than 2 or 3, a phenomenon 
known as the “pKa rule” (Guillory, 2003). A larger pKa separation is expected to result in salt 
formation. Bhogala et al. commented that in pyridine / carboxylic acid complexes, a negative 
pKa difference between the acid / base pairs will invariably result in co-crystal formation 
(Bhogala et al., 2005). 
Cruz-Cabeza conducted a statistical study of the pKa separations of 6465 salts and co-crystals. 
The statistical analysis validated the pKa rule and it was confirmed that salts were observed 
exclusively where ∆pKa > 4 and co-crystals were observed exclusively when ∆pKa < -1. For 
∆pKa separations between –1 and 4, the probability of salt formation was found to have a linear 
relationship to the ∆pKa value (Cruz-Cabeza, 2012). 
More recently, Lemmerer et al. presented empirical evidence to suggest that in pyridine / 
carboxylic acid complexes, an absolute ∆pKa separation of less than 3 will greatly enhance the 
formation of a co-crystal rather than a salt (the “Rule of Three”) (Lemmerer et al., 2015). A 
series of carboxylic acid complexes with nine pyridines, and 109 literature examples containing 
pyridine and carboxylic functional groups were used for this study. The results obtained by 
Lemmerer show that a salt can be formed if ∆pKa < 3, but that the likelihood of salt formation 
increases as the ∆pKa increases from 0. Likewise, co-crystal formation is extremely unlikely at 
∆pKa >3. This can be shown in the plot of ∆pKa vs salt/co-crystal distribution shown in Figure 
2.31 (Lemmerer et al., 2015) 
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Figure 2.31. A plot of 109 complexes found in the CSD that have a carboxylic acid group and a 
pyridine group, respectively, on separate molecules, plotted as a function of ∆pKa and the 
observed co-crystal or salt complex. Diagram taken directly from CrystEngComm. (2015). 17, 
3591-3595. 
Stilnović et al. prepared a series of 22 co-crystals and salts of various pyridines with gentisic 
acid and analysed the proton transfer in the formation of these complexes. Proton transfer was 
found to be absent where ∆pKa was less than 2, and always occurred when ∆pKa was greater than 
2 (Stilinović and Kaitner, 2012). Stilnović reported that the carboxylic acid – pyridine synthon 
existed in all but one of the structures and made the interesting observation that this bond was 
shorter and stronger in the co-crystals than in the salts. 
 
2.6.3 The covalent modification of 4-aminoantipyrine 
 
In a recent study of Schiff base derivatives of 4-aminoantipyrine, Mnguni and Lemmerer 
reported that in 4AAP that has been covalently modified to form Schiff bases to form enamines, 
six-membered intermolecular N−H···O hydrogen bonding is favoured, with imines having 
C−H···O bonds. It was noted that of 146 structures of modified isoniazid that crystallize with an 
imine backbone, all 136 non-solvated or hydrated structures have an intramolecular C−H···O 
bond. All five structures having an enamine backbone contain intramolecular N−H···O hydrogen 
bonding  (Mnguni and Lemmerer, 2015).  
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Chapter 3:  Experimental 
 
3.1 Covalent modification and supramolecular synthesis 
 
The covalent modification of isoniazid with benzophenone and its derivatives generally requires 
heating, increased pressure and extended refluxing over several days, as isoniazid does not 
readily react with benzophenone and its derivatives at ambient conditions. As many crystals 
were often synthesized simultaneously, and since small volumes of solvent (typically 3 mL) 
were used, the setup of reflux apparatus was not practical. Hence, a novel method of creating the 
required conditions was developed, using high-pressure glass screw-top rubber-lined dram vials 
(Figure 3.1a). 
Glass screw-top rubber-lined dram vials were purchased, which were airtight when screwed 
closed. The reagents were added to the vials and roughly 3mL of solvent was added to each vial 
so that the vial was no more than half full. A magnetic stirrer bar was added and the top was 
tightly closed and the vial placed on a heater-stirrer and heated to up to 120°C. This resulted in 
considerable convection currents within the vial which mimicked a reflux setup on a small scale 
(Figure 3.1b). The reflux could be carried out for several days in these vials at up to 120°C 
without any noticeable loss of solvent. This method also allowed reflux to be carried out at 
higher temperatures than the boiling points of the solvents. However, heating the vial to above 
150°C  or filling the vial more than half full caused too high pressure and resulted in the vial 
bursting, and this method should therefore only be used noting these limitations. For safety 
reasons, an inverted beaker was placed over the sealed vials while heating at all times. Should 
this method be used, care should be taken to prevent injury in the case of the vial bursting. 
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Figure 3.1: (a) The glass screw-top rubber-lined dram vials used for refluxing. The vials have a 
rubberized seal and can boil without significant loss of solvent. (b) When refluxing in the closed 
vial, solvent evaporates and flows back down the side of the vial. 
 
In general, the slow evaporation method was used for growing crystals. After the reagents are 
completely reacted and dissolved in solution, the solution is added to a poly-top vial. The top is 
loosely placed on the vial, which is left open to the atmosphere for several days. In cases where 
the resulting crystals were small, the solution was re-dissolved, and the vial was covered with a 
plastic film to slow evaporation, and small holes punched in the film. 
Detailed information on the synthetic methods and crystallization techniques can be found in the 
chapters that follow. 
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3.2 Crystal data and X-ray structure analysis 
 
Single crystal data was collected on a Bruker APEX II CCD area detector diffractometer fitted 
with an Oxford CRYOSTREAM 700. All temperature collections were carried out at 173K. Data 
reduction was carried out using SAINT+ version 6.02.6 software and SADABS was used to make 
empirical absorption corrections (Bruker, 2004). 
 
3.3 Powder X-ray diffraction 
 
In certain cases of polymorphism (Chapter 4.2), powder diffraction patterns were required to 
confirm that the single crystal structures were representative of the bulk material. Where powder 
diffraction patterns were required, these were collected on a Bruker D2 Phaser using Co Kα1/2 
radiation (Kα1 =1.788960 Å and Kα2 = 1.789879 Å) and a Lynxeye PSD detector. Pawley 
refinements were carried out using Bruker AXS TOPAS version 4.2. Powder X-ray diffraction 
patterns for the polymorphs synthesized in Chapter 4.2 are presented in Appendix 1. 
 
3.4  Melting points and differential scanning calorimetry (DSC)  
 
Melting points were collected on a Mettler Toledo MP50 melting point system.  
 
Where polymorphism was present (Chapter 4.2), DSC and powder diffraction measurements 
were done to characterize the purity and stability of the materials. Differential scanning 
calorimetry traces were collected using a using a Mettler Toledo 822
e
 with aluminium pans 
under air purge. STAR SW 9.20 was used for instrument control and data analysis. Exothermic 
events were shown as peaks. Various heating and cooling protocols were performed as 
quantitative analysis of certain polymorphs in Chapter 4.2. The temperature and energy 
calibrations were performed using pure indium (purity 99.99%, m.p 156.6 °C, heat of fusion 
28.45J.g
-1
). DSC thermograms for the polymorphs synthesized in Chapter 4.2 are presented in 
Appendix 1. 
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3.5 Software used 
 
All crystal structures were solved using direct methods on SHELXS-97. All non-hydrogen atoms 
were first refined isotropically, followed by anisotropic refinement by full matrix least-squares 
calculations based on F
2
 using SHELXS-97 (Sheldrick, 2015). All structures which had not yet 
been published by the time of release of the later SHELXL-2017 (Sheldrick, 2015) version were 
refined further using this latest version of the software.  
Publication material and diagrams of crystals structures were generated using WinGX (Farrugia, 
2012), ORTEP-3 (Farrugia, 2012), PLATON (Spek, 2009), and MERCURY-3 (Macrae et al., 
2008). In general, diagrams of asymmetric units were generated using ORTEP-3 and packing 
diagrams were generated using MERCURY. 
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Chapter 4:  Co-crystal engineering of isoniazid: covalent assisted 
supramolecular synthesis 
 
4.1 Introduction 
 
This chapter contains two papers on co-crystal engineering.  
In the first paper, covalent assisted supramolecular synthesis of co-crystals is reported and details 
how co-crystal engineering was used to mask functional groups in co-crystal structures and 
control the dimensionality of packing.  
The second paper examines the effect of changing experimental and crystallization conditions to 
induce stoichiometric variation, polymorphism, and the formation of solvates by changing 
crystallization conditions. 
Details of the publication status of each paper precede the relevant paper. 
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4.2 Covalent assisted supramolecular synthesis: Masking of amides in co-crystal 
synthesis using benzophenone derivatives 
 
Title of paper:  Covalent Assisted Supramolecular Synthesis: Masking of Amides in Co-
    Crystal Synthesis using Benzophenone Derivatives 
Journal:  Crystal Growth and Design 
Reference:  Cryst. Growth Des. 2015, 15, 3813−3821 
Status:   Published 
Date Received:  April 2015 
Date Revised:  09 June 2015 
Date Published: 11 June 2015 
 
Synopsis of Paper 
In this paper, eight co-crystals of salicylic acid with covalently modified isoniazid were 
prepared. Co-crystal engineering was used to control the dimensionality of the supramolecular 
structures. Bulky modifiers (benzophenone derivatives) were used to mask the hydrogen bonding 
functionality of the amide group on the isoniazid. No hydrogen bonding or short intermolecular 
contacts were present between the amide nitrogen atoms in isoniazid and any neighboring 
isoniazid or salicylic acid atoms. 
The paper was published in the Crystal Growth & Design Mikhail Antipin Memorial virtual 
special issue.  
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Table 4.1: List of compounds reported in chapter 4.2  
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ABSTRACT:   
Control over hydrogen bonding patterns and the dimensionality of supramolecular structures is 
possible through covalent assisted supramolecular synthesis. Consistent and predictable 
'masking' of the amide functionality has been achieved through the covalent modification of 
isoniazid with benzophenone and benzophenone derivatives while co-crystallizing with salicylic 
acid. A series of co-crystals using benzophenones as masking agents was prepared using one-pot 
synthetic methods.  No short intermolecular contacts were present between the amide nitrogen 
atoms in isoniazid and neighbouring isoniazid or salicylic acid atoms.  
 
KEYWORDS:   
Masking, Amides, Co-crystals, Supramolecular synthesis, Crystal engineering, Robust 
heterosynthons, Benzophenone 
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Introduction 
 
In crystal engineering, ‘robust heterosynthons’ are molecules containing functional groups which 
have predictable and reliable hydrogen bonding functionality.
1
 A prime example of such 
functionality can be found in the carboxylic acid···pyridine hydrogen bond. The robustness of 
the functionality has been illustrated by the consistent hydrogen bonding pattern that occurs 
between the COOH···N bond of carboxylic acid groups and the pyridine nitrogen atom of 
isonicotinic acid hydrazide (isoniazid).
2
 A rapidly growing field of research in co-crystal 
engineering is that of exercising control over the dimensionality of such supramolecular 
assemblies. A recent review by Burrows highlights the progress that has been made to date in the 
synthesis of one-, two-, and three-dimensional hydrogen-bonded networks.
3
 A co-crystal will 
pack as a 3-dimensional network, a 2-dimensional sheet, or a 1-dimensional ribbon or chain, 
depending largely on the number of hydrogen bonding sites between the co-crystallizing 
molecules. Masking of specific hydrogen bond functionalities has recently been achieved 
through the covalent modification of supramolecular reagents.
4
 By reacting isoniazid with 
molecules containing ketone or aldehyde functional groups, the NH2 group of the hydrazide 
moiety undergoes a condensation reaction and replaces the two H atoms with alkyl groups. This 
process is called ‘modifying’ isoniazid’s hydrogen bonding functionality.4a Subsequently, 
depending on the steric size of the now added R groups, the amide H donor and/or the imine lone 
pair can be ‘masked’ by making access to them impossible for any hydrogen bonding donors or 
acceptors. For example, the crystal structure of the unmodified co-crystal (isoniazid)·(2-
hydroxybenzoic acid) has been determined, and the packing diagrams show that isoniazid and 2-
hydroxybenzoic acid (salicylic acid) molecules are connected through hydrogen bonding 
between the pyridine nitrogen atom and the nitrogen and oxygen atoms on the carbohydrazide 
functional group on isoniazid to form a 2-dimensional sheet along the bc plane (Fig. 1a); 
whereas the crystal packing where isoniazid is modified with an isopropyl group (by reacting 
with acetone), a 1-dimensional chain is formed by the isoniazid, with the salicylic acid 
carboxylic acid group still hydrogen bonding to the pyridine nitrogen atom (Fig. 1b).
4c
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Figure 1:  The hydrogen boding functionality of isoniazid and the carboxylic acid···pyridine 
heterosynthon with salicylic acid (a), compared with the reduced hydrogen functionality of a 
modified isoniazid with acetone (b). Hydrogen atoms not involved in hydrogen bonding are 
omitted for clarity. (Adapted from ref. 4c)  
 
Through in situ modification of the carbohydrazide functional group on isoniazid, where 
isoniazid was reacted with numerous covalent modifiers, the dimensionality of supramolecular 
structures formed between the co-crystallization of modified isoniazid and carboxylic acids was 
reduced to 1-dimensional ribbons, due to the NH2 group being replaced with a ketone group, and 
the N-H···O hydrogen bonds no longer being able to form.
c
 Lemmerer et al. also demonstrated 
that when diphenylmethylene (benzophenone) was used as a covalent modifier in the 
supramolecular synthesis of (N’-(diphenylmethylene)isonicotinohydrazide)·(3-hydroxybenzoic 
acid), the steric effects from the bulky benzophenone moiety rendered the lone pair on the amide 
N atom completely inaccessible to the 3-hydroxybenzoic acid phenol as an acceptor group, as 
well as masking the amide H atom from hydrogen bonding with adjacent amide groups.
4a
 
 
We wished to investigate the robustness of bulky groups similar to benzophenone in their ability 
to mask the amide nitrogen atom in isoniazid, and we report here the synthesis of eight co-crystal 
structures where isoniazid has been covalently modified by benzophenone and benzophenone 
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derivatives and co-crystallized with salicylic acid (Fig. 2). Due to the position of the phenolic 
group on salicylic acid, it was expected that the molecule should be stabilized via intramolecular 
hydrogen bonding and the salicylic acid molecule therefore only bond to the modified 
supramolecular reagent via the carboxylic acid group's hydrogen atom.  In addition, we 
demonstrate that benzophenone and its derivatives as amide masking agents can be prepared in a 
three component one-pot synthesis through the condensation reaction of these modifiers with 
isoniazid, while co-crystallizing at the same time with salicylic acid. A further reason to 
investigate isoniazid being reacted with benzophenone derivatives is that the isoniazid molecule 
is a pro-drug, and must be activated by a bacterial catalase-peroxidase enzyme that in 
Mycobacterium tuberculosis is called KatG.
5a
 KatG couples the isonicotinic acyl with the 
reduced form of nicotinamide adenine dinucleotide (NADH) to form a isonicotinic acyl-NADH 
complex which then becomes the active molecule. However, the isoniazid efficacy can be 
reduced by a class of enzymes known as N-arylaminoacetyl transferases (NAT), which rapidly 
acetylate the NH2 position preventing the reaction with NADH. A way to overcome this problem 
is to react the NH2 group with aldehyde or ketone groups that then structurally block isoniazid 
from the effects of NAT.
5b
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Figure 2:   Summary of reagents and products in the covalent assisted supramolecular synthesis. 
Part (a) summarizes the general one-pot reaction scheme, where isoniazid reacts with a 
benzophenone modifier to form a modified hydrazide, which co-crystallizes with salicylic acid. 
The various benzophenone modifiers and their corresponding isonicotinohydrazide products 
(modified isoniazid) are shown in (b). Supramolecular synthesis resulting from the co-
crystallization of the modified isoniazid molecules in (b) with salicylic acid resulted in eight co-
crystal structures (c), with co-crystals 3a and 3b, as well as 6a and 6b, having dimorphic 
structures. 
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Experimental Methods 
Synthesis: 
The general method for the one-pot synthesis of co-crystals 1-6 follows the method described for 
co-crystal 1 below. Compounds 2 - 6 were synthesized in a similar manner. The masses of 
reagents, modifiers, solvents and catalysts used, as well as reflux and crystallization conditions 
are described in Table 1. 
 
Method of synthesis of co-crystal 1, N'-(diphenylmethylene)isonicotinohydrazide)·(salicylic 
acid): 
0.1165 g of isonicotinic acid hydrazide (0.8495 mmol), 0.1562 g of benzophenone (0.8572 
mmol) and 0.1160 g of salicylic acid (0.8398 mmol) were added into a sample vial. The solids 
were dissolved in AP-grade methanol (10 mL), refluxed in a closed vial for 72 hours at 110°C, 
and were left to stand at room temperature open to the atmosphere. Colourless needles were 
afforded after 3 days.  
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Table 1      Reagents and conditions for synthesis of co-crystals 1-6 
Co-
Cry
stal 
Mass of 
Isoniazid 
Mass of Modifier Mass of 
Salicylic Acid 
Catalyst Solvent Reflux 
Conditions 
Crystallization 
1 
0.1165g 
(0.8495mmol) 
0.1562g benzophenone 
(0.8572mmol) 
0.1160g 
(0.8398mmol) 
None 
10mL 
methanol 
Closed vial,  
72 hours at 
110°C. 
Slow evaporation at 
room temperature. 
Colourless needles 
afforded after 3 days 
2 
0.1003g 
(0.7314mmol) 
0.1595g  
2,2'-
dihydroxybenzophenone 
(0.7446mmol) 
0.1136g 
(0.8225mmol) 
0.0106g 
nickel nitrate 
(0.0364mmol) 
10mL 
acetonitrile 
Closed vial, 
4 days at 
70°C. 
Slow evaporation at 
room temperature. 
Clear plates afforded 
after 5 days. 
3a 
0.1175g 
(0.8567mmol) 
0.1803g  
4,4'-dimethylbenzophenone 
(0.8574mmol) 
0.1175g 
(1.2851mmol) 
None 
10mL 
methanol 
Closed vial, 
72 hours at 
room 
temperature. 
Slow evaporation at 
room temperature. 
Yellow cubes 
afforded after 3 days. 
3b 
0.0988g 
(0.720mmol) 
0.1514g 
4,4'-dimethylbenzophenone 
(0.7200mmol) 
0.1994g 
(1.4437mmol) 
None 
10mL 
methanol 
Closed vial, 
24 hours at 
90°C. 
Slow evaporation at 
room temperature. 
Yellow plates 
afforded after 3 days. 
4 
0.1100g 
(0.8021mmol) 
0.1571g  
4-methylbenzophenone 
(0.8005mmol) 
0.1107g 
(0.8015mmol) 
None 
10mL 
methanol 
Closed vial, 
24 hours at 
70°C. 
Slow evaporation at 
room temperature. 
Colourless needles 
afforded after 3 days 
5 
0.1037g 
(0.7561mmol) 
0.1707g  
4-(dimethylamino)-
benzophenone  
(0.7577mmol) 
0.1045g 
(0.7565mmol) 
None 
10mL 
methanol 
Closed vial, 
24 hours at 
90°C. 
Slow evaporation at 
room temperature. 
Red Needles afforded 
after 3 days. 
6a 
0.1015g 
(0.7401mmol) 
0.1484g  
4-aminobenzophenone 
(0.7446mmol) 
0.1014g 
(0.7341mmol) 
0.0094g 
nickel nitrate 
(0.0323mmol) 
10mL 
methanol 
Closed vial, 
18 hours at 
50°C. 
Slow evaporation at 
room temperature. 
Clear plates afforded 
after 7 days. 
6b 
0.1005g 
(0.7328mmol) 
0.1467g  
4-aminobenzophenone 
(0.7438mmol) 
0.2240g 
(1.6218mmol) 
0.0097g 
nickel nitrate 
(0.0334mmol) 
10mL 
methanol 
Closed vial, 
18 hours at 
50°C. 
Slow evaporation at 
room temperature. 
Clear plates afforded 
after 5 days. 
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Crystal Data and X-ray Structure Analysis. The intensity data for the eight co-crystals were 
collected on a Bruker APEX II CCD area detector diffractometer with graphite monochromated 
Mo-Kα radiation (50 kV, 30 mA) at 173K. The collection method involved ω-scans having a 
width of 0.5°. Data reduction was carried out using SAINT+ version 6.02.6 software and 
SADABS was used to make empirical absorption corrections.
6
 The crystal structures were solved 
through direct methods using SHELXS-97.
7
 Non-hydrogen atoms were first refined isotropically 
followed by anisotropic refinement by full matrix least-squares calculations based on F
2
 using 
SHELXL-97.
7
 C-bound H atoms were first located in the difference electron density map, then 
positioned geometrically and allowed to ride on their respective parent atoms, with thermal 
displacement parameters 1.2 times that of the parent C atom. Where possible, the coordinates 
and isotropic displacement parameters of the N-bound and O-bound H atoms involved in 
hydrogen bonding interactions were allowed to refine freely, except for co-crystals 2 and 5 due 
to poor refinement stability. The diffraction data and refinement statistics of co-crystal 2 were 
poor even after numerous attempts at recrystallization. Diagrams and publication material were 
generated using WinGX,
8
 ORTEP-3,
9
 PLATON
10
  and DIAMOND.
11
 The crystallographic data of 
each co-crystal is summarized in Table 2.  
 
Powder X-ray Diffraction.  Experimental diffraction patterns of Co-crystals 1 – 6b were 
collected on a Bruker D2 Phaser using Co Kα1/2 radiation (Kα1 =1.788960 and Kα2 = 1.789879 Å) 
and a Lynxeye PSD detector. Pawley refinements were carried out on all data using Bruker AXS 
TOPAS version 4.2.  Powder X-ray diffraction confirmed that the single crystal structures were 
representative of the bulk material except for 5, which shows some impurity phases (See ESI). 
 
Melting Points. Melting points of all compounds except the dimorphs 3 and 6 were collected on 
a Mettler Toledo MP50 melting point system. The melting points of dimorphic structures 3a and 
3b and for 6a and 6b, were done using DSC (below). Melting points of all compounds can be 
found in the ESI and Table 2.  
 
Differential Scanning Calorimetry (DSC). Differential scanning calorimetry traces were 
collected using a using a Mettler Toledo 822
e
 with aluminium pans under air purge.” STAR SW 
9.20 was used for instrument control and data analysis. Exothermic events were shown as peaks. 
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Various heating and cooling protocols were performed as quantitative analysis of the 
polymorphs. The temperature and energy calibrations were performed using pure indium (purity 
99.99%, m.p 156.6 °C, heat of fusion 28.45 J g-1). DSC traces are given in the supporting 
information. 
 
 
Table 2      Crystallographic data for all co-crystals. 
 1 2 3a 3b 
Formula 
(C19H15N3O)· 
(C7H6O3) 
(C19H15N3O3)· 
(C7H6O3) 
(C21H19N3O)· 
(C7H6O3) 
(C21H19N3O)· 
(C7H6O3) 
Mr 439.46 471.46 467.51 467.51 
Melting point (°C) 146 128 134 152 
Temperature/K 173(2) 173(2) 173(2) 173(2) 
Wavelength/Å 0.71073 0.71073 0.71073 0.71073 
Crystal size/mm3 0.54×0.41×0.25 0.47×0.40×0.10 0.90×0.28×0.21 0.40×0.39×0.26 
Crystal system Monoclinic Monoclinic Triclinic Triclinic 
Space group P21/c P21/c P1 P1 
a/Å 25.8071(6) 25.010(2) 9.9062(2) 8.2520(3) 
b/Å 6.9240(2) 6.9708(7) 12.0906(3) 11.2852(4) 
c/Å 12.2426(3) 12.4779(11) 12.4633(3) 12.9411(5) 
α/° 90 90 113.5360(10) 77.516(2) 
β/° 103.5010(10) 90.949(6) 113.0770(10) 85.880(2) 
γ/° 90 90 96.2970(10) 82.910(2) 
V/Å3 2127.16(9) 2175.1(4) 1194.70(5) 1166.39(7) 
Z 4 4 2 2 
ρ (calcd)/Mg m-3 1.372 1.440 1.300 1.331 
μ/mm-1 0.094 0.104 0.088 0.090 
F(000) 920 984 492 492 
ϴ Range for data/° collection/° 1.62 to 28.00 0.81 to 22.99 1.94 to 28.00 1.61 to 28.00 
Reflections collected 14559 13760 18654 20720 
No. of unique data [R(int)] 4952 [0.0371] 3030 [0.0799] 5748 [0.0427] 5618 [0.0440] 
   No. data with I ≥ 2σ(I) 3895 2548 4586 4409 
Final R(I > 2σ(I)) 0.0417 0.1378 0.0460 0.0428 
Final wR2 (all data) 0.1178 0.4083 0.1373 0.1219 
CCDC deposition number 998017 998011 998014 998015 
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4 5 6a 6b 
Formula 
(C20H17N3O)· 
(C7H6O3) 
(C21H20N4O)· 
(C7H6O3) 
(C19H16N4O)· 
(C7H6O3) 
(C19H16N4O)· 
(C7H6O3) 
Mr 453.48 482.53 454.48 454.48 
Melting point (°C) 128 205 137 163 
Temperature/K 173(2) 173(2) 173(2) 173(2) 
Wavelength/Å 0.71073 0.71073 0.71073 0.71073 
Crystal size/mm3 0.45×0.15×0.10 0.42×0.17×0.11 0.48×0.24×0.12 0.41×0.20×0.16 
Crystal system Triclinic Triclinic Triclinic Monoclinic 
Space group P1 P1 P1 P21 
a/Å 6.6193(2) 7.0057(4) 9.2815(3) 7.8452(3) 
b/Å 12.3234(3) 11.5495(7) 11.7198(3) 10.7034(4) 
c/Å 14.4180(3) 15.6046(9) 12.2187(3) 13.1775(5) 
α/° 98.727(2) 87.598(4) 94.4050(10) 90 
β/° 98.596(2) 82.792(4) 110.971(2) 93.234(3) 
γ/° 100.665(2) 72.850(3) 113.076(2) 90 
V/Å3 1123.17(5) 1196.91(12) 1104.72(5) 1104.76(7) 
Z 2 2 2 2 
ρ (calcd)/Mg m-3 1.341 1.339 1.366 1.366 
μ/mm-1 0.091 0.091 0.091 0.091 
F(000) 476 508 476 476 
ϴ Range for data/° collection/° 1.45 to 28.00 1.32 to 28.00 1.84 to 28.00 1.55 to 27.99 
Reflections collected 19872 17076 18697 9610 
No. of unique data [R(int)] 5411 [0.0321] 5783 [0.1444] 5336 [0.0397] 2801 [0.0538] 
   No. data with I ≥ 2σ(I) 3823 2927 3894 1952 
Final R(I > 2σ(I)) 0.0469 0.0572 0.0483 0.0713 
Final wR2 (all data) 0.1338 0.1511 0.1403 0.2280 
CCDC deposition number 998013 998016 1056771 1056772 
 
 
 
 
Results and discussion  
 
Eight co-crystals were synthesized using one-pot synthetic methods. Six benzophenone 
derivatives were used to modify isoniazid to form eight modified hydrazide molecules, including 
two sets of dimorphic structures (Fig. 2). Each of these modified hydrazide molecules were co-
crystallized with salicylic acid to form eight co-crystals (Fig. 2), numbered 1-6, with the 
dimorphic structures being labelled 3a and 3b, and 6a and 6b respectively. The asymmetric units 
and atomic numbering schemes for each co-crystal are shown in Figure 3. Hydrogen bonding 
details of co-crystals 1-6 are given in Table 3; and comparative structural and packing features 
are summarized in Table 4. 
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Figure 3:   Asymmetric units of co-crystals 1-6, showing the atomic numbering scheme for each 
co-crystal. Note the repeated intermolecular COOH···N and intramolecular O-H···O hydrogen 
bonds. 
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Compound 1 crystallizes in the P21/c space group, and the asymmetric unit contains one 
molecule of (N'-(diphenylmethylene)isonicotinohydrazide) and one molecule of salicylic acid. 
As is expected from co-crystals reported in the literature,
12
 the robust carboxylic acid···pyridine 
heterosynthon is present, O2─H2···N2 (Table 3). The phenol group on the salicylic molecules 
forms the expected intramolecular S(6) hydrogen bond.
13
 However, the N─H hydrogen bonding 
is markedly absent, as the bulky benzophenone group has masked the H1 donor and the :N3 
acceptor, by making the amide and hydrazide group inaccessible to any donors and acceptors, 
such as for example the two lone pairs on the amide carbonyl O1. Hence, all the strong hydrogen 
bonding interactions occur within the asymmetric unit to form 0-dimensional hydrogen bonded 
heteromolecular entities (Fig. 3), and there are no further intermolecular hydrogen bonds to any 
neighbouring entities. The pyridine ring is essentially coplanar with the salicylic acid molecule, 
with a 2.7° angle between the planes. The relative orientation of the two moieties is such that the 
salicylic carbonyl C26=O2 lies on the same side of the pyridine/salicylic acid plane as the 
isoniazid carbonyl C6=O1. The packing of the salicylic molecules is such that they are enfolded 
by the diphenylmethylene rings of the modified isoniazid on neighbouring entities, and stabilized 
by π-stacking along the b-axis (Figure 4a). 
 
Compound 2 crystallizes in the P21/c space group, and has similar unit cell axis lengths to 1 (Fig. 
4b), but has a significantly different packing to co-crystals 3-6a as will be described below. In 
this compound, the amide N1-H1 donor and :N3 lone pair are masked from the other donor and 
acceptor hydrogen bond functionalities not only by the steric effect of the benzophenone 
derivative groups, but by intramolecular hydrogen bonding between the phenol donor groups in 
the 2-position of the 2-hydroxyphenyl rings, O2 and O3, and the N1 and N3 atoms to form N1-
H1···O2 and O3-H3···N3 hydrogen bonds (Table 3). However, one of the phenol groups, O3, 
has its hydrogen atom free to hydrogen bond further, and in fact forms a O2─H2···O1 
heterosynthon to the amide O1 to form 1-dimensional ribbons not observed in the other 
structures except for 6b (Fig. 5). It is significant, however, that the amide group in compound 2 
is still masked by the bulky dihydroxybenzophenone moiety, and the lone pair on :N3 remains 
inaccessible to the phenol donor of salicylic acid. 
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Figure 4: (a) Packing of the salicylic and N'-(diphenylmethylene)isonicotinohydrazide in co-
crystal 1. Note the interdigitation of the co-crystal former and supramolecular reagent. (b) The 
isostructural crystal packing of salicylic acid and the related modified N'-bis(2-
hydroxyphenyl)methylene)isonicotinohydrazide in co-crystal 2. All C-bound H atoms are 
omitted for clarity. 
 
 
 
Figure 5:   The 1-D hydrogen bonded chain formed by hydrogen bonds between one of the 
phenol groups on the 2-hydroxyphenyl rings and the carbonyl O of the amide in 2. Shown are 
also the intramolecular hydrogen bonds of the amide and the phenol groups. All C-bound H 
atoms are omitted for clarity. 
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Compounds 3, 4 and 5 crystallize in the P1space group forming similar isolated hydrogen 
bonding entities as 1. These compounds follow the same hydrogen bonding pattern as 1, with 
only the intermolecular carboxylic acid···pyridine heterosynthon present (Table 3). The packing 
of 4 and 5 has the salicylic molecules and modified isoniazid molecules packing in distinct layers 
(Fig. 6a and b). Structures 3a and 3b are dimorphs, and only differ in their molecular 
conformations and packing arrangements. Structure 3a has a layered packing, where each layer 
-
stacking of the di-p-tolylmethylene rings (Fig. 7a). Structure 3b -stacking between 
the salicylic and N'-(di-p-tolylmethylene)isonicotinohydrazide as seen in 1 and 2 (Fig. 7b). The 
DSC traces of 3a and 3b show phase transition endotherms at approx. 117°C. 3a then melts at 
134.3°C and 3b at 151.7°C showing possible extra phases in this system. 
 
The C9-C8-C7-N3 torsion angle of 3b is -61.6°, and is comparable to that of the other five co-
crystals, whereas the two benzophenone rings in 3a have an angle of +82.5°, with one 
benzophenone ring being almost perpendicular to the other. The pyridine ring in all co-crystals 
except for 5 is co-planar with the salicylic acid molecule, but 5 is notably different from the 
other co-crystals in that salicylic acid lies perpendicular to the plane of the pyridine ring, with an 
angle of -86.1° between the planes. The orientation of the salicylic acid molecule in 3a and 3b is 
different to that of 1 and 2 in that the salicylic carbonyl C28=O2 lies on the opposite side of the 
pyridine/salicylic acid plane as the isoniazid carbonyl C6=O1.    
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Figure 6:   Similar layer packing of the salicylic and (E)-N'-(phenyl(p-tolyl)methylene)- 
isonicotinohydrazide (a) and ((E)-N'-((4-(dimethylamino)phenyl)(phenyl)methylene)-
isonicotinohydrazide (b) molecules in co-crystals 4 and 5 respectively. Note especially the 
similar anti-parallel orientations of neighbouring salicylic and modified isoniazid molecules. All 
H atoms are omitted for clarity. 
 
 
 
 
Figure 7:   The different packing of (N'-(di-p-tolylmethylene)isonicotinohydrazide)·(salicylic 
acid) units in polymorphs 3a and 3b. All H atoms are omitted for clarity. 
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Compounds 6a and 6b are dimorphs, but differ significantly from each other in their molecular 
conformations, dimensionality and packing arrangements. Compound 6a crystallizes in the P1 
space group, and 6b in the P21 space group. In both compounds, the amino groups of the 4-
aminobenzophenone moiety are involved in intermolecular bonding. In addition to the 
intermolecular carboxylic acid···pyridine heterosynthon, each modified isoniazid molecule in 6a 
is hydrogen bonded to a second modified isoniazid molecule through two N4─H4A···O1 
hydrogen bonds to form dimers with 0-dimensional packing dimensionality (Fig. 8a). In 6b, each 
modified isoniazid molecule hydrogen bonds through its N4─H4A to one adjacent molecule, 
forming 1-dimensional ribbons instead (Fig. 8b). In both 6a and 6b, the salicylic acid molecule is 
co-planar with the pyridine ring of isoniazid. However, the orientation of the salicylic carboxylic 
acid C=O bond for 6a is syn with respect to the amide C6=O1 of the modified isoniazid, whereas 
for 6b, the orientation is anti. There is no hydrogen bonding between the second amide N4─H4B 
with any neighbouring entities. The DSC trace of 6a shows a melting point at 136.6 °C, followed 
by a recrystallization exotherm for a new phase which then melts at 160.0 °C. Instead, 6b show 
no phase transition endotherms and melts at 163.2°C. 
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Figure 8:  Packing of dimorphic structures 6a (a) and 6b (b), showing their differing 
supramolecular dimensionality. 6a has a zero-dimensional supramolecular structure, whereas 6b 
forms a one-dimensional ribbon. The orientation of the salicylic carboxylic acid C=O bond for 
6a is syn with respect to the amide C6=O1, whereas for 6b, the orientation is anti. All C-bound 
H atoms are omitted for clarity. 
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Table 3 Hydrogen bonding details of co-crystals 1-6 
 
 
(i): x, -y+1/2, z-1/2 
(ii): -x+1, -y, -z+1 
(iii): x, y-1, z 
 
  
 d(D─H)/Å d(H···A)/Å d(D···A)/Å ∠(D─H···A)
/° 1     
O2─H2···N2 1.01(2) 1.58(2) 2.5904(13) 171(2) 
O4─H4···O3 0.91(2) 1.79(2) 2.6195(13) 149(2) 
2     
N1─H1···O2 0.88 2.31 2.812 116 
O2─H2···O1 0.84 1.84 2.5737(13) 145i 
O3─H3···N3 1.05 1.92 2.685(8) 127 
O4─H4···N2 1.05 1.66 2.633(7) 152 
O6─H6···O5 0.96 1.83 2.603(11) 136 
3a Form I     
O2─H2···N2 0.99(2) 1.65(2) 2.6381(13) 175(2) 
O4─H4···O3 0.95(3) 1.67(3) 2.5651(14) 154(2) 
3b Form II     
O2─H2···N2 1.05(2) 1.59(3) 2.6383(14) 175(2) 
O4─H4···O3 0.91(2) 1.77(2) 2.6031(14) 152(2) 
4     
O2─H2···N2 0.97(3) 1.61(3) 2.5704(16) 171(3) 
O4─H4···O3 0.90(3) 1.77(3) 2.6073(19) 154(3) 
5     
O2─H2···N2 0.84 1.78 2.615(2) 172 
O4─H4···O3 0.84 1.82 2.548(3) 144 
 
6a Form I 
 
 
    
N4─H4A···O1 0.87(2) 2.16(2) 2.989(2) 160(2) ii 
O2─H2···N2 0.96(2) 1.71(2) 2.6720(18) 177(2) 
O4─H4···O3 1.08(3) 1.56(3) 2.5681(18) 153(2) 
6b Form II 
 
    
N4─H4A···O1 0.88 2.23 3.068(8) 159 iii 
O2─H2···N2 0.84 1.73 2.563(6) 170 
O4─H4···O3 0.84 1.87 2.599(8) 145 
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Table 4 Comparison of planar orientations and torsion angles in co-crystals 1-6 
 1 2 3a 3b 4 5 6a 6b 
Orientation of  plane of salicylic acid 
ring wrt plane of pyridine ring 
Co- 
planar 
Co-planar 
Co-
planar 
Co-
planar 
Co-
planar 
Perpendicular 
Co-
planar 
Co-planar 
Angle between plane of salicylic acid 
ring and plane of pyridine ring 
2.7° 5.9° -6.9° -28.6° 1.4° -86.1° -4.0° 4.1° 
Orientation of salicylic carboxylic acid 
C28/C26=O2 wrt amide C6=O1  
anti anti syn syn Anti Perpendicular syn anti 
Hydrogen bonding dimensionality 0D 1D 0D 0D 0D 0D 0D 1D 
Packing dimensionality 0D 1D_chains 0D 0D 0D 0D 0D 1D_chains 
Torsion angles:         
     C13-C8-C14-C19 -80.7° 68.1° 65.9° -63.4° 74.0° -63.2° 69.0° 72.9° 
     N3-N1-C6-C7 7.6° -12.1° -3.9° 2.50° -9.5° 2.0° 2.1° 4.4° 
     C9-C8-C7-N3 -73.9° 65.2° 82.5° -61.6° 63.5° -67.9° 71.4° 62.8° 
 
 
 
 
Conclusion 
 
In this paper, we have described eight co-crystals formed between isoniazid, which has been 
covalently modified with a series of benzophenone derivatives, and then co-crystallized with 
salicylic acid. Each co-crystal was synthesized in a one-pot synthesis, with covalent modification 
occurring in situ. In all eight co-crystals, the benzophenone derivative effectively masked the 
amide nitrogen on the carbohydrazide group of isoniazid. The only intermolecular hydrogen 
bonding observed in co-crystals 1, 3-6a was the carboxylic acid···pyridine N2 hydrogen bonding 
to form isolated hydrogen bonded entities; and in 2, additional hydrogen bonding between the 
carbonyl oxygen of isoniazid and the phenol donor group of the 2-hydroxybenzophenone ring 
was observed to form 1-dimensional chains. Structures 3a and 3b are dimorphs, and only differ 
in their molecular conformation and packing arrangement. Dimorphs 6a and 6b differ in the 
dimensionality of their supramolecular structure. 6a packs in a zero-dimensional arrangement, 
whereas 6b forms one-dimensional ribbons. In all cases, the amide nitrogen was completely 
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inaccessible to either the phenol donor group of salicylic acid or the amide carbonyl group. In 
conclusion, benzophenone and its derivatives are reliable and predictable in their ability to mask 
the amide group in the carbohydrazide moiety. Co-crystals 2 and 6b shows further that if 
additional hydrogen bonding functionalities exist on the phenyl rings of the benzophenone 
modifiers, they can replace the amide moiety to form 1-dimensional chains in a similar way to 
the amide group if it were not masked. 
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4.3 Covalent assisted supramolecular synthesis: The influence of crystallization 
conditions on co-crystals of “masked” isoniazid derivatives 
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Synopsis of Paper 
In this paper, eight co-crystals of salicylic acid with covalently modified isoniazid were 
prepared. The effect of crystallization conditions on co-crystals of “masked” isoniazid 
derivatives was studied and reported. Co-crystal engineering was applied to induce 
stoichiometric variation, polymorphism and solvate formation via changes in reflux time, 
stoichiometry of reagents (additives), addition of catalysts and addition of substituents to the 
aromatic rings. 
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Table 4.2: List of compounds reported in chapter 4.3 
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ABSTRACT:   
Eight co-crystals of covalently modified isoniazid were synthesized, using either 3- or 4- 
hydroxybenzoic acid as the co-former. It was demonstrated that for the co-crystallization of 
“masked” isoniazid by benzophenone derivatives, a small change in reaction or crystallization 
conditions played a large role in the outcome of the resulting supramolecular structure, whereas 
the addition of either one or two methyl substituents to the benzophenone rings did not affect the 
supramolecular structure of the resulting co-crystals. Changing the reflux time for the 
supramolecular synthesis resulted in stoichiometric variation. Adding larger quantities of one of 
the starting supramolecular reagents as “additives” resulted in polymorphism. Using a catalyst 
for the covalent modification of isoniazid during one-pot supramolecular synthesis prevented the 
formation of a solvate. 
 
 
KEYWORDS:   
Isoniazid, Co-crystals, Supramolecular synthesis, Crystal engineering, Robust heterosynthons, 
Crystallization Conditions 
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Introduction 
 
The influence of crystallization conditions on the synthesis of 4-aminosalicylic acid and of 
various forms of multicomponent crystals has been very recently published.
1
 Andre’ et al. 
highlighted how making changes such as changing of evaporating conditions, grinding of 
reagents (LAG) rather than the use of solvents, and choice of synthon results in different forms 
of the supramolecular products.
1
  
A series of papers have been written on covalent assisted supramolecular synthesis.
2-5
 Covalent 
assisted supramolecular synthesis can be defined as the covalent modification of a molecule with 
the purpose of gaining control over some aspect of the supramolecular synthesis (for example, 
the altering the hydrogen bonding characteristics of a functional group
3 
or control over 
dimensionality of the packing),
5
 together with the co-crystallization of the modified molecule 
with a co-former. 
In Lemmerer et al.
2
, it was demonstrated that the covalent modification of isoniazid with acetone 
and 2-butanone did not affect the supramolecular synthesis of isoniazid co-crystals, as the 
essential functional groups, pyridine and carboxylic acid, were not affected by the modification.  
A series of covalently assisted co-crystallizations have been reported
4 
showing the potential 
medical importance of covalent assisted molecular synthesis and showed how the physical 
properties of co-crystals could be manipulated through this technique, which could potentially 
allow for the biological activity of Active Pharmaceutical Ingredients (APIs) to be improved and 
modified. 
Lemmerer et al.
3
 then demonstrated that the modifiers bonded to the isoniazid could give a 
measure of control of the outcome of the supramolecular synthesis depending on the identity and 
steric size of the modifier used. It was shown that the steric size itself can be used to shield or to 
‘‘mask’’ the remaining hydrogen bonding functionality of isoniazid in such a way that common 
hydrogen bonds and intermolecular interactions are prevented from taking place. The concept of 
“masked” synthons in co-crystal engineering was developed concurrently by MacGillivray et al.6 
where interjected water molecules were used to inhibit hydrogen bonding between the co-crystal 
components. 
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In Smith et al.,
5 
isoniazid was modified with a series of benzophenone derivatives and co-
crystallized with 2-hydroxybenzoic acid. The predictable “masking” of the amide functionality 
was achieved, and it was shown that the bulky benzophenone modifiers rendered the amide 
nitrogen atom inaccessible for hydrogen bonding and no short intermolecular contacts were 
present between the amide nitrogen atoms in “masked” isoniazid derivatives and any 
neighbouring isoniazid or 2-hydroxybenzoic acid atoms.  
Grobelny et al. has synthesized two drug-drug co-crystals of isoniazid, having pyrazinamide and 
4-aminosalicylic acid as co-formers. In 4-aminosalicylic acid, there are two distinct symmetry 
independent carboxylic acid – pyridine heterosynthons. The extent of proton transfer is 
dependent on the temperature, and although the first heterosynthon clearly has the characteristics 
of a co-crystal, the second may be more indicative of a salt.
7 
Aitipamula et al. reported the co-crystallization of isoniazid with succinic acid, fumaric acid, 4-
hydroxybenzoic acid (pHBA) and nicotinamide. Co-crystallization of isoniazid with pHBA 
yielded two polymorphs of the hydrated co-crystal. Co-crystallization with fumaric acid likewise 
produced a novel polymorph. A ternary co-crystal of isoniazid, nicotinamide and succinic acid 
was also reported.
8 
Sarcevica et al. has reported that the use of different solvents may result in polymorphism. They 
have reported three co-crystals of isoniazid with cinnamic acid, as well as polymorphism in 
isoniazid/suberic acid, where the experimental method was changed to make use of a different 
solvent. A 1:1 ratio of isoniazid : cinamic acid, crystallized from a 2:1 mixture of ethanol : 
acetonitrile afforded two polymorphs.
9
 However, a 1:1 ratio of isoniazid : cinamic acid, 
crystallized from a 1:1 mixture of ethyl acetate : acetonitrile resulted in a third polymorph.
10
 
 Mashhadi et al. reported the synthesis of 1:1 co-crystals of isoniazid with 3-hydroxybenzoic 
acid, 2,3-dihydroxybenzoic acid, 3,5-dihydroxybenzoic acid and 3,4,5-trihydroxybenzoic acid. A 
notable deviation from previously reported isoniazid co-crystals was the absence of the 
carboxylic acid – pyridine heterosynthon with the 3,5-dihydroxybenzoic acid co-former.11 
Swapna et al. has noted that isoniazid undergoes degradation in fixed-dose combination drugs, 
and has reported co-crystals of isoniazid with vanillic acid, ferulic acid, caffeic acid and 
resorcinol. The synthesized co-crystals of isoniazid and vanillic acid were dimorphic. Likewise, 
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those of isoniazid and ferulic acid were also dimorphic, and those with caffeic acid were 
trimorphic. The co-crystal of isoniazid and resorcinol was the only co-crystal in their report that 
did not exhibit polymorphism.
12
  
In this report, we have continued the systematic study of the covalent modification of isoniazid 
with bulky benzophenone modifiers, and have replaced the 2-hydroxybenzoic acid co-former 
with 3-hydroxybenzoic acid (meta-hydroxybenzoic acid or mHBA) and 4-hydroxybenzoic acid 
(para-hydroxybenzoic acid, or pHBA), with four co-crystal structures reported for each of these 
co-formers. The effect of the reaction and crystallization conditions on the resulting co-crystals 
of “masked” isoniazid derivatives is described. A general reaction scheme and summary of 
reagents used in the covalent assisted supramolecular synthesis is shown in Scheme 1. 
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(E)-N'-(phenyl(p-tolyl)-
methylene)-
isonicotinohydrazide
N'-(di-p-tolyl-
methylene)-
isonicotinohydrazide
(E)-N'-((4-aminophenyl)-(phenyl)methylene)-
isonicotinohydrazide
I:  (N'-(diphenylmethylene)isonicotinohydrazide)2·(3-hydroxybenzoic acid)*
II:  (N'-(diphenylmethylene)isonicotinohydrazide)·(3-hydroxybenzoic acid)
IIIa:  ((E)-N'-(phenyl(p-tolyl)methylene)isonicotinohydrazide)·(3-hydroxybenzoic acid) Form I
IIIb:  ((E)-N'-(phenyl(p-tolyl)methylene)isonicotinohydrazide)·(3-hydroxybenzoic acid) Form II 
IV:  ((E)-N'-((4-aminophenyl)(phenyl)methylene)isonicotinohydrazide)·(4-hydroxybenzoic acid)
V:  ((E)-N'-((4-aminophenyl)(phenyl)methylene)isonicotinohydrazide)·(4-hydroxybenzoic acid)·(methanol)
VI:  ((E)-N'-(phenyl(p-tolyl)methylene)isonicotinohydrazide)·(4-hydroxybenzoic acid)2
VII:  (N'-(di-p-tolylmethylene)isonicotinohydrazide)·(4-hydroxybenzoic acid)2
(b)
(c)
R
R'
O OH
 
Scheme 1: General reaction scheme and summary of reagents used in the covalent assisted 
supramolecular synthesis. Part (a) shows the general reaction scheme of isoniazid with a 
benzophenone modifier, which results in a modified hydrazide, and co-crystallizes with a 
benzoic acid derivative. Part (b) shows the different benzophenone modifiers and their 
corresponding isonicotinohydrazide products. Part (c) is a summary of the co-crystals that were 
synthesized, presented here for easy reference. IIIa and IIIb are dimorphic structures. *Stucture 
I has been published in CrystEngComm, 2011, 13, 5692 
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Experimental Methods 
The covalent modification of isoniazid generally required significant heating, increased pressure 
and extended refluxing over several days, as isoniazid does not readily react with benzophenone 
and its derivatives at ambient conditions. Hearn et al. observed that stereo-electronic effects 
often make the covalent modification of isoniazid more difficult with bulky modifiers and 
explained that “with alkyl modifiers larger than methyl in the ketone component of the transition 
state, the conformational preference for the lone pair on N
2
 renders this nitrogen poorly poised 
for nucleophilic attack.” (Hearn et al., 2009). Since small volumes of solvent were typically 
used, the setup of a traditional reflux apparatus was not practical. As a practical alternative, glass 
screw-top, airtight rubber-lined dram vials were used for refluxing. The reagents and solvent 
were added to the vial, a magnetic stirrer bar was added and the top was tightly closed and the 
vial placed on a heater-stirrer. This mimicked a reflux setup on a small scale (Figure 1). It also 
allowed for heating to above the boiling point of the solvent, which was occasionally necessary 
in order for the condensation reaction to occur. The reflux could be carried out for several days 
in these vials at up to 120°C without any noticeable loss of solvent. Note, for safety reasons, that 
heating the vial to above 150°C  or filling the vial more than half full caused too high a pressure 
and resulted in the vial bursting, and this method should therefore only be used noting these 
limitations. For safety reasons, an inverted beaker was placed over the sealed vials while heating 
at all times. Should this method be used, care should be taken to prevent injury in the case of the 
vial bursting. 
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Figure 1: (a) The glass screw-top rubber-lined dram vials used for refluxing. The vials have a 
rubberized seal and can boil without significant loss of solvent. (b) When refluxing in the closed 
vial, solvent evaporates and flows back down the side of the vial. 
 
Synthesis: 
 
I:  (N’-(diphenylmethylene)isonicotinohydrazide)2·(3-hydroxybenzoic acid), 
The method for the synthesis of this compound is published in CrystEngComm. (2011). 13, 5692 
and is reproduced here: “0.200 g of isonicotinic acid hydrazide (1.46 mmol), 0.213 g of 3-
hydroxybenzoic acid (1.54 mmol) and 0.266 g of benzophenone (1.46 mmol) were added into a 
sample vial. The solids were dissolved in AP-grade hot methanol (5 ml), refluxed for 3 hours at 
in a closed vial, and left to stand at room temperature open to the atmosphere. Colourless plates 
were afforded after 7 days. 
 
II:  (N’-(diphenylmethylene)isonicotinohydrazide)·(3-hydroxybenzoic acid), 
0.1057 g of isonicotinic acid hydrazide (0.7709 mmol), 0.1420 g of benzophenone (0.7793 
mmol) and 0.1076 g of 3-hydroxybenzoic acid (0.7790 mmol) were added into a sample vial. 
The solids were dissolved in AP-grade methanol (3 mL), refluxed in a closed vial for 72 hours at 
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70°C, and were left to stand at room temperature open to the atmosphere. Colourless blocks were 
afforded after 7 days.  
 
IIIa:  ((E)-N’-(phenyl(p-tolyl)methylene)isonicotinohydrazide)·(3-hydroxybenzoic acid) 
Form I, 
0.1050 g of isonicotinic acid hydrazide (0.7658 mmol), 0.1598 g of 4-methylbenzophenone 
(0.8143 mmol) and 0.1059 g of 3-hydroxybenzoic acid (0.7666 mmol) were added into a sample 
vial. The solids were dissolved in AP-grade methanol (10 mL), refluxed in a closed vial for 24 
hours at 70°C, and were left to stand at room temperature open to the atmosphere. Colourless 
plates were afforded after 7 days.  
 
IIIb:  ((E)-N’-(phenyl(p-tolyl)methylene)isonicotinohydrazide)·(3-hydroxybenzoic acid) 
Form II 0.0937 g of isonicotinic acid hydrazide (0.683 mmol), 0.1352 g of 4-
methylbenzophenone (0.6889 mmol) and 0.1539 g of 3-hydroxybenzoic acid (1.1142 mmol) 
were added into a sample vial. The solids were dissolved in AP-grade methanol (10 mL), 
refluxed in a closed vial for 24 hours at 70°C, and were left to stand at room temperature open to 
the atmosphere. Colourless plates were afforded after 7 days.  
 
IV:  ((E)-N’-((4-aminophenyl)(phenyl)methylene)isonicotinohydrazide)·(4-hydroxybenzoic 
acid) 
0.1008 g of isonicotinic acid hydrazide (0.7351 mmol), 0.1370 g of 4-aminobenzophenone 
(0.6946 mmol) and 0.1020 g of 4-hydroxybenzoic acid (0.7384 mmol) were added into a sample 
vial. 1 drop of concentrated HCl was added to catalyze the condensation reaction of isonicotinic 
acid hydrazide and 4-aminobenzophenone. The solids were dissolved in AP-grade methanol (10 
mL), refluxed in a closed vial for 72 hours at 110°C, followed by work-up with sodium 
bicarbonate: the solution was saturated with sodium bicarbonate, stirred for 5 minutes and then 
filtered. The filtered solution was then left to stand at room temperature open to the atmosphere. 
Clear plates were afforded after 7 days.  
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V:  ((E)-N’-((4-aminophenyl)(phenyl)methylene)isonicotinohydrazide)·(4-hydroxybenzoic 
acid)· (methanol) 
0.0967 g of isonicotinic acid hydrazide (0.705 mmol), 0.0974 g of 4-aminobenzophenone (0.705 
mmol) and 0.0973 g of 4-hydroxybenzoic acid (0.704 mmol) were added into a sample vial. The 
solids were dissolved in AP-grade methanol (10 mL), refluxed in a closed vial for 24 hours at 
110°C, and were left to stand at room temperature open to the atmosphere. Yellow plates were 
afforded after 7 days.  
 
VI:  ((E)-N’-(phenyl(p-tolyl)methylene)isonicotinohydrazide)·(4-hydroxybenzoic acid)2  
0.0866 g of isonicotinic acid hydrazide (0.632 mmol), 0.1239 g of 4-methylbenzophenone 
(0.6313 mmol) and 0.1740 g of 4-hydroxybenzoic acid (1.260 mmol) were added into a sample 
vial. The solids were dissolved in AP-grade methanol (10 mL), refluxed in a closed vial for 5 
days at 110°C, and were left to stand at room temperature open to the atmosphere. Colourless 
blocks were afforded after 7 days.  
 
 
VII:  (N’-(di-p-tolylmethylene)isonicotinohydrazide)·(4-hydroxybenzoic acid)2 
0.0989 g of isonicotinic acid hydrazide (0.721 mmol), 0.1520 g of 4,4’-dimethylbenzophenone 
(0.7228 mmol) and 0.2038 g of 4-hydroxybenzoic acid (1.4755 mmol) were added into a sample 
vial. The solids were dissolved in AP-grade methanol (10 mL), refluxed in a closed vial for 24 
hours at 110°C, and were left to stand at room temperature open to the atmosphere. Colourless 
blocks were afforded after 7 days.  
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Crystal Data and X-ray Structure Analysis.  
The intensity data for the new crystal structures reported here (II – VII) were collected on a 
Bruker APEX II CCD area detector diffractometer with graphite monochromated Mo-Kα 
radiation (50 kV, 30 mA) at -100°C. The collection method involved ω-scans with a 0.5° width. 
SAINT+ version 6.02.6 software was used for data reduction and SADABS was used to make 
empirical absorption corrections.
13
 The crystal structures were solved using direct methods on 
SHELXS-97.
14
 Non-hydrogen atoms were first refined isotropically, followed by anisotropic 
refinement by full matrix least-squares calculations based on F
2
 using SHELXL-2017.
14
 C-bound 
H atoms were located in the difference electron density map, then positioned geometrically and 
were allowed to ride on their respective parent atoms, with thermal displacement parameters 1.2 
times that of the parent C atom. Where possible, the coordinates and isotropic displacement 
parameters of the N-bound and O-bound H atoms involved in hydrogen bonding interactions 
were allowed to refine freely, except for co-crystal IIIb to poor refinement stability. The 
diffraction data and refinement statistics of co-crystal IIIb was poor even after numerous 
attempts at recrystallization. Diagrams and publication material were generated using WinGX,
15
 
ORTEP-3,
15
 PLATON
16 
and MERCURY
17
. The crystallographic data of each co-crystal is 
summarized in Table 1.  
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Table 1 Crystallographic data for compounds I-VII 
 
 
 
I* II IIIa  IIIb  
Formula 
(C19H15N3O)2· 
(C7H6O3) 
(C19H15N3O)· 
(C7H6O3) 
(C20H17N3O)· 
(C7H6O3) 
(C20H17N3O)· 
(C7H6O3) 
Mr 740.80 439.46 453.48 453.48 
Temperature/K 173(2) 173(2) 173(2) 173(2) 
Wavelength/Å 1.5418 0.71073 0.71073 0.71073 
Crystal size/mm3 0.42×0.33×0.20 0.09×0.32×0.34 0.07×0.15×0.59 0.08×0.15×0.26 
Crystal system Triclinic Triclinic Triclinic Triclinic 
Space group P1 P1 P1 P1 
a/Å 9.8338(9) 6.8909(2) 7.0137(3) 7.2172(10) 
b/Å 10.2475(9) 
 
10.5354(3) 10.5797(6) 11.5224(16) 
c/Å 10.8863(10) 15.3153(4) 15.5605(8) 15.070(2) 
α/° 104.295(8) 89.916(2) 90.635(3) 110.481(7) 
β/° 112.784(8) 83.7670(10) 94.052(3) 97.188(7) 
γ/° 103.370(8) 
 
85.9270(10) 93.174(3) 95.826(7) 
V/Å3 912.17(14) 
 
1102.48(5) 1149.85(10) 1150.4(3) 
Z 1 2 2 2 
ρ (calcd)/Mg m-3 1.350 1.324 1.310 1.309 
μ/mm-1 0.727 0.091 0.089 0.089 
F(000) 389 460 476 476 
 
ϴ Range for data collection/° 4.75 to 62.65 1.938 to 28.000 2.316 to 25.498 1.464 to 25.499 
Reflections collected 4365 20075 11166 10843 
No. of unique data [R(int)] 2793 [0.0202] 5320 [0.0588] 4189 [0.0606] 4199 [0.0944] 
No. data with I ≥ 2σ(I) 2516 4244 2771 1678 
Final R(I > 2σ(I)) 0.0568 0.0418 0.0652 0.1041 
Final wR2 (all data) 0.1618 0.1121 0.1785 0.1739 
CCDC deposition number SAYPEP 1810898 1810897 1810899 
*CrystEngComm, 2011, 13, 5692 
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 IV V  VI VII 
Formula 
(C19H16N4O)· 
(C7H6O3) 
(C19H16N4O)· 
(C7H6O3)·(CH4O) 
(C20H17N3O)· 
(C7H6O3)2 
(C21H19N3O)· 
(C7H6O3)2 
Mr 454.47 486.52 591.60 
 
605.63 
Temperature/K 173(2) 173(2) 173(2) 173(2) 
Wavelength/Å 0.71073 0.71073 0.71073 0.71073 
Crystal size/mm3 0.10×0.22×0.24 0.11×0.19×0.56 0.06×0.15×0.20 0.12×0.15×0.25 
Crystal system Triclinic Triclinic Triclinic Triclinic 
Space group P1 P1 P1 P1 
a/Å 8.3764(5) 8.8944(2) 8.8777(3) 9.0790(3) 
b/Å 8.8620(6) 10.8401(3) 13.2137(5) 13.2861(5) 
c/Å 16.1081(10) 13.3606(3) 13.9693(4) 14.0354(5) 
α/° 75.315(3) 70.5460(10) 112.474(2) 114.298(2) 
β/° 76.160(3) 81.4800(10) 102.586(2) 103.514(2) 
γ/° 73.677(3) 79.6840(10) 91.773(2) 90.060(2) 
V/Å3 1091.73(12) 1189.55(5) 1465.95(9) 1491.27(9) 
Z 2 2 2 2 
ρ (calcd)/Mg m-3 1.383 1.358 1.340 1.349 
μ/mm-1 0.095 0.093 0.095 0.095 
F(000) 476 
 
512 620 
 
636 
ϴ Range for data collection/° 1.329 to 25.498 1.624 to 27.998 1.681 to 25.496 1.647 to 25.498 
Reflections collected 12420 24184 19566 
 
23071 
No. of unique data [R(int)] 4063 [0.0805] 5753 [0.0410] 
 
5452 [0.0762] 
 
5530 [0.0597] 
   No. data with I ≥ 2σ(I) 2366 4483 2364 3183 
Final R(I > 2σ(I)) 0.0519 0.0414 0.0598 0.0647 
Final wR2 (all data) 0.1434 0.1113 0.1820 0.1937 
CCDC deposition number 1810900 1810901 1810902 1810903 
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Table 2 A summary of the angles between the planes of three rings of modified isoniazid and the 
co-former. A general scheme of the ring numbering is shown in the diagram included in the 
table. 
 
Angle 
between 
Rings (°) 
 
Rings 
1,2 
 
Rings 
1,3 
 
 
Rings 
1,4 
 
Rings 
2,3 
 
Rings 
2,4 
 
Rings 
3,4 
I 72.7 13.3 0.9 82.94 71.9 14.2 
 
II 70.28 1.55 61.63 69.5 83.52 63.15 
IIIa 70.90 0.37 62.14 70.69 82.41 62.49 
IIIb 76.35 14.24 85.41 73.79 29.33 86.32 
IV 71.79 44.40 23.55 71.41 54.31 58.84 
V 84.18 7.53 6.64 88.30 78.69 9.94 
VI* 56.8 42.06 37.5 80.0 76.6 4.63 
VII* 64.24 34.27 32.1 82.39 80.36 2.40 
 The angles for the second pHBA molecule in VI and VII is not shown on the table. For VI, the 
angle between the plane of the two pHBA molecules is 46.79°, and for VII, 48.55°. 
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a
-x, -y + 1, -z + 1. 
b
-x - 1, -y, -z + 2, 
c
x + 1, -y + 1, -z. 
d
x, y, z - 1. 
e
x + 2, y + 1, z + 1. 
f –x + 2, -y + 1, -z + 1. g-x + 3, 
-y, -z + 1. 
h
-x - 1, -y, -z + 2. 
i
x - 2, y-1, z. 
j
-x + 2, -y + 1, -z + 1. 
k
x - 1, y, z - 1. 
l
-x + 1, -y, -z + 1. 
m
x - 1, y, z - 1. 
n
 –x 
+ 1, -y, -z + 1. 
 
 
 
Table 3 Hydrogen bonding details of compounds I - VII 
 d(D─H)/Å d(H···A)/Å d(D···A)/Å ∠(D─H···A)/° 
I     
O1-H1∙∙∙N1 0.85(3) 1.89(3) 2.745(3) 178(3) 
C10A-H10A∙∙∙O2 0.95 2.84 3.498(12) 127 
II     
O2-H2∙∙∙N2 1.01(3) 1.59(3) 2.6008(13) 176(2) 
O4-H4∙∙∙O3a 0.87(2) 1.88(2) 2.7517(15) 171(2) 
IIIa     
O2-H2∙∙∙N2 0.84 1.78 2.613(3) 173 
O4-H4∙∙∙O3b 0.84 1.94 2.775(3) 178 
IIIb     
N1-H1∙∙∙O3c 0.88 2.08 2.840(4) 145 
O2-H2∙∙∙O1d 0.84 1.86 2.665(3) 159 
O4-H4∙∙∙N2 0.84 1.92 2.758(4) 179 
IV     
O2-H2∙∙∙N2 0.98(3) 1.74(3) 2.722(3) 178(3) 
O4-H4∙∙∙N4e 0.96(3) 1.87(3) 2.786(3) 160(3) 
N4-H4A∙∙∙O3f 0.97(3) 1.97(3) 2.926(3) 172(3) 
N4-H4B∙∙∙O1g 0.98(3) 1.98(3) 2.929(3) 164(2) 
V     
N4-H4A∙∙∙O1h 0.92(2) 2.12(2) 3.0060(16) 163(2) 
N4-H4B∙∙∙O4i 0.901(18) 2.407(18) 3.2621(17) 159(2) 
O2-H2∙∙∙N2 1.01(2) 1.63(2) 2.6352(14) 178(2) 
O4-H4∙∙∙O5 0.93(2) 1.76(2) 2.6665(17) 163(2) 
O5-H5∙∙∙O3j 0.88(2) 1.93(2) 2.8082(16) 174(2) 
VI     
O2-H2∙∙∙N2 0.82 1.82 2.640(4) 174 
O4-H4∙∙∙O1k 0.77(4) 1.98(4) 2.751(4) 177(5) 
O5-H5∙∙∙O6l 1.00(5) 1.63(5) 2.628(3) 173(5) 
O7-H7∙∙∙O3 0.77(3) 1.92(3) 2.669(4) 163(4) 
VII     
O2-H2∙∙∙N2 0.84 1.80 2.639(3) 173 
O4-H4∙∙∙O1m 0.90(5) 1.89(5) 2.757(4) 161(5) 
O5-H5∙∙∙O6n 0.84 1.81 2.652(3) 177 
O7-H7∙∙∙O3 0.90(4) 1.79(4) 2.674(4) 170(4) 
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Results 
 
The steps of a supramolecular synthetic process are discreet and the crystallization process is 
independent of the assembly of the supramolecular structure in situ.
18
 In this study eight co-
crystals were synthesized using one-pot synthetic methods (Figure 2). In all eight co-crystals 
reported, the same solvent (methanol) was used throughout and the method of crystallization was 
kept identical (slow evaporation method at room temperature over a seven day period). We here 
describe how simply changing only the synthetic method resulted in polymorphism, 
stoichiometric variation, a solvate vs non-solvate, change in dimensionality of packing, and 
bonding through differing heterosynthons in “masked” isoniazid derivatives. Four modified 
isoniazids were co-crystallized with 3-hydroxybenzoic acid and four with 4-hydroxybenzoic 
acid. As we were interested in the effect of changes in the synthetic method on the results of co-
crystallization, the eight co-crystals were divided in to pairs, where the synthetic method for each 
pair was kept the same, except for one substantial change in the synthetic method having been 
applied to each pair. For the first pair of co-crystals (I and II), the refluxing time of the reagents 
was changed. For the second pair (IIIa and IIIb), the stoichiometric ratio of the reagents was 
changed. For the third pair (IV and V), the reaction was carried out in the presence and absence 
of a catalyst respectively, and for the fourth pair (VI and VII) a methyl group was added to one 
of the aromatic rings. 
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               I                II 
        
                IIIa                IIIb 
                
             IV           V 
                            
             VI               VII                  
Figure 2:    Asymmetric units of co-crystals I - VII, showing the atomic numbering scheme for 
each co-crystal. *Stucture I was previously published in CrystEngComm. (2011). 13, 5692 
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Change in reflux time of one-pot synthesis 
 
In co-crystals I and II, isoniazid has been modified with benzophenone and co-crystallized with 
mHBA. For both I and II, a 1:1:1 ratio of isoniazid : benzophenone : mHBA were dissolved in 
methanol. The reagents for I were reluxed for 3 hours and for II were refluxed for 72 hours. 
Both were then  allowed to crystallize out for 7 days by slow evaporation. Therefore, the only 
substantial change to the synthetic method was the change in reflux time. The result was the 
formation of two co-crystals, I and II, having different stoichiometric ratios.  
 
The structure of I has been described in CrystEngComm. (2011). 13, 5692. A summary of the 
results is reported here for comparison purposes. Compound I crystallizes in the P  space group. 
The asymmetric unit of I contains one modified isoniazid molecule and one half mHBA acid 
molecule (Figure 2). The mHBA acid molecule crystallizes with static disorder around a centre 
of inversion (Figure 3). The carboxylic acid group and four carbon atoms of the aromatic ring of 
mHBA are found in the asymetric unit. The carboxylic acid functions as both the alcohol group 
as well as the carboxylic acid group. The two missing C atoms of the aromatic ring are generated 
by the O2 atom and the C7 atom of the carboxylic acid functional group. The mHBA molecule 
therefore exists in two different arrangements in between the modified isoniazid molecules, 
shown in Figure 3a and 3b.  
 
Compound II crystallizes in the P  space group and the asymmetric unit contains one modified 
isoniazid molecule and one mHBA molecule (Figure 2). The hydrogen bonding in the 
asymmetric unit is via the typical expected robust COOH···Npyr heterosynthon reported in 
literature, namely via O2―H2···N2.19 Also, as expected from literature, the amide group is 
rendered inaccessible to any hydrogen bond acceptors of neighbouring isoniazid or mHBA 
molecules by the steric effects of the bulky benzophenone group.
5
 Each modified isoniazid 
molecule is hydrogen bonded by a single O2―H2···N2 hydrogen bond to a mHBA molecule.  
Each mHBA is also hydrogen bonded via its phenol O―H donor to the carbonyl oxygen 
acceptor of the COOH functional group of an adjacent mHBA molecule, thus forming an  2
2 14  
ring in graph-set notation.
20
 (Figure 4a). All the hydrogen bonding interactions in II occur within 
the asymmetric unit to form zero-dimensional (0D) hydrogen bonded heteromolecular entities. 
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The pyridine ring of the modified isoniazid is essentially coplanar with one ring of the 
benzophenone, with an angle between the planes of 1.55°, and the packing is thus stabilized by 
π-stacking along the a-axis (Figure 4b).            
 
 
          (c) 
Figure 3: Disordered hydrogen bonding of I, and hydrogen bonding of II. 
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(a) 
 
 
(b) 
 
Figure 4: Part (a) shows the packing of II. (b) shows the planes of the pyridine ring and one of 
the benzophenone rings, which are essentially parallel and therefore suitable for π-stacking 
interactions along the a-axis. 
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Change in stoichiometry of reagents  
 
In co-crystals IIIa and IIIb, isoniazid was modified with 4-methylbenzophenone and co-
crystallized with mHBA. For IIIa, the ratio of isoniazid : 4-methylbenzophenone : mHBA used 
in the one-pot synthesis was 1:1:1, but for IIIb, a 1:1:1.6 ratio was used, with all other reaction 
and crystallizing conditions remaining the same. The result was the formation of two 
polymorphs, IIIa and IIIb, having very different hydrogen bonding and packing arrangements 
from each other. 
 
Compound IIIa crystallizes in the P  space group and contains one isoniazid molecule modified 
with 4-methylbenzophenone and one mHBA molecule. The hydrogen bonding in the asymmetric 
unit is via the COOH···Npyr heterosynthon (Figure 2). The methyl group on the benzophenone 
moiety is directed away from the sites of any intermolecular interactions and does not therefore 
interfere with the π-stacking interactions along the a-axis found in II, and therefore, the 
hydrogen bonding and packing arrangement in IIIa remains essentially isostructural to co-crystal 
II, despite the presence of the extra methyl group (Figure 5). A comparison of the angles 
between the four rings (Table 2) confirms the isostructural packing as the difference in all angles 
is negligible. The hydrogen bonding interactions within the packing form zero-dimensional (0D) 
hydrogen bonded heteromolecular entities. The pyridine ring is coplanar with the methylated 
ring of the 4-methylbenzophenone, with the acute angle between the planes in IIIa being 0.37°, 
and the packing is thus stabilized by π-stacking of the pyridine and 4-methylated ring of the 
modified isoniazid along the a-axis. 
 
Compound IIIb crystallizes in the P  space group and the asymmetric unit contains one 
isoniazid molecule modified with 4-methylbenzophenone and one mHBA molecule (Figure 2). 
The hydrogen bonding arrangement is unusual as the mHBA hydrogen bonds to the pyridine ring 
via its phenol hydrogen (H4) rather than through the expected COOH···Npyr heterosynthon. The 
4-methylbenzophenone moiety is disordered, with the methyl group being found on either 
aromatic ring of the 4-methylbenzophenone. IIIb packs in one dimensional (1D) tubes along the 
c-axis (Figure 6a). The geometrical shape of the tubes are almost square, with the “walls” of the 
tube being formed by two modified isoniazid molecules and two mHBA molecules. with the 
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plane of the pyridine ring of the modified isoniazid being almost normal to the plane of the mBA 
with an acute angle of 85.41° between the planes. These “walls” are held together by an  4
4 16  
ring, where the mHBA carboxylic acid group acts as the hydrogen bond donor (H2) to the 
modified isoniazid carbonyl acceptor (O1). The amide hydrogen of the modified isoniazid 
provides the other hydrogen bond donor (H1A) with the carbonyl carbon of the mHBA 
carboxylic acid group being the acceptor. This is highly unusual as the amide hydrogen is 
usually masked from intermolecular interactions by the steric effects of the benzophenone 
modifier. To date, this is the only reported structure of isoniazid which has been modified with a 
benzophenone modifier where the amide hydrogen is not masked. This unusual interaction 
occurs because the small size and planar geometry of the mHBA allows the mHBA to align itself 
in a plane which is fairly well aligned to the plane of the strerically blocking benzophenone ring 
with an acute angle of 29.33° between the two planes. This allows the mHBA to “sneak in” 
between the pyridine ring and the benzophenone ring and hydrogen bond to the amide hydrogen 
atom (Figure 6b). 
 
In co-crystal IIIb, there is therefore a marked deviation in the hydrogen bonding and packing 
arrangements of the co-crystal from the patterns expected from literature. It has been 
demonstrated that the presence of additives during a crystallization process will invariably affect 
the morphology and crystal structure during crystallization.
21,22
 The frequent variation found in 
crystal morphology and structure as a result of changes in stoichiometry of the reagents during 
crystallization may be understood if one considers an excess of one of the reagents as an 
additive. In this sense, the change of ratio of isoniazid : 4-methylbenzophenone : mHBA from 
1:1:1 in IIIa to 1:1:1.6 in IIIb should be seen as the addition of a mole ratio of 0.6 mHBA as an 
additive, and if one considers the profound impact of additives on crystal structure as decribed 
by Lahav
21,22
 then the large variation in crystal structure between IIIa and IIIb is therefore not 
unexpected. Changing the reagent stoichimetry during co-crystallization could thus be a rich 
source of polymorphs and certainly warrants further investigation. 
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Figure 5: Packing diagram of IIIa, which is isostructural to the packing of II. 
  
         (a)       (b) 
Figure 6: Packing of IIIb. Part (a) shows the almost square tube formed along the c-axis with an 
angle of 85.41° between the plane of the modified isoniazid pyridine ring and the mHBA plane. 
Part (b) shows the orientation of the mHBA molecule relative to the sterically hindering 
benzophenone ring, allowing the mHBA molecule to “sneak in” between the pyridine ring and 
benzophenone ring to hydrogen bond to the amide hydrogen atom. 
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Presence or absence of a catalyst in the covalent modification of Isoniazid during one-pot 
synthesis 
 
In co-crystals IV and V, isoniazid was modified with 4-aminobenzophenone, and co-crystallized 
with pHBA. The ratio of isoniazid : 4-aminobenzophenone : pHBA used in the one-pot synthesis 
was 1:1:1. A drop of concentrated HCl was added to the reaction solution of IV to catalyze the 
condensation reaction of isonicotinic acid hydrazide and 4-aminobenzophenone followed by 
work-up with sodium bicarbonate and filtration. V was allowed to react without the catalyst. All 
other reaction and crystallizing conditions remaining the same. Therefore, the only substantial 
change to the synthetic method of the two co-crystals was the use of a catalyst in IV, and the 
absence thereof in V. The presence of the catalyst in IV prevented the formation of a solvate, 
whereas in co-crystal V, the solvate was formed. 
 
Compound IV crystallizes in the P  space group. The asymmetric unit contains one modified 
isoniazid molecule and one pHBA molecule. In the asymmetric unit, the modified isoniazid is 
hydrogen bonded to the pHBA molecule via an COOH···Npyr heterosynthon. Co-crystal IV 
packs in a three dimensional (3D) network with extensive hydrogen bonding. Apart from the 
amide funcional group of the modified isoniazid, which is effectively masked by the steric 
effects of the benzophenone modifier, every potential hydrogen bonding atom on the modified 
isoniazid, as well as every potential hydrogen bonding atom on the pHBA is involved in 
hydrogen bonding. Each modified isoniazid molecule is hydrogen bonded to five different 
molecules. Three of its atoms act as hydrogen bond acceptors: 1) the pyridine nitrogen (N1) is 
hydrogen bonded to the carboxylic acid group donor (H2) of a pHBA molecule via the robust 
COOH···Npyr heterosynthon. 2) its amine nitrogen to the phenol hydrogen (H4) of pHBA. 3) its 
carbonyl oxygen (O1) to one of the amine hydrogens (H4B) of an adjacent modified isoniazid 
molecule. Both amine hydrogens act as hydrogen bond donors: 1) H4A hydrogen bonds to the 
carbonyl oxygen of the carboxylic acid group of a pHBA molecule. 2) H4B to the carbonyl of a 
modified isoniazid (Figure 7). Each pHBA is hydrogen bonded to three modified isoniazid 
molecules via O3, H2 and H4 in the synthons described in the hydrogen bonding description of 
the modified isoniazid above. 
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Figure 7: Packing diagram of IV showing the extensive hydrogen bonded 3D network. Apart 
from the amide functional group, which is masked by the benzophenone ring, every potential 
hydrogen bonding atom in the modified isoniazid, as well as in pHBA, is involved in hydrogen 
bonding. 
 
 
Compound V crystallizes in the P  space group. The asymmetric unit contains one modified 
isoniazid molecule, one pHBA molecule and one methanol molecule (a solvate of IV). The 
modified isoniazid is hydrogen bonded to the pHBA molecule via an COOH···Npyr 
heterosynthon. The pHBA phenol hydrogen donor atom (H4) is hydrogen bonded to the 
methanol oxygen atom (O5). Co-crystal V packs in a one dimensional (1D) ribbon. Each 
modified isoniazid forms a dimer with another modified isoniazid molecule where the carbonyl 
of one molecule is hydrogen bonded to an amine hydrogen of another, forming an an  2
2 22  
ring. Unlike co-crystal IV, only one of the amine hydrogens is involved in hydrogen bonding. 
There is a centre of inversion about the centre of the ring. A tetramer, consisting of two pHBA 
and two methanol molecules is also formed, with pHBA and methanol alternating. The methanol 
hydroxyl hydrogen is hydrogen bonded to the carbonyl oxygen of the carboxylic acid group of 
pHBA and the methanol oxygen is hydrogen bonded to the phenol hydrogen of another pHBA 
molecule to form an  4
4 20  ring with a centre of inversion in the centre of the ring. Each 
modified isoniazid dimer is connected to a pHBA tetramer through an COOH···Npyr 
heterosynthon (Figure 8). 
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Figure 8: Packing diagram of V showing the 1D ribbon. Apart from the amide functional group, 
which is masked by the benzophenone ring, every potential hydrogen bonding atom in the 
modified isoniazid, as well as in pHBA, is involved in hydrogen bonding. 
 
 
Addition of substituent to benzophenone ring 
 
In co-crystals VI and VII, isoniazid was modified with 4-methylbenzophenone and 4,4’-
dimethylbenzophenone respectively, and co-crystallized with pHBA. For VI and VII, the ratio of 
isoniazid : 4-methylbenzophenone / 4,4’-dimethylbenzophenone : pHBA used in the one-pot 
synthesis was 1:1:2. All reaction and crystallizing conditions remaining the same. Therefore, the 
only substantial change to the synthetic method of the two co-crystals was the addition of a 
methyl group on one of the benzophenone rings.  
 
Co-crystal VI and VII are isostructural (Figure 9(a) and (b)). Both crystallize in the P  space 
group and each asymmetric unit contains one modified isoniazid molecule and two pHBA 
molecules. In the asymmetric unit, the modified isoniazid is hydrogen bonded to one of the 
pHBA molecules via the expected COOH···Npyr heterosynthon. This pHBA is also hydrogen 
bonded to the second pHBA molecule through the carbonyl oxygen (O3) of its carboxylic acid 
group to the phenol hydrogen donor atom (H7) of the second pHBA molecule (Figure 2). VI and 
VII pack into a thick one dimensional (1D) tape with all of the modified isoniazid molecules on 
the edge of the tape and all the pHBA molecules forming a four molecule thick arrangement of 
pHBA molecules in the centre of the tape. Thus, the modified isoniazid and pHBA molecules 
(which have a 1:2 ratio in the asymmetric unit) form a six-molecule thick tape with the 
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arrangement I-p-p-p-p-I (where I denotes modified isoniazid and p denotes pHBA) (Figure 9(c)). 
Each modified isoniazid molecule is hydrogen bonded to two pHBA molecules, one in which its 
carbonyl oxygen (O1) acts as the acceptor to the phenol hydrogen bond donor atom (H5) of a 
pHBA molecule, and secondly, in which its pyridine nitrogen atom accepts hydrogen bonding 
from the carboxylic acid group hydrogen of another pHBA molecule. Each of these pHBA 
molecules is the first pHBA molecule in a chain of four pHBA molecules which form the centre 
of the tape. The first pHBA molecule hydrogen bonds to the second via its carboxylic acid group 
carbonyl oxygen (O3). The two centre pHBA molecules are hydrogen bonded to each other 
through a robust COOH···COOH homosynthon, forming a  2
2 8  ring. The other half of the tape 
is the symmetrical inverse of the half which has been described, with the centre of symmetry 
about the centre of the  2
2 8  ring. 
 
The crystal structures of II and IIIa have already been discussed. However, it should be 
mentioned here that in co-crystals II and IIIa, their method of synthesis was kept constant 
except that a methyl group to one of the benzophenone rings in IIIa. As with co-crystals VI and 
VII, the addition of an additional methyl group to the benzophenone modifier did not affect the 
supramolecular synthesis. To summarize the addition of benzophenone rings, in II, 
benzophenone was used as a modifier and in IIIa, 4-methylbenzophenone was used, and the 
resulting co-crystals were isostructural. In VI, 4-methylbenzophenone was used as the modifier, 
and in VII, 4,4-dimethylbenzophenone was used, and the resulting co-crystals VI and VII were 
also isostructural. Therefore, the addition of a methyl substituent to the benzophnone modifiers 
has no effect on the supramolecular outcome. 
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(a)  
 
 
(b) 
 
                   (c) 
 
Figure 9:  Parts (a) and (b) show the isostructural packing of VI and VII respectively. Part (c) 
shows how the molecules of the co-crystal pack into a tape with all the modified isoniazid 
molecules on the edge of the tape and all the pHBA molecules in the centre of the tape. 
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In summary, therefore, in this study, any small change in the reaction and crystallization 
conditions had a big effect on the outcome of crystallization, whereas changing a substituent on a 
molecule did not. For masked isoniazid molecules, it would thus appear that small changes in the 
crystallization and reaction conditons play a bigger role in the resulting supramolecular structure 
than the addition of small substituents or making small changes to the molecules themselves. 
 
 
Conclusion 
 
Eight co-crystals of isoniazid which have modified by benzophenone or a derivative thereof, 
were co-crystallized with either 3- or 4-hydroxybenzoic acid. The co-crystals were divided into 
pairs and all crystallization conditions were kept constant except for one substantial change in 
crystallization conditions being made per pair. Pairs of co-crystals were then compared and the 
results are tabulated in Table 4.  
 
Table 4 A summary of the changes made to the crystallization conditions and the effect of the 
change of the outcome of supramolecular synthesis. 
 
Co-crystals compared 
 
 
Change made to reaction or  
crystallization conditions 
Effects of change on outcome of 
supramolecular synthesis 
I and II 
Reflux time in one-pot synthesis was 
changed 
Stoichiometric variation of the products 
resulted 
IIIa and IIIb 
The stoichiometry of reagents was 
changed to create an “additive” 
Polymorphs were formed 
IV and V 
A acid catalyst was added to the one-pot 
synthesis 
A solvate was formed in one structure and 
prevented in the other 
VI and VII 
A second methyl group was added to the 
benzophenone rings (one methyl group on 
each ring) 
No effect on supramolecular structure 
II and IIIa 
An extra methyl group was added to a 
benzophenone ring 
No effect on supramolecular structure 
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Where a small change was made to the reaction conditions, a large change in the hydrogen 
bonding and packing arrangements resulted. A change in reflux time of the one-pot synthesis 
resulted in stoichiometric variation of the products. The addition of extra co-former reagent as an 
“additive” resulted in polymorphism, where hydrogen bonding through different heterosynthons 
was observed, as well as a change in dimensionality of the packing. Adding an acid catalyst to 
catalyze the modification of isoniazid prevented the formation of a solvate, whereas in the 
absence of the catalyst, the solvate was formed. On the other hand, adding either one or two 
methyl groups to the benzophenone had no effect on the supramolecular structure, and both pairs 
where the number of methyl groups were varied were isostructural. Thus, in this study, the 
changes in reaction and crystallization conditions had a bigger effect on the supramolecular 
structure than changing small substituents on the reagents. 
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Chapter 5:  Crystal engineering of isoniazid 
 
5.1 Introduction 
 
Isoniazid was covalently modified with bulky benzophenone and benzophenone derivative 
modifiers in the absence of co-formers. This chapter details the synthesis of the crystals and a 
structural study of crystalline covalently modified isoniazid molecules is reported. 
Details of the publication status of the paper precede the paper. 
  
122 
 
5.2 Synthesis and structural study of crystalline isoniazid derivatives with 
benzophenone modifiers 
 
 
Title of paper: Synthesis and structural study of crystalline isoniazid derivatives with 
benzophenone modifiers 
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Synopsis of Paper 
In this paper, ten crystalline derivatives of isonicotinic acid hydrazide (isoniazid) that have been 
covalently modified with bulky benzophenone and benzophenone derivative modifiers have been 
synthesized and structurally characterized. 
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Table 5.1: List of compounds reported in chapter 5.2  
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ABSTRACT:   
Isonicotinic acid hydrazide (isoniazid) has been covalently modified with bulky benzophenone 
and benzophenone derivatives to yield a series of potentially pharmaceutically active Schiff 
bases. The acid-catalyzed condensation reaction between isoniazid and the modifiers yielded ten  
crystalline isoniazid derivatives, including one salt solvate, namely: 
 N’-(diphenylmethylene)isonicotinohydrazide, C19H15N3O, (I), 
 (E)-N’-(phenyl(p-tolyl)methylene)isonicotinohydrazide), C20H17N3O, (II), 
 N’-(di-p-tolylmethylene)isonicotinohydrazide monohydrate, C21H19N3O·H2O, (III), 
 (E)-N’-(phenyl(p-hydroxy)methylene)isonicotinohydrazide), C19H15N3O2, (IV), 
 N’-(bis(2-hydroxyphenyl)methylene)isonicotinohydrazide, C19H15N3O3, (V), 
 N’-(di-p-tolylmethylene)isonicotinohydrazide chloride salt dihydrate, C19H15N3O3
+
 
·H2O·Cl
-
, (VI), 
 N’-(bis(2-hydroxy-4-methoxyphenyl)methylene)isonicotinohydrazide, C21H19N3O5, (VII), 
 (E)-N’-(4-aminophenyl(phenyl)methylene)isonicotinohydrazide), C19H16N4O, (VIII), 
 N’-(bis(4-aminophenyl)methylene)isonicotinohydrazide), C19H17N5O, (IX),  and 
(E)-N’-((4-(dimethylamino)phenyl)(phenyl)methylene)isonicotinohydrazide), C20H20N4O2, (X).  
The choice of acid catalyst for the synthesis was dependent on the nature of the substituents on 
the benzophenone rings. The synthesis of these Schiff bases is described and a full structural 
study of these isoniazid derivatives is reported. 
  
 
 
KEYWORDS:   
Isoniazid, Crystal engineering, Benzophenone,  Mycobacterium  Tuberculosis drugs 
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Introduction 
 
The covalent modification of isonicotinic acid hydrazide (isoniazid) via the replacement of the 
NH2 hydrogen atoms with ketone modifiers is the primary focus in the synthesis of medicines 
that target drug-resistant strains of tuberculosis. This covalent modification prevents the enzymes 
of the Mycobacterium tuberculosis bacteria (TB) from rendering the drug ineffective (Hearn et 
al., 2009). Hearn et al. prepared a series of Schiff bases of isoniazid and compared the biological 
activity of pure isoniazid with that of covalently modified isoniazid on mice. Hearn 
demonstrated that the NH2 functional group of isoniazid is subject to deactivating acetylation by 
a class of enzymes known as N-arylaminoacetyl transferases (NATs). He explained that this 
deactivation is the reason for the resistance of the tuberculosis bacteria against isoniazid. 
However, if the isoniazid drug is modified by the covalent modification of the isoniazid to form 
Schiff bases (Figure 1), the enzymatic deactivation process no longer works to deactivate the 
drug and the resulting modified isoniazid can be effective for the treatment of multi-drug 
resistant strains of the bacteria. Hearn et al. prepared 46 Schiff bases of isoniazid and found that 
in nearly all of them, the biological activity of the drug was effective against multidrug-resistant 
strains of TB. When the Schiff bases were crystallized, the drugs were reported to be pure. In his 
conclusion Hearn noted that “Schiff bases [of isoniazid (INH)] may serve as discovery tools in 
probing INH-based treatment modalities, particularly for those patients chronically underdosed 
in conventional INH therapy.” (Hearn et al., 2009). 
N
H
NO
NH2
N
H
NO N C
R1
R2
 
       (a)         (b) 
Figure 1: (a) Isoniazid. (b) The general structure of the Schiff bases prepared and tested by 
Hearn et al. (Hearn et al., 2009) 
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Coelho et al. prepared a series of 23 N-acylhydrazones derived from isoniazid and determined 
the biological activity of those modified isoniazid derivatives. Thirteen of the modified isoniazid 
products showed a more than 10-fold higher biological activity against katG-resistant strains of 
M. tuberculosis (Coelho et al., 2012). 
In Smith et al. (Smith et al., 2015), isoniazid was modified with a series of benzophenone 
derivatives and co-crystallized with 2-hydroxybenzoic acid. The predictable “masking” of the 
amide functionality was achieved, and it was shown that the bulky benzophenone modifiers 
rendered the amide nitrogen atom inaccessible for hydrogen bonding and no short intermolecular 
contacts were present between the amide nitrogen atoms in “masked” isoniazid derivatives and 
any neighbouring isoniazid or 2-hydroxybenzoic acid atoms. Sevukarajan et al. synthesized a co-
crystal of isoniazid with L(+) tartaric acid and observed that with this particular co-former, 
solubility decreased and the anti-tubercular activity decreased as compared with pure isoniazid 
(Sevukarajan et al., 2011). In contrast, Aitipamula et al. synthesized a ternary co-crystallization 
of isoniazid with nicotinamide and succinic acid and reported that the in co-crystal, the solubility 
was increased compared with pure isoniazid (Aitipamula et al., 2013). It is clear that the 
solubility and activity of isoniazid and modified isoniazid against tuberculosis may either 
increase or decrease with a co-former in its supramolecular structure, but may be more effective 
in the absence of a co-former.  
This report contains a structural study of isoniazid that has been modified with bulky 
benzophenone and benzophenone derivatives to form Schiff bases in the absence of any co-
formers. 
 
Experimental Methods 
Nˈ-(diphenylmethylene)isonicotinohydrazide, I 
0.0920 g of isonicotinic acid hydrazide (0.671 mmol) and 0.1202 g of benzophenone (0.6596 
mmol) were added into a sample vial. 0.0111 g of p-toluenesulphonic acid monohydrate (0.0584 
mmol) was added to catalyze the reaction. The solids were dissolved in 3 mL of a 1:1 mixture of 
AP-grade 1,2-dichloroethane and 1,1,1-trichloroethane and refluxed in a closed sealed screw-top 
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vial for 72 hours at 50°C, and were left to stand at room temperature very slightly opened to the 
atmosphere. Colourless needles were afforded after 3 days.  
 
 (E)-Nˈ-(phenyl(p-tolyl)methylene)isonicotinohydrazide), II 
0.0964 g of isonicotinic acid hydrazide (0.703 mmol) and 0.1386 g of 4-methylbenzophenone 
(0.7062 mmol) were added into a sample vial. 0.0124 g of p-toluenesulphonic acid monohydrate 
(0.0652 mmol) was added to catalyze the reaction. The solids were dissolved in 3 mL of a 2:1 
mixture of AP-grade ethanol and acetonitrile and refluxed in a closed sealed screw-top vial for 5 
days at 110°C, and were left to stand at room temperature very slightly opened to the 
atmosphere. Colourless needles were afforded after 3 days.  
 
N’-(di-p-tolylmethylene)isonicotinohydrazide monohydrate, III 
0.1197 g of isonicotinic acid hydrazide (0.8728 mmol) and 0.1841 g of 4,4-
dimethylbenzophenone (0.8755 mmol) were added into a sample vial. 1 drop of 5M hydrochloric 
acid was added to catalyze the reaction. The solids were dissolved in 3 mL of methanol and 
refluxed in a closed sealed screw-top vial for 3 days at room temperature, followed by work-up 
with sodium bicarbonate: the solution was saturated with sodium bicarbonate, stirred for 5 
minutes and then filtered. The filtered solution was then left to stand at room temperature very 
slightly opened to the atmosphere. Yellow plates were afforded after 3 days.  
 
(E)-Nˈ-(phenyl(p-hydroxy)methylene)isonicotinohydrazide), IV 
0.0975 g of isonicotinic acid hydrazide (0.711 mmol) and 0.1410 g of 4-hydroxybenzophenone 
(0.7113 mmol) were added into a sample vial. 0.0981 g of p-hydroxybenzoic acid (0.0981 mmol) 
was added to catalyze the reaction. The solids were dissolved in 3 mL of AP-grade methanol and 
refluxed in a closed sealed screw-top vial for 24 hours at 67°C, and were left to stand at room 
temperature very slightly opened to the atmosphere. Colourless needles were afforded after 3 
days.  
 
Nˈ-(bis(2-hydroxyphenyl)methylene)isonicotinohydrazide, V 
0.0857 g of isonicotinic acid hydrazide (0.625 mmol) and 0.1340 g of 2,2’-
dihydroxybenzophenone (0.6255 mmol) were added into a sample vial. 0.0864 g of p-
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hydroxybenzoic acid (0.626 mmol) was added to catalyze the reaction. The solids were dissolved 
in 3 mL of AP-grade methanol and refluxed in a closed sealed screw-top vial for 24 hours at 
67°C, and were left to stand at room temperature very slightly opened to the atmosphere. Yellow 
plates were afforded after 3 days.  
 
 
N'-(di-p-tolylmethylene)isonicotinohydrazide, chloride salt dihydrate, VI 
0.1094 g of isonicotinic acid hydrazide (0.7977 mmol) and 0.1737 g of 2,2’-
dihydroxybenzophenone (0.8108 mmol) were added into a sample vial. 0.1202 g of salicylic acid 
(0.8702 mmol) was added to catalyze the reaction. The solids were dissolved in 3 mL of a 1:1 
mixture of 1,2-dichloroethane and AP-grade methanol and refluxed in a closed sealed screw-top 
vial for 6 hours at 70°C, and were left to stand at room temperature very slightly opened to the 
atmosphere. Yellow plates were afforded after 3 days.  
 
 
N'-(bis(2-hydroxy-4-methoxyphenyl)methylene)isonicotinohydrazide, VII 
0.0710 g of isonicotinic acid hydrazide (0.518 mmol) and 0.1425 g of 2,2’-dihydroxy-4,4’-
dimethoxybenzophenone (0.5196 mmol) were added into a sample vial. 0.0728 g of salicylic 
acid (0.527 mmol) and 0.0195 g p-toluenesulphonic acid monohydrate (0.103 mmol) were added 
to catalyze the reaction. The solids were dissolved in 10 mL of a ethanol and refluxed in a closed 
sealed screw-top vial for 48 hours at 90°C, and were left to stand at room temperature very 
slightly opened to the atmosphere. Yellow needles were afforded after 5 days.  
 
 
(E)-Nˈ-(4-aminophenyl(phenyl)methylene)isonicotinohydrazide), VIII 
0.0995 g of isonicotinic acid hydrazide (0.726 mmol) and 0.1441 g of 4-aminobenzophenone 
(0.7306 mmol) were added into a sample vial. 0.0159 g of p-toluenesulphonic acid monohydrate 
(0.0836 mmol) was added to catalyze the reaction. The solids were dissolved in 3 mL of AP-
grade methanol and refluxed in a closed sealed screw-top vial for 72 hours at 125°C, and were 
left to stand at room temperature very slightly opened to the atmosphere. Colourless blocks were 
afforded after 3 days.  
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Nˈ-(bis(4-aminophenyl)methylene)isonicotinohydrazide), IX 
0.0540 g of isonicotinic acid hydrazide (0.394 mmol) and 0.0749 g of 4,4’-
diaminobenzophenone (0.353 mmol) were added into a sample vial. 0.0176 g of p-
toluenesulphonic acid monohydrate (0.0925 mmol) was added to catalyze the reaction. The 
solids were dissolved in 3 mL of AP-grade methanol and refluxed in a closed sealed screw-top 
vial for 72 hours at 100°C, and were left to stand at room temperature very slightly opened to the 
atmosphere. Red blocks were afforded after 3 days.  
 
 
(E)-N'-((4-(dimethylamino)phenyl)(phenyl)methylene)isonicotinohydrazide), X 
0.1043 g of isonicotinic acid hydrazide (0.7605 mmol) and 0.1732 g of 4-
(dimethylamino)benzophenone (0.7688 mmol) were added into a sample vial. 0.0232 g of p-
toluenesulphonic acid monohydrate (0.122 mmol) was added to catalyze the reaction. The solids 
were dissolved in 3 mL of a methanol and refluxed in a closed sealed screw-top vial for 72 hours 
at 100°C, and were left to stand at room temperature very slightly opened to the atmosphere. 
Yellow blocks were afforded after 3 days.  
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Crystal Data and X-ray Structure Analysis.  
 
Intensity data for the ten crystal structures were collected on a Bruker APEX II CCD area 
detector diffractometer with graphite monochromated Mo-Kα radiation (50 kV, 30 mA) at 173K. 
The collection method involved ω-scans with a 0.5° width. SAINT+ version 6.02.6 software was 
used for data reduction and SADABS was used to make empirical absorption corrections (Bruker, 
2004). The crystal structures were solved using direct methods on SHELXS-97 (Sheldrick, 2015). 
Non-hydrogen atoms were first refined isotropically, followed by anisotropic refinement by full 
matrix least-squares calculations based on F
2
 using SHELXL-2017 (Sheldrick, 2015). C-bound H 
atoms were located in the difference electron density map, then positioned geometrically and 
were allowed to ride on their respective parent atoms, with thermal displacement parameters 1.2 
times that of the parent C atom. The diffraction data and refinement statistics of crystal X was 
poor even after numerous attempts at recrystallization. Diagrams and publication material were 
generated using WinGX (Farrugia, 2012), ORTEP-3 (Farrugia, 2012), PLATON (Spek, 2009) and 
MERCURY (Macrae, C. F. et al., 2008). The crystallographic data of each crystal is summarized 
in Table 1 and the hydrogen bonding geometries in Table 2. 
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Table 1 Crystallographic data for compounds I-X 
 I II III IV V 
Formula C19H15N3O C20H17N3O C21H19N3O·H2O C19H15N3O2 C19H15N3O3 
Mr 301.34 
 
315.36 347.41 317.34 333.34 
Temperature/K 173(2) 173(2) 173(2) 173(2) 173(2) 
Wavelength/Å 0.71073 0.71073 0.71073 0.71073 0.71073 
Crystal size/mm3 0.226×0.324×0.522 0.066×0.091×0.325 0.084×0.169×0.384 0.072×0.103×0.395 0.242×0.419×0.521 
Crystal system Orthorhombic Triclinic Monoclinic Orthorhombic Monoclinic 
Space group P212121 P1 P21/c P212121 C2/c 
a/Å 9.7738(4) 7.1641(7) 21.3512(13) 9.8650(5) 20.6917(6) 
b/Å 9.9605(5) 10.7669(10) 5.9227(4) 9.9131(5) 10.1392(3) 
c/Å 15.8005(7) 12.0237(10) 14.8729(11) 15.8923(7) 16.9544(5) 
α/° 90 64.009(4) 90 90 90 
β/° 90 82.346(5) 106.040(6) 90 115.7390 
γ/° 90 82.885(5) 90 90 90 
V/Å3 1538.21(12) 823.99(13) 1807.6(2) 1554.15(13) 3204.07(16) 
Z 4 2 4 4 8 
ρ (calcd)/Mg m-3 1.301 1.271 1.277 1.356 1.382 
μ/mm-1 0.083 0.081 0.084 0.091 0.096 
F(000) 632 332 736 664 1392 
ϴ Range for data 
collection/° 
2.417 to 27.989 1.892 to 25.495 1.985 to 25.491 2.421 to 27.992 2.185 to 27.995 
Reflections collected 27237 9199 10908 8892 23999 
No. of unique data 
[R(int)] 
3710 [0.0421] 3066 [0.0755] 3256 [0.1805] 3455 [0.0400] 3872 [0.0371] 
] 
   No. data with I ≥ 2σ(I) 3496 1430 1139 2913 3340 
Final R(I ≥ 2σ(I)) 0.0309 0.0627 0.0521 0.0410 0.0375 
Final wR2 (all data) 0.0816 0.1525 0.1103 0.0970 0.1054 
CCDC deposition 
number 
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 VI VII VIII IX X 
Formula C19H15N3O3
+
 
·H2O·Cl
- 
C21H19N3O5 C19H16N4O C19H17N5O C20H20N4O2 
Mr 387.81 393.39 316.36 331.38 348.40 
Temperature/K 173(2) 173(2) 173(2) 173(2) 173(2) 
Wavelength/Å 0.71073 0.71073 0.71073 0.71073 0.71073 
Crystal size/mm3 0.082×0.160×0.393 0.063×0.125×0.821 0.211×0.322×0.689 0.118×0.242×0.306 0.093×0.196×0.256 
Crystal system Orthorhombic Monoclininc Monoclinic Monoclinic Monoclinic 
Space group Pca21 P21/c P21/c P21/c Cc 
a/Å 8.0689(2) 17.1398(12) 9.2605(3) 9.3882(2) 13.200(2) 
b/Å 10.7998(2) 14.5323(10) 15.4712(5) 15.8901(4) 13.698(2) 
c/Å 42.4741(10) 7.9026(6) 12.0003(4) 11.7784(3) 39.908(7) 
α/° 90 90 90 90 90 
β/° 90 91.731(4) 111.6250(10) 111.6510(10) 97.004(5) 
γ/° 90 90 90 90 90 
V/Å3 3701.30(14) 1967.5(2) 1598.28(9) 1633.13(7) 7162(2) 
Z 8 4 4 4 16 
ρ (calcd)/Mg m-3 1.392 1.328 1.315 1.348 1.292 
μ/mm-1 0.237 0.096 0.085 0.088 0.086 
F(000) 1616 824 664 696 2944 
ϴ Range for data 
collection/° 
1.886 to 27.998 1.838 to 27.997 2.251 to 27.996 2.259 to 27.990 2.76 to 26.36 
Reflections collected 23895 18049 23604 22908 17910 
No. of unique data 
[R(int)] 
8160 [0.0792] 4753 [0.0908] 3841 [0.0541] 3936 [0.0592] 10563 [0.0512] 
   No. data with I ≥ 2σ(I) 6067 2587 3221 3329 7867 
Final R(I ≥ 2σ(I)) 0.0543 0.0567 0.0602 0.0423 0.1265 
Final wR2 (all data) 0.1437 0.1549 0.1438 0.1159 0.4207 
CCDC deposition 
number 
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Table 2 Hydrogen bonding details of compounds I-X 
 d(D─H)/Å d(H···A)/Å d(D···A)/Å ∠(D─H···A)/° 
I     
 N1-H1···N2a 0.85(2) 2.32(2) 3.0568(19) 146(2) 
 N1-H1···N2a 0.85(2) 2.32(2) 3.0568(19) 146(2) 
III     
N1-H1···O1W 0.95(3) 2.00(4) 2.935(4) 166(3) 
 O1W-H1W···N2b 0.85 1.98 2.799(4) 163 
O1W-H2W···O1c 0.85 2.55 3.034(4) 117 
IV     
 C3-H3···O2Bd 0.95 2.41 3.261(19) 149 
 O2B-H2B···O1e 0.84 1.93 2.773(19) 176 
 C12-H12···O2Af 0.95 2.59 3.405(3) 144 
 O2A-H2A···O1d 0.84 1.87 2.703(3) 169 
 C18-H18···O2Bg 0.95 2.50 3.351(16) 150 
 N1-H1···N2h 0.88 2.35 2.990(3) 130 
V     
 N1-H1···O2i 0.88 2.22 2.8802(12) 132 
 O2-H2···N2j 0.84 1.83 2.6526(13) 165 
 O3-H3···N3 0.84 1.85 2.5807(12) 145 
VI     
 C4-H4A···Cl2k 0.95 2.77 3.485(6) 133 
 C4-H4A···Cl2l 0.95 2.69 3.343(5) 127 
 N1-H1···O1l 0.88 1.99 2.808(5) 155 
 N2-H2···Cl1l 0.88 2.29 3.083(4) 151 
 O2-H2A···Cl2 0.84 2.22 3.050(3) 171 
 O3-H3···N3 0.84 1.89 2.609(5) 144 
 C22-H22···Cl2m 0.95 2.68 3.386(5) 132 
 N4-H4···O4n 0.88 2.02 2.845(5) 156 
 N5-H5···O2Wo 0.88 1.81 2.684(5) 173 
 O5-H5A···O1Wm 0.84 1.88 2.714(5) 176 
 O6-H6···N6 0.84 1.91 2.617(5) 141 
 O1W-H1W···Cl1l 0.859(14) 2.31(2) 3.150(4) 166(7) 
 O1W-H2W···Cl1 0.856(14) 2.284(15) 3.140(4) 178(7) 
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a
 x+1/2,-y+1/2,-z+2. 
b
 -x+1,y+1/2,-z+1/2. 
c
 x,-y+3/2,z-1/2. 
d
 -x+3/2,-y+2,z-1/2.
 e
 x,y+1,z.
 f
 -x+1,y+1/2,-z+1/2.
  
g
 -x+3/2,-y+3,z-1/2.
 h
 -x+2,y+1/2,-z+1/2.
 i
 -x,y,-z+1/2.
 j
 x+1/2,-y+3/2,z+1/2.
 k
 x,y-1,z. 
l
 x+1/2,-y,z. 
m
 -x+1/2,y,z-1/2.  
n
 x+1/2,-y+1,z.
 o
 -x+1,-y+1,z-1/2.
 p
 -x,y-1/2,-z+1/2.
 q
 -x+1,-y+1,-z+2.
 r
 x,-y+1/2,z-1/2. 
s
 x+1,y,z.
  
t
 -x+2,y+1/2,-z+3/2.
 u
 -x,-y,-z+1.
 v
 x-1,y,z. 
w
 x,-y+1/2,z+1/2. 
x
 -x-1,y-1/2,-z+1/2. 
y
 -x+1,-y+1,-z+1. 
z
 x-1,y,z. 
aa
 x,-
y+1/2,-z+1/2. 
ab
 –x-1,y-1/2,-z+1/2. ac -x+1,-y+1,-z+1. 
 
 
 
 
 
 
 
 O2W-H3W···Cl1 0.848(14) 2.408(17) 3.239(4) 166(5) 
 O2W-H4W···Cl2n 0.848(13) 2.52(3) 3.271(4) 149(5) 
VII     
 C10-H10···N2p 0.95 2.68 3.354(3) 128 
 C16-H16···O5q 0.95 2.62 3.511(3) 157 
 O2-H2···N2p 0.84 1.89 2.730(2) 176 
 O4-H4···N3 0.84 1.81 2.535(2) 144 
VIII     
C12-H12···N3r 0.95 2.68 3.596(3) 162 
 N1-H1···N4Bs 0.88 2.58 3.356(4) 148 
 N4A-H4A···O1r 0.95(5) 2.22(5) 3.157(4) 168(4) 
 N4A-H4B···N2t 1.00(5) 2.14(5) 3.093(4) 159(4) 
 N4B-H4D···O1u 0.95(6) 1.86(6) 2.800(5) 168(5) 
IX     
 N(1)-H(1)···N(5)v 0.88 2.41 3.2167(15) 153 
 N(4)-H(4A)···O(1)w 0.882(19) 2.221(19) 3.0644(16) 160(16) 
 N(4)-H(4B)···N(2)x 0.89(2) 2.26(2) 3.0794(16) 153(17) 
 N(5)-H(5B)···O(1)y 0.907(18) 2.024(18) 2.9242(15) 172(16) 
X     
 N(1)-H(1)...N(5)
z
 0.88 2.41 3.2167(15) 152.7 
 N(4)-H(4A)...O(1)
aa
 0.882(19) 2.221(19) 3.0644(16) 160.1(16) 
 N(4)-H(4B)...N(2)
ab
 0.89(2) 2.26(2) 3.0794(16) 153.4(17) 
 N(5)-H(5B)...O(1)
ac
 0.907(18) 2.024(18) 2.9242(15) 171.8(16) 
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Results 
 
The covalent modification of isoniazid with a ketone occurs via an acid-catalyzed condensation 
reaction. The reaction involves the nucleophilic attack on the carbonyl group by the amine 
nitrogen to form an unstable carbinolamine moiety, followed by acid catalyzed dehydration to 
form an imine. This resulting imine is referred to as “modified isoniazid.” However, isoniazid 
does not readily undergo condensation reactions with benzophenone or its derivatives and 
requires harsh reaction conditions and the use of acid catalysts for a successful reaction. Hearn et 
al. observed that stereo-electronic effects often make the covalent modification more difficult 
with bulky modifiers and explained that “with alkyl modifiers larger than methyl in the ketone 
component of the transition state, the conformational preference for the lone pair on N renders 
this nitrogen poorly poised for nucleophilic attack.” (Hearn et al., 2009). The conditions required 
for the reaction generally required significant heating, increased pressure and extended refluxing 
over several days. Glass screw-top, airtight rubber-lined dram vials were used for refluxing. The 
reagents and solvent were added to the vial, a magnetic stirrer bar was added and the top was 
tightly closed and the vial placed on a heater-stirrer. This mimicked a reflux setup on a small 
scale. It also allowed for heating to a temperature considerably higher than that of the boiling 
point of methanol. 
The choice of acid catalyst was also important. In order to avoid salt formation, weak acids were 
chosen, but where these failed, stronger acids were applied. Originally, the covalent modification 
of isoniazid was attempted with the GRAS acids, salicylic acid or p-hydroxybenzoic acid, which 
proved successful only for structures IV and VI. The apparent ease of reaction of isoniazid with 
these two modifiers (4-hydroxybenzophenone and 2,2’-dihydroxybenzophenone) is due to the 
electron withdrawing hydroxyl groups on these molecules rendering the electrophilic carbon 
atom more positive. For all but one of the remaining reactions, p-toluenesulfonic acid proved a 
successful catalyst. As the electron donating nature of the benzophenone substituents increased, 
the required reaction conditions became increasingly harsh. With 4-methylbenzophenone as a 
modifier, reflux at 110°C for 5 days was required with the p-toluenesulfonic acid catalyst. With 
the 4,4’-dimethylbenzophenone modifier, having two electron donating substituents, the reaction 
failed completely and concentrated hydrochloric acid was required for the reaction to occur. 
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            I                       II 
           (a)       (b) 
       
                     III                   IV 
   (c)       (d) 
 
                     V                   VI 
   (e)       (f) 
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                     VII                  VIII 
   (g)       (h) 
         
                    IX                   X 
   (i)       (j) 
 
 
  X 
           (k) 
Figure 2: Asymmetric units (a)-(i) of crystals I-IX, showing the numbering schemes. Part (j) 
shows the numbering scheme of a quarter of the asymmetric unit of crystal X (which has four 
molecules in the asymmetric unit). The complete asymmetric unit of X is shown in (k) without 
atom labels. 
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Compound I crystallizes in the P212121 space group and the asymmetric unit contains one 
molecule of N’-(diphenylmethylene)isonicotinohydrazide, the product of  the covalent 
modification of isoniazid with benzophenone. The modified isoniazid molecules in I hydrogen 
bond to each other via the NHamide···Npyridine heterosynthon (Figure 3) and form one-dimensional 
(1D) ribbons along the a-axis with translational symmetry via a twofold screw axis along the 
crystallographic a-axis, stabilized by π-stacking. The ribbons are formed via chains of seven 
atoms between hydrogen bonds, with graph-set notation  1
1 7  (Bernstein et al., 1995). 
 
Figure 3: Packing diagram of I. One dimensional ribbons extend along the a-axis. 
 
Compound II crystallizes in the P  space group and the asymmetric unit contains one molecule 
of (E)-N’-(phenyl(p-tolyl)methylene)isonicotinohydrazide). The molecules are aligned in parallel 
planes, and held together via multiple weak C−H···O and C−H···N interactions and further 
stabilized via π···π stacking. Each molecule interacts with an adjacent molecule on one side of 
its plane by a carbonyl oxygen atom (O1) that is hydrogen bonded via a weak C−H···O  
interaction to a C−H hydrogen atom (H13) of the non-substituted benzophenone ring on an 
adjacent molecule to form a  2
2 16  ring. The pyridyl nitrogen atom (N2) also interacts with a 
hydrogen atom of the methyl group substituent of the other benzophenone ring of the adjacent 
molecule (H20C) via a weak C−H···N hydrogen bond. On the opposite side of each plane, the 
hydrazide nitrogen (N3) of each molecule is similarly involved in C−H···N hydrogen bonding, 
but to a C−H hydrogen atom on the non-substituted benzophenone ring of the adjacent molecule 
to form a  2
2 10  ring. The packing is further stabilized by π···π stacking to form 1D ribbons 
along the a-axis (Figure 4). 
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 Figure 4: Packing diagram of  II. 
 
Compound III crystallizes in the monoclinic P21/c space group and the asymmetric unit contains 
one molecule of N’-(di-p-tolylmethylene)isonicotinohydrazide and one water molecule. The 
hydrate version of isoniazid molecules that have been covalently modified via reaction with 
ketones are common, as the water molecule is a byproduct of the acid-catalyzed condensation 
reaction. This reaction occurs via nucleophilic attack on the carbonyl group by the amine 
nitrogen to form an unstable carbinolamine moiety, followed by acid catalyzed dehydration to 
form an imine (Xavier and Srividhya, 2014). In the asymmetric unit the hydrogen bond occurs 
between the amide nitrogen atom (H1) and the water oxygen atom (O1W). The packing of III is 
a three-dimensional (3D) network with all molecules being hydrogen bonded to water. Each 
water molecule has three hydrogen bonds and an O−H···π interaction. The bonding of the 
carbonyl oxygen atom acceptor of the modified isoniazid molecule is bifurcated and hydrogen 
bonds to both water hydrogen donors. One of the water hydrogen atoms is also hydrogen bonded 
to the isoniazid pyridine nitrogen acceptor atom (Figure 5a). The other water hydrogen atom 
forms an O−H···π interaction with one of the benzophenone rings on an adjacent modified 
isoniazid molecule (Figure 5b). The oxygen atom of this water molecule acts as a hydrogen 
bond acceptor to the amide N−H donor atom. The packing is further stabilized by π···π stacking 
of the pyridyl rings along the c-axis. 
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(a) 
 
(b) 
Figure 5: Packing diagram of III showing (a) regular heterosynthons of water with modified 
isoniazid and (b) the O−H···π interaction between water and the aromatic benzophenone ring. 
142 
 
 
Compound IV crystallizes in the orthorhombic P212121 space group and the asymmetric unit 
contains one molecule of (E)-N’-(phenyl(p-hydroxy)methylene)isonicotinohydrazide). Each 
molecule has three hydrogen bonding sites, resulting in a 3D packing network. The hydrogen 
bonding of each molecule involves its hydroxyl group, carbonyl oxygen atom and either a 
pyridyl nitrogen acceptor atom or the amide N−H donor. The hydroxyl donor on each molecule 
is hydrogen bonded to the carbonyl oxygen atom of an adjacent atom, and the amide hydrogen 
atom is bonded to the pyridyl nitrogen atom of an adjacent molecule (Figure 6). The hydroxyl 
group on the benzophenone ring is disordered. The position of the hydroxyl group is on either of 
the two benzophenone rings, with the major disorder component percentage being 89.143(4) %.  
 
 
Figure 6: Packing diagram of  IV. 
 
Compound V crystallizes in the orthorhombic C2/c space group and the asymmetric unit 
contains one molecule of N’-(bis(2-hydroxyphenyl)methylene)isonicotinohydrazide. There is 
one hydroxyl group on each of the benzophenone rings. As expected from Etter’s rules of 
hydrogen bonding (Etter et al., 1990), one of the hydroxyl groups forms a six-membered 
intramolecular hydrogen bonded ring with the hydrazide nitrogen atom (N3) and is not involved 
in any intermolecular interactions (Figure 2e). The other hydroxyl group is hydrogen bonded to 
the pyridyl nitrogen atom of an adjacent molecule via the robust O−H···Npyridine heterosynthon. 
Its oxygen atom acts as an acceptor to the amide hydrogen atom donor (H1). The packing of V 
forms 1D ribbons with a 21 screw axis. This hydrogen bonding pattern forms two rings, namely 
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an  4
4 18  ring involving four molecules, and an  4
4 14  ring involving three molecules as shown 
in Figure 7b. 
 
       (a) 
 
(b) 
Figure 7: Packing diagram of V, showing (a) the 1D ribbon packing pattern and (b) the two 
rings formed between the four molecules. As there is a center of inversion, the third ring 
appearing on the left of the diagram is simply the inverse of the  4
4 14  ring shown to the right of 
the diagram. 
 
 
Structure VI is a salt solvate of  isoniazid that has been modified with 2,2-
dihydroxybenzophenone to yield N’-(di-p-tolylmethylene)isonicotinohydrazide, chloride salt 
dihydrate. The source of the chloride ions is via an elimination reaction of the 1,2-dichloroethane 
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solvent. The salt crystallizes in the Pca21 space group and the asymmetric unit consists of two 
molecules of N’-(di-p-tolylmethylene)isonicotinohydrazide, two water molecules, and two 
chloride ions. Both modified isoniazid molecules in the asymmetric unit form intramolecular six-
membered hydrogen bonded rings involving one of the hydroxyl groups and the hydrazide 
nitrogen atom (N3). These groups are not involved in intermolecular bonding.  The hydrogen 
atom of the second hydroxyl group of one of the modified isoniazid molecules is hydrogen 
bonded to a chloride ion. This chloride ion is then hydrogen bonded to a water donor atom, 
which is in turn bonded to another chloride ion and then another water molecule to form a five 
molecule long chain (modified isoniazid – chloride – water – chloride – water) (Figure 2f). In 
the packing of structure VI, the acidic proton of the pyridyl salt of one molecule is bonded to a 
chloride ion (one end of the five molecule chain), and the acidic proton of the other modified 
isoniazid molecule is bonded to a water molecule (the other end of the chain.) The extensive 
hydrogen bonding of the water molecules and chloride ions result in a 3D packing network. The 
carbonyl oxygen atom of each modified isoniazid is involved in a C−H···π interaction, 
stabilizing one of the benzophenone rings. : A packing diagram of VI, shown along the b-axis, is 
shown in Figure 8. 
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Figure 8: A packing diagram of VI, shown along the b-axis. 
 
Compound VII crystallizes in the P21/c space group, and the unit cell contains one molecule of 
N’-(bis(2-hydroxy-4-methoxyphenyl)methylene)isonicotinohydrazide. Each ring of the 
benzophenone moiety contains one phenol group in the 2-position and one methoxy group in the 
4-position. In this compound, the amide :N3 lone pair is masked from the donor and acceptor 
hydrogen bond functionalities of adjacent molecules by both the steric effect of the 
benzophenone derivative groups, and by intramolecular hydrogen bonding between the phenol 
donor group in the 2-position of the 2-hydroxyphenyl ring, O4, and the N3 atom to form a six-
membered O4−H4···N3 hydrogen bond. However, one of the phenol groups, O2, has its 
hydrogen atom free to hydrogen bond further, and forms an O2─H2···N1 heterosynthon to the 
pyridyl N1. The carbonyl oxygen, O1 bonds to the amide donor atom H1 of an adjacent 
molecule. These intermolecular bonds result in a 3-dimensional packing network. The methoxy 
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groups are not involved in any intra- or intermolecular interactions. The packing pattern contains 
a twofold rotation and a center of inversion about the centre (Figure 9). 
 
 
Figure 9: The 3D network formed in the packing of crystal VII. 
 
Compound VIII crystallizes in the P21/c space group, and the unit cell contains one molecule of 
(E)-N’-(4-aminophenyl(phenyl)methylene)isonicotinohydrazide). One of the benzophenone rings 
contains an amino group in the 4-position, although the amino group is disordered over the two 
rings, with the major disorder component percentage being 57.239(5) %. Each molecule utilizes 
only two hydrogen bonding sites, namely the carbonyl acceptor, O1 and the amino acceptor, 
H4D, and the two N1─H4D···O1 heterosynthons form zero-dimensional dimers. This hydrogen 
bonding pattern forms an  2
2 22  ring, as shown in Figure 10. 
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Figure 10: The 0D dimers and  2
2 22  ring formed by two modified isoniazid molecules in VIII. 
 
Compound IX crystallizes in the P21/c space group, and the unit cell contains one molecule of 
N’-(bis(4-aminophenyl)methylene)isonicotinohydrazide). Each of the benzophenone rings has an 
amino group in the 4-position. Although crystal IX is similar to VIII, with only an additional 
amino group, the intermolecular interactions are much more extensive. The pyridyl nitrogen N2 
provides a hydrogen bond acceptor for the amino donor, H4B, of an adjacent molecule via a 
regular N4─H4B···N2 heterosynthon. The bonding of the carbonyl oxygen atom on each 
molecule is bifurcated, and bonds to two amino group donors of two different molecules. One 
hydrogen atom of each amino group bonds to the carbonyl acceptor and the other to the pyridyl 
nitrogen of neighbouring molecules, thus forming a 3D packing network. The packing is further 
stabilized by π···π stacking between the benzophenone rings (Figure 11). The same  2
2 22  ring 
found in crystal VIII is also found in IX, but the differences in packing between the two crystals 
are due to the bifurcated bonding of the carbonyl oxygen atom and the involvement of the 
pyridyl nitrogen atom in intermolecular interactions. 
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Figure 11: The packing of IX, showing the π···π stacking of the benzophenone rings and the 
carbonyl-amino and pyridyl-amino heterosynthons. 
 
Compound X crystallizes in the Cc space group and the asymmetric unit contains four molecules 
of (E)-N’-((4-(dimethylamino)phenyl)(phenyl)methylene)isonicotinohydrazide), which will be 
referred to as molecules A-D. Molecule A in the asymmetric unit is hydrogen bonded to 
molecule B via two N−Hamide···Npyridine heterosynthons which form a  2
2 14  ring. There is 
additional π···π stabilization between the pyridyl rings of molecules A and B, which are stacked 
on top of each other. There is an additional weak C−H··· π interaction between one of the 
hydrogen atoms of the pyridyl ring in molecule A to the unsubstituted benzophenone ring in 
molecule B. Molecule B is hydrogen bonded to molecule C solely via three C−H···π 
interactions. The unsubstituted benzophenone ring of molecule B interacts with an N-methyl 
hydrogen atom of the dimethylamino group of molecule C via one of the a C−H···π interactions. 
The second of these interactions is from the N-methyl hydrogen atom of the dimethylamino 
group of molecule B to the substituted benzophenone ring of molecule C, and the third is a 
C−H···π interaction of the same substituted benzophenone ring of molecule C to one of the 
hydrogen atoms on the substituted ring of molecule B. Molecule B then hydrogen bonds to 
molecule D via a weak C−H···O interaction between the carbonyl oxygen of molecule B and one 
of the hydrogen atoms of the unsubstituted benzophenone rings of molecule D (Figure 12a). The 
packing interactions of crystal X consists of  weak C−H···π and C−H···O interactions. In 
addition to the C−H···π interactions already described in the asymmetric units, the bonding of 
the carbonyl oxygen atom acceptor is bifurcated and interacts with two C−H hydrogen donor 
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atoms on the unsubstituted benzophenone ring of an adjacent molecule (Figure 12b). This 
results in a 1D tape packing arrangement at a 45° angle to the a-axis. 
 
 
 
       (a) 
 
       (b) 
Figure 12: Heterosynthons and weak C−H···O and C−H···π hydrogen bonding in crystal X. Part 
(a) shows the interactions in the asymmetric unit of X, and Part (b) shows the packing.  
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Conclusion 
Ten crystalline derivatives of isoniazid, including one salt solvate were synthesized and 
structurally characterized. Structure III is a hydrate, due to the presence of a water molecule 
from the dehydration step of the acid-catalyzed condensation reaction. One chloride salt (VI) 
was afforded due to the presence of chloride ions from the elimination reaction of 1,2-
dichloroethane. The choice of acid catalyst for the synthesis was dependent on the nature of the 
electron withdrawing or electron donating properties of the substituents on the benzophenone 
rings. The synthesized Schiff bases have the desired properties described by Hearn et al. as 
potential agents against multi-drug resistant strains of tuberculosis. 
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Chapter 6:  Photodimerization of Benzophenone and its Derivatives 
6.1 Introduction 
 
This chapter details a new method of synthesizing benzophenone azines via a photodimerization 
process and examines the role of the weak C−H···π packing interactions in their supramolecular 
stucture. The four intermediates of the photodimerization process were also crystallized and their 
crystal structures are discussed. The crystal structure of di-isoniazid azine, an expected by-
product of the photodimerization process, was also described. 
 
 
NOTE ON CRYSTAL STRUCTURES OF MODIFIED ISONIAZID IN THIS CHAPTER: 
Four of the crystals reported in this paper are the same modified isoniazid crystals found in 
Chapter 5. Their descriptions and crystal structures are repeated in this chapter, but for purposes 
of publication, depending on which paper is published first, these will paraphrased and fully 
referenced in the second paper, as the crystal structures of these four crystals are relevant to both 
studies. 
The correlation between the four duplicated structures in the two Chapters is as follows: 
Chapter 5 Chapter 6 
Structure I Structure I 
Structure II Structure II 
Structure III Structure III 
Structure X Structure IV 
 
 
Details of the publication status of the paper precede the paper. 
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6.2 The photodimerization of Schiff bases: synthesis and crystal structures of 
benzophenone azines and their weak C−H···π interactions 
 
 
Title of paper: The photodimerization of Schiff bases: Synthesis and crystal structures of 
benzophenone azines and their weak C−H···π interactions 
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Synopsis of Paper 
A new method of synthesizing benzophenone azines via a photodimerization process is 
described. The role of the weak C−H···π packing interactions in their supramolecular stucture is 
discussed. The four intermediates of the photodimerization process were also crystallized and 
their crystal structures are discussed. The crystal structure of di-isoniazid azine, an expected by-
product of the photodimerization process, was also described. 
. 
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Table 6.1: List of compounds reported in chapter 6.2  
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ABSTRACT:   
Four benzophenone azines were synthesized through a photodimerization process. The crystals 
are constructed purely through weak C−H···π  packing interactions, with additional π···π 
stabilization in two of the crystals. The four intermediates of the photodimerization process were 
also crystallized and their crystal structures are discussed. The packing of three of these 
intermediates involves weak C−H···O interactions. The crystal structure of di-isoniazid azine, an 
expected by-product of the photodimerization process, was also described. 
 
 
KEYWORDS:  Photodimerization, Schiff bases, isoniazid, benzophenone, azines,  
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Introduction 
 
Ketone azides are frequently used in synthetic chemistry as starting materials for the synthesis of 
basic aromatic rings (Kost and Grandberg, 1959, Carty, 1972, Wuts and Greene, 2006), as well 
as for ligands in metal complex catalysis (Verner and Potacek, 2006). The synthesis of 
benzophenone azine was first proposed by Lauer and Dyer in 1942 (Lauer and Dyer, 1942). 
They reported benzophenone azine as one of several products of the oxidation of benzophenone 
oxime (Figure 1). Separation of the product from the other reaction products was required. The 
presence of benzophenone azine was supported by molecular weight determinations. In 1995, 
Saha et al. (Saha et al., 1995) synthesized benzophenone azine via the reaction of the iron-
containing Lewis acid complex [ɳ5-(C5H5)Fe(CO)2(THF)]
+
[BF4]
-
 and provided evidence of an 
iron carbine intermediate. Inert conditions were required for the synthesis. The crystal and 
molecular structure was determined and was used to confirm that the azine, rather than the 
azitine product was afforded. 
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N
N
N
N2 (g)
HO
O
N
O
N
+ + +
Benzophenone oxime Benzophenone azine
Benzophenone o-diphenylmethyleneamino oximeBenzophenoneNitrogen gas  
Figure 1: Lauer and Dyer’s method of synthesis of benzophenone azine from benzophenone 
oxime showing also the many side products produced from their method of synthesis 
 
The structures reported in this study describe the synthesis of benzophenone azine and three 
other benzophenone azine derivatives via a two step synthesis: (1) Step 1 is the covalent 
modification of isonicotinic acid hydrazide (isoniazid) with benzophenone (or a derivative of 
benzophenone) via a condensation reaction to form an imine (Schiff base). (2) Step 2 is the 
photodimerization of this Schiff base intermediate by exposure to sunlight. 
As proof of concept, four benzophenone derivatives, namely benzophenone, 4-
methylbenzophenone, 4,4-dimethylbenzophenone and 4-(dimethylamino)benzophenone were 
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reacted with isoniazid in an acid catalyzed condensation reaction to yield the corresponding 
Schiff base intermediates and then photodimerized in sunlight to yield the corresponding 
benzophenone azine products (Scheme 1). 
N
H
NO NH2
+
O
R'
N
NO N
R
N
N
R
RN
NO
N
N
O
+
(1)   R = H, R' = H
(2)   R = CH3, R' = H
(3)   R = CH3, R' = CH3
(4)   R = N(CH3)2, R' = H
(5)
Isoniazid Benzophenone
Derivative
Schiff Base Intermediate
Benzophenone azine
derivative
Hydrazide Dimer
R'
R
R'
R'
(6)   R = H, R' = H
(7)   R = CH3, R' = H
(8)   R = CH3, R' = CH3
(9)   R = N(CH3)2, R' = H
Direct 
Sunlight
Acid 
Catalyzed
 
Scheme 1: A schematic diagram detailing the synthesis pathway of benzophenone azines. 
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The photodimerization process is supported by the fact that, theoretically, photodimerization 
should result not only in the expected product, the benzophenone azines, but should also yield a 
hydrazide dimer byproduct (5 in Scheme 1). The hydrazide dimer was indeed observed and 
confirmed as a byproduct of each reaction. The single-crystal XRD structures of the four Schiff 
base imine intermediates, the four azine products, as well as the expected hydrazide byproduct 
are reported here.  
In Desiraju’s article on weak hydrogen bonds, he describes C−H···π interactions as being 
“supportive” interactions and mentions that although C−H···π interactions are fairly ubiquitous, 
they are “very weak and merely exist in a structure that is wholly determined by other 
interactions” (Desiraju, 2005). He also asks the question of whether it is possible to engineer 
crystal structures consisting of only weak interactions. Two of the benzophenone azines 
described in this paper are constructed purely of weak C−H···π interactions and two more are 
constructed of only C−H···π interactions with additional π···π stacking between their aromatic 
rings. All four benzophenone azines do not have any traditional hydrogen bonds between 
molecules. In addition to the weak C−H···π interactions described, three of the intermediate 
products that were crystallized and described in this paper pack together via the much rarer 
C−H···O and C−H···N interactions discussed by Desiraju in his same publication (Desiraju, 
2005). 
In this paper, we therefore describe four benzophenone azines synthesized through a 
photodimerization process. We describe how these azines crystals are constructed purely through 
weak C−H···π  interactions, with additional π···π stabilization in two of the crystals. We also 
describe the crystallization and crystal structures of the four intermediates of the synthetic 
process, and the C−H···O interactions in the packing of three of these intermediates. Finally, we 
describe the crystal structure of the di-isoniazid azine, which is a necessary by-product of the 
photodimerization process and was crystallized in this study. 
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Experimental Methods 
Synthesis.  
 
Synthesis of Schiff base intermediates: 
 
N’-(diphenylmethylene)isonicotinohydrazide, I 
0.0920 g of isonicotinic acid hydrazide (0.6708 mmol) and 0.1202 g of benzophenone (0.6596 
mmol) were added into a sample vial. 0.0111 g of p-toluenesulphonic acid monohydrate (0.0584 
mmol) was added to catalyze the reaction. The solids were dissolved in 3 mL of a 1:1 mixture of 
AP-grade 1,2-dichloroethane and 1,1,1-trichloroethane and refluxed in a closed sealed screw-top 
vial for 72 hours at 50°C, and were left to stand at room temperature very slightly opened to the 
atmosphere. Colourless needles were afforded after 3 days.  
 
 (E)-N’-(phenyl(p-tolyl)methylene)isonicotinohydrazide), II 
0.0964 g of isonicotinic acid hydrazide (0.703 mmol) and 0.1386 g of 4-methylbenzophenone 
(0.7062 mmol) were added into a sample vial. 0.0124 g of p-toluenesulphonic acid monohydrate 
(0.0652 mmol) was added to catalyze the reaction. The solids were dissolved in 3 mL of a 2:1 
mixture of AP-grade ethanol and acetonitrile and refluxed in a closed sealed screw-top vial for 5 
days at 110°C, and were left to stand at room temperature very slightly opened to the 
atmosphere. Colourless needles were afforded after 3 days.  
 
N’-(di-p-tolylmethylene)isonicotinohydrazide, III 
0.1197 g of isonicotinic acid hydrazide (0.8728 mmol) and 0.1841 g of 4,4-
dimethylbenzophenone (0.8755 mmol) were added into a sample vial. 1 drop of 5M hydrochloric 
acid was added to catalyze the reaction. The solids were dissolved in 3 mL of methanol and 
refluxed in a closed sealed screw-top vial for 3 days at room temperature, followed by work-up 
with sodium bicarbonate: the solution was saturated with sodium bicarbonate, stirred for 5 
minutes and then filtered. The filtered solution was then left to stand at room temperature very 
slightly opened to the atmosphere. Yellow plates were afforded after 3 days.  
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 (E)-N’-((4-(dimethylamino)phenyl)(phenyl)methylene)isonicotinohydrazide), IV 
0.1043 g of isonicotinic acid hydrazide (0.7605 mmol) and 0.1732 g of 4-
(dimethylamino)benzophenone (0.7688 mmol) were added into a sample vial. 0.0232 g of p-
toluenesulphonic acid monohydrate (0.122 mmol) was added to catalyze the reaction. The solids 
were dissolved in 3 mL of a methanol and refluxed in a closed sealed screw-top vial for 72 hours 
at 100°C, and were left to stand at room temperature very slightly opened to the atmosphere. 
Yellow blocks were afforded after 3 days.  
 
Outcome of the photodimerization reactions: 
 
The method of synthesis for crystals V, VI, VII, VIII and IX is identical and is therefore 
summarized below the names described here: 
 
(E)-diazene-1,2-diylbis(pyridine-4-ylmethanone), V 
1,2-bis(diphenylmethylene)hydrazine, VI 
(1Z,2Z)-1,2-bis(phenyl(p-tolyl)methylene)hydrazine, VII 
1,2-bis(di-p-tolylmethylene)hydrazine, VIII 
4,4’-(1Z,1’Z)-hydrazine-1,2-diylidenebis(phenylmethan-1-yl-1-ylidene)bis(N,N-
dimethylaniline), IX 
 
After crystals I, II, III, IV had crystallized, the clear glass vials still containing some of the 
solvent and the crystals were sealed and placed on the windowsill in direct sunlight for 4 weeks. 
Crystals V and VI were afforded from crystal I, crystals V and VII were afforded from crystal 
II, crystals V and VIII were afforded from crystal III, and crystals V and IX were afforded from 
crystal IV. 
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Crystal Data and X-ray Structure Analysis.  
 
Intensity data for the nine crystal structures were collected on a Bruker APEX II CCD area 
detector diffractometer with graphite monochromated Mo-Kα radiation (50 kV, 30 mA) at 173K. 
The collection method involved ω-scans with a 0.5° width. SAINT+ version 6.02.6 software was 
used for data reduction and SADABS was used to make empirical absorption corrections (Bruker, 
2004). The crystal structures were solved using direct methods on SHELXS-97 (Sheldrick, 2015). 
Non-hydrogen atoms were first refined isotropically, followed by anisotropic refinement by full 
matrix least-squares calculations based on F
2
 using SHELXL-2017 (Sheldrick, 2015). C-bound H 
atoms were located in the difference electron density map, then positioned geometrically and 
were allowed to ride on their respective parent atoms, with thermal displacement parameters 1.2 
times that of the parent C atom. Where possible, the coordinates and isotropic displacement 
parameters of the N-bound and O-bound H atoms involved in hydrogen bonding interactions 
were allowed to refine freely, except for crystals IV due to poor refinement stability. The 
diffraction data and refinement statistics of crystal IV was poor even after numerous attempts at 
recrystallization. Diagrams and publication material were generated using WinGX (Farrugia, 
2012), ORTEP-3 (Farrugia, 2012), PLATON (Spek, 2009) and MERCURY (Macrae, C. F. et al., 
2008). The crystallographic data of each crystal is summarized in Table 1. 
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Table 1 Crystallographic data for compounds I-V 
 I II III IV V 
Formula C19H15N3O C20H17N3O C21H21N3O2 C20H20N4O2 C12H14N4O4 
Mr 301.34 
 
315.36 347.41 348.40 278.27 
Temperature/K 173(2) 173(2) 173(2) 173(2) 173(2) 
Wavelength/Å 0.71073 0.71073 0.71073 0.71073 0.71073 
Crystal size/mm3 0.226×0.324×0.522 0.066×0.091×0.325 0.084×0.169×0.384 0.093×0.196×0.256 0.124×0.169×0.382 
Crystal system Orthorhombic Triclinic Monoclinic Monoclinic Orthorhombic 
Space group P212121 P1 P21/c Cc Fdd2 
a/Å 9.7738(4) 7.1641(7) 21.3512(13) 13.200(2) 24.2397(12) 
b/Å 9.9605(5) 10.7669(10) 5.9227(4) 13.698(2) 28.1272(13) 
c/Å 15.8005(7) 12.0237(10) 14.8729(11) 39.908(7) 3.7546(2) 
α/° 90 64.009(4) 90 90 90 
β/° 90 82.346(5) 106.040(6) 97.004(5) 90 
γ/° 90 82.885(5) 90 90 90 
V/Å3 1538.21(12) 823.99(13) 1807.6(2) 7162(2) 2559.9(2) 
Z 4 2 4 16 8 
ρ (calcd)/Mg m-3 1.301 1.271 1.277 1.292 1.444 
μ/mm-1 0.083 0.081 0.084 0.086 0.111 
F(000) 632 332 736 2944 1168 
ϴ Range for data 
collection/° 
2.417 to 27.989 1.892 to 25.495 1.985 to 25.491 2.76 to 26.36 2.218 to 27.997 
Reflections collected 27237 9199 10908 17910 5738 
No. of unique data 
[R(int)] 
3710 [0.0421] 3066 [0.0755] 3256 [0.1805] 10563 [0.0512] 1439 [0.0503] 
   No. data with I ≥ 2σ(I) 3496 1430 1139 11901 1306 
Final R(I ≥ 2σ(I)) 0.0309 0.0627 0.0521 0.1265 0.0394 
Final wR2 (all data) 0.0816 0.1525 0.1103 0.4207 0.0970 
CCDC deposition 
number 
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 VI VII VIII IX 
Formula C26H20N2 C28H24N2 C30H28N2 C30H30N4 
Mr 360.44 388.49 416.54 446.58 
Temperature/K 173(2) 173(2) 173(2) 173(2) 
Wavelength/Å 0.71073 0.71073 0.71073 0.71073 
Crystal size/mm3 0.260×0.271×0.307 0.088×0.146×0.502 0.403×0.127×0.094 0.085×0.107×0.226 
Crystal system Monoclinic Orthorhombic Triclinic Triclinic 
Space group C2/c Pca21 P1 P1 
a/Å 21.9428(18) 18.5504(15) 6.4018(2) 6.4693(2) 
b/Å 5.4417(4) 5.3952(5) 10.0182(3) 9.3909(3) 
c/Å 16.1168(14) 21.3459(16) 10.3622(3) 11.0678(4) 
α/° 90 90 116.288(2) 111.711(2) 
β/° 94.450(4) 90 92.941(2) 98.257(2) 
γ/° 90 90 99.725(2) 100.123(2) 
V/Å3 1918.6(3) 2136.4(3) 581.27(3) 598.76(4) 
Z 4 4 1 1 
ρ (calcd)/Mg m-3 1.248 1.208 1.190 1.238 
μ/mm-1 0.073 0.070 0.069 0.074 
F(000) 760 824 222 238 
ϴ Range for data 
collection/° 
1.862 to 27.998 1.908 to 25.496 2.215 to 27.998 2.034 to 27.996 
Reflections collected 9256 13097 13248 6110 
No. of unique data [R(int)] 2283 [0.0400] 3956 [0.1038] 2805 [0.0662] 2768 [0.0341] 
   No. data with I ≥ 2σ(I) 2024 2009 1866 1512 
Final R(I ≥ 2σ(I)) 0.0392 0.0673 0.0528 0.0532 
Final wR2 (all data) 0.1124 0.1645 0.1498 0.1295 
CCDC deposition number     
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Results and discussion  
 
The photodimerization of the covalently modified isoniazid compound (I) to afford the 
benzophenone azide (VI) was discovered after the solution for (I) was inadvertently placed on 
the windowsill in direct sunlight and had been allowed to crystallize. On determining the crystal 
structure, the structure was found to be that of the isoniazid dimer (V). Photodimerization was 
suspected, and on examining the crystals, it was found that the benzophenone azine (VI) was 
also present in the vial. As proof of concept, isoniazid was then covalently modified with four 
different benzophenone derivatives (benzophenone, 4-methylbenzophenone, 4,4-
dimethylbenzophenone and 4-dimethylaminobenzophenone) and the crystal structures of the 
corresponding Schiff base products was determined (crystal structures I, II, III and IV). These 
were then placed in direct sunlight for four weeks and the crystal structures of the products were 
determined (crystal structures V, VI, VII, VIII, IX). Crystals V and VI were afforded from 
crystal I, crystals V and VII were afforded from crystal II, crystals V and VIII were afforded 
from crystal III, and crystals V and IX were afforded from crystal IV. The crystal structures of 
the products are described here. 
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           (a)       (b) 
 
        
     (c)       (d) 
 
       (e) 
 
Figure 2: Asymmetric units of (a) crystal I, (b) crystal II, (c) crystal III. Part (d) shows the 
numbering scheme of a quarter of the asymmetric unit of crystal IV (which has four molecules in 
the asymmetric unit), for clarity. The complete asymmetric unit of IV is shown in (e) without 
atom labels. 
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Compound I crystallizes in the P212121 space group and the asymmetric unit contains one 
molecule of N’-(diphenylmethylene)isonicotinohydrazide, the product of  the covalent 
modification of isoniazid with benzophenone. The modified isoniazid molecules in I hydrogen 
bond to each other via the N−Hamide···Npyridine heterosynthon (Figure 3) and form one-
dimensional (1D) ribbons along the a-axis with translational symmetry via a twofold screw axis 
along the crystallographic a-axis, stabilized by π-stacking. The ribbons are formed via chains of 
seven atoms between hydrogen bonds, with graph-set notation  1
1 7  (Bernstein et al., 1995). 
 
Figure 3: Packing diagram of I. One dimensional ribbons extend along the a-axis. 
 
Compound II crystallizes in the P  space group and the asymmetric unit contains one molecule 
of (E)-N’-(phenyl(p-tolyl)methylene)isonicotinohydrazide). The molecules are aligned in parallel 
planes, and held together via multiple weak C−H···O and C−H···N interactions and further 
stabilized via π···π stacking. Each molecule interacts with an adjacent molecule on one side of 
its plane by a carbonyl oxygen atom (O1) that is hydrogen bonded via a weak C−H···O  
interaction to a C−H hydrogen atom (H13) of the non-substituted benzophenone ring on an 
adjacent molecule to form a  2
2 16  ring. The pyridyl nitrogen atom (N2) also interacts with a 
hydrogen atom of the methyl group substituent of the other benzophenone ring of the adjacent 
molecule (H20C) via a weak C−H···N hydrogen bond. On the opposite side of each plane, the 
hydrazide nitrogen (N3) of each molecule is similarly involved in C−H···N hydrogen bonding, 
but to a C−H hydrogen atom on the non-substituted benzophenone ring of the adjacent molecule 
to form a  2
2 10  ring. The packing is further stabilized by π···π stacking along to form 1D 
ribbons along the a-axis (Figure 4). 
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Figure 4: Packing diagram of II. 
 
Compound III crystallizes in the monoclininc P21/c space group and the asymmetric unit 
contains one molecule of N’-(di-p-tolylmethylene)isonicotinohydrazide and one water molecule. 
The hydrate version of isoniazid molecules that have been covalently modified via reaction with 
ketones are common, as the water molecule is is a byproduct of the acid-catalyzed condensation 
reaction. This reaction occurs via nucleophilic attack on the carbonyl group by the amine 
nitrogen to form an unstable carbinolamine moiety, followed by acid catalyzed dehydration to 
form an imine (Xavier and Srividhya, 2014). In the asymmetric unit the hydrogen bond occurs 
between the amide nitrogen atom (H1) and the water oxygen atom (O1w). The packing of III is 
a three-dimensional (3D) network with all molecules being hydrogen bonded to water. Each 
water molecule has three hydrogen bonds and an O−H···π interaction. The bonding of the 
carbonyl oxygen atom acceptor of the modified isoniazid molecule is bifurcated and hydrogen 
bonds to both water hydrogen donors. One of the water hydrogen atoms is also hydrogen bonded 
to the isoniazid pyridine nitrogen acceptor atom (Figure 5a). The other water hydrogen atom 
forms an O−H···π interaction with one of the benzophenone rings on an adjacent modified 
isoniazid molecule (Figure 5b). The oxygen atom of this water molecule acts as a hydrogen 
bond acceptor to the amide N−H donor atom. The packing is further stabilized by π···π stacking 
of the pyridyl rings along the c-axis. 
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(a) 
 
          (b) 
Figure 5: Packing diagram of III showing (a) regular heterosynthons of water with modified 
isoniazid and (b) the O−H···π interaction between water and the aromatic benzophenone ring. 
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Compound IV crystallizes in the Cc space group and the asymmetric unit contains four 
molecules  of (E)-N’-((4-(dimethylamino)phenyl)(phenyl)methylene)isonicotinohydrazide), 
which will be referred to as molecules A-D. Molecule A in the asymmetric unit is hydrogen 
bonded to molecule B via two N−Hamide···Npyridine heterosynthons which form a  2
2 14  ring. 
There is additional π···π stabilization between the pyridyl rings of molecules A and B, which are 
stacked on top of each other. There is an additional weak C−H··· π interaction between one of 
the hydrogen atoms of the pyridyl ring in molecule A to the unsubstituted benzophenone ring in 
molecule B. Molecule B is hydrogen bonded to molecule C solely via three C−H···π 
interactions. The unsubstituted benzophenone ring of molecule B interacts with an N-methyl 
hydrogen atom of the dimethylamino group of molecule C via one of the a C−H···π interactions. 
The second of these interactions is from the N-methyl hydrogen atom of the dimethylamino 
group of molecule B to the substituted benzphenone ring of molecule C, and the third is a 
C−H···π interaction of the same substituted benzophenone ring of molecule C to one of the 
hydrogen atoms on the substituted ring of molecule B. Molecule B then hydrogen bonds to 
molecule D via a weak C−H···O interaction between the carbonyl oxygen of molecule B and one 
of the hydrogen atoms of the unsubstituted benzophenone rings of molecule D (Figure 6a). The 
packing interactions of crystal IV consists of  weak C−H···π and C−H···O interactions. In 
addition to the C−H···π interactions already described in the asymmetric unit, the bonding of the 
carbonyl oxygen atom acceptor is bifurcated and interacts with two C−H hydrogen donor atoms 
on the unsubstituted benzophenone ring of an adjacent molecule (Figure 6b). This results in a 
1D tape packing arrangement at a 45° angle to the a-axis. 
 
 
172 
 
 
       (a) 
 
       (b) 
 
Figure 6: Heterosynthons and weak C−H···O and C−H···π hydrogen bonding in crystal IV. Part 
(a) shows the interactions in the asymmetric unit of IV, and Part (b) shows the packing. Note that 
the only interactions in the packing are weak C−H···O hydrogen bonds. 
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Figure 7:  Asymmetric unit of di-isoniazid azine . 
 
Compound V is the di-isoniazid azine that was found to form concurrently with crystals VI, VII, 
VIII and IX. It crystallizes in the orthorhombic Fdd2 space group and the asymmetric unit 
contains half a molecule of the di-isoniazid azine, (E)-diazene-1,2-diylbis(pyridine-4-
ylmethanone, and one water molecule (Figure 7). The source of the water molecule is the 
byproduct from the previous step of the synthesis, namely the covalent modification of isoniazid, 
as previously described for crystal III, and the water molecule crystallizes together with the di-
isoniazid azine molecule. The hydrogen bonding in the asymmetric unit is via the 
N−Hamide···Owater heterosynthon with one of the two amide hydrogen atoms (H1) acting as the 
hydrogen bond donor, and the water oxygen atom as the acceptor. Lemmerer et al. has reported a 
series of five hydrates of modified isoniazid. In all five structures, the hydrazide 
N−Hamide···Owater and the O−Hwater···Ocarbonyl synthons were observed. The hydrogen bonding 
pattern observed in crystal V  corresponds to the synthons observed in the five reported hydrates 
(Lemmerer et al., 2011). Crystal V packs in a 3D network, with the crystal structure being held 
together by hydrogen bonding to the water molecule. Each water molecule is bonded to three 
different isoniazid azine molecules. In addition to the N−Hamide···Owater heterosynthon described 
in the asymmetric unit, one of the water hydrogen atoms acts as the hydrogen bond donor in the 
O−Hwater···Npyridine heterosynthon to a second azine molecule, and the carbonyl oxygen atom 
(O2) of the third azine molecule provides the acceptor for the other hydrogen donor of the water 
molecule (Figure 8a). Each set of four azine molecules and two water molecules form a  4
4 14  
ring (Figure 8b). 
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      (a)      
  
 
            (b) 
 
Figure 8: The heterosynthons found in the packing of crystal V are shown in part (a). Note, 
however, that part (a) is shown down the c-axis and does not show the depth of the 3D packing. 
Each molecule of water is hydrogen bonded to three different azine molecules as shown in Part 
(b). 
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(VI)       (VII) 
 
(VIII)       (IX) 
 
Figure 9: Asymmetric units of benzophenone azines. The asymmetric units of compounds (VI), 
(VIII) and (IX) each contain half a molecule of the benzophenone azines and the diagrams of the 
complete dimers are generated by symmetry. The asymmetric unit of (VII) contains one 
molecule of the benzophenone azine. The different way in which the asymmetric unit diagrams 
are generated by ORTEP-3 (Farrugia, 2012) accounts for the apparent disproportionally larger 
thermal ellipsoids for (VII).  
 
Crystals VI-IX are the benzophenone azine products formed by the photodimerization of 
compounds I-IV respectively (Figure 9). The packing of these benzophenone azines is 
exclusively via weak C−H···π interactions, with additional π···π stacking in only two of the four 
azines. No traditional hydrogen bonds or heterosynthons are present in any of their crystal 
structures. 
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Compound VI crystallizes in the C2/c space group and the asymmetric unit contains half a 
molecule of 1,2-bis(diphenylmethylene)hydrazine. The molecule is centrosymmetric, with the 
second half of the molecule related to the first by a two-fold rotation giving the molecule a C2 
symmetry. Although the many aromatic rings and lone pairs on the nitrogen allow for resonance 
structures that might give the N−N bond a double bond character, the bond length between the 
two nitrogen atoms is 1.400 Å, which is typical of a single N−N bond (Saha et al., 1995). The 
only hydrogen bonding interactions found in the packing of VI are weak C−H···π interactions 
between the terminal hydrogen atom of a benzophenone ring on one azine molecule and the 
benzophenone ring of an adjacent molecule (Figure 10). The packing is further stabilized by 
π···π stacking between benzophenone rings of adjacent molecules. 
 
 
(a) 
 
 
(b) 
Figure 10: The packing of VI showing (a) the C−H··· π interactions between the terminal 
hydrogen atom of a benzophenone ring on one azine molecule and the benzophenone ring of an 
adjacent molecule and (b) the  π···π stacking of the benzophenone rings. 
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Compound VII crystallizes in the Pca21 space group and the asymmetric unit contains one 
molecule of (1Z,2Z)-1,2-bis(phenyl(p-tolyl)methylene)hydrazine. As with crystal VI, crystal VII 
is centrosymmetric with C2 symmetry. The packing involves C−H···π interactions between a 
methyl hydrogen atom donor and a benzophenone ring π-system acceptor of an adjacent 
molecule to from 1D ribbons along the c-axis. The packing is further stabilized by π···π stacking 
of the non-substituted benzophenone rings (Figure 11). Crystal VIII crystallizes in the P  space 
group and the asymmetric unit contains half a molecule of 1,2-bis(di-p-
tolylmethylene)hydrazine. The second half of the molecule is related to the first by an inversion 
about the center of the molecule. The packing of VIII is purely through weak C−H···π 
interactions. Unlike in crystal VII, the interaction in VIII is not via the methyl hydrogen atom 
donor, but rather through one of the hydrogen atom donors of the substituted benzophenone ring 
and the unsubstituted ring π–system of an adjacent molecule. Crystal IX crystallizes in the P  
space group and the asymmetric unit contains half a molecule of 4,4’-(1Z,1’Z)-hydrazine-1,2-
diylidenebis(phenylmethan-1-yl-1-ylidene)bis(N,N-dimethylaniline). The second half of the 
molecule is related to the first by an inversion about the center of the molecule. As with crystal 
VIII, the packing of IX is purely through weak C−H···π interactions. The C−H···π in this case 
are, similarly to VII, between a methyl hydrogen atom donor and the benzophenone ring π-
system acceptor of an adjacent molecule. The interactions result in the formation of layers of 
two-dimensional (2D) sheets.  
 
 
      (a)  
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        (b) 
 
(c) 
 
(d) 
Figure 11: Part (a) is a diagram of the packing of crystal VII showing the C−H···π interactions 
between the methyl hydrogen atoms and the benzophenone rings of adjacent molecules and (b) 
the  π···π stacking of the benzophenone rings. Part (c) shows the C−H···π interactions of crystal 
VIII. The interaction in VIII is not via the methyl hydrogen atom donor as in VII, but rather 
through one of the hydrogen atom donors of the substituted benzophenone ring and the 
unsubstituted ring π–system of an adjacent molecule. Part (d) shows the packing of crystal IX, 
like VIII, is held together purely by C−H··· π interactions. 
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Conclusion 
 
Isoniazid was covalently modified with four benzophenone derivatives. Crystals of these 
compounds were harvested and the crystal structures were determined. The packing of three of 
the four modified isoniazid crystals contain weak C−H···O interactions. The four modified 
isoniazid crystals were then subjected to direct sunlight, resulting in benzophenone azine and 
three other benzophenone azine derivatives. The crystal structures were described. Two of the 
four benzophenone azine crystals were constructed solely through C−H···π  packing interactions. 
The other two azines contained only C−H···π  packing interactions, but were further stabilized 
by π···π stacking. Crystals of di-isoniazid azine, an expected by-product of the 
photodimerization process were also harvested, and the crystal structure determined. 
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Chapter 7:  Co-crystal engineering of 4-aminoantipyrine 
 
7.1 Introduction 
 
This chapter details the systematic implementation of crystal engineering techniques that were 
employed in order to produce the first reported co-crystal of 4-aminoantipyrine. The synthesis of 
additional salts of 4AAP and co-crystals of covalently modified 4-AAP are included in the 
report. 
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7.2 Novel crystal forms of 4-aminoantipyrine and its derivatives 
 
Title of paper: Novel crystal forms of 4-aminoantipyrine and its derivatives 
Journal:  Crystal Growth and Design 
Reference:  Pending 
Status: Submitted. Has been reviewed and currently attending to reviewers’ 
comments as per editor’s request. 
Date Received: December 2017 
Date Revised:  February 2018 
Date Published:   
 
Synopsis of Paper 
The first co-crystallization of the pharmaceutical ingredient 4-aminoantipyrine is reported and 
the method used for its supramolecular synthesis is discussed. Two molecular salts of 4-
aminoantipyrine, as well as two co-crystals of a derivative of 4-aminoantipyrine were also 
synthesized. The complexes discussed show that careful application of synthon theory, choice of 
solvent and consideration of the pKa difference between 4-aminoantipyrine and the co-former are 
required to successfully co-crystallize this molecule.  
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Table 7.1: List of compounds reported in chapter 7.2  
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ABSTRACT:   
The first co-crystallization of the pharmaceutical ingredient 4-aminoantipyrine is reported with 
2-aminobenzoic acid as the co-former, and the method used for its supramolecular synthesis is 
discussed. Two molecular salts of 4-aminoantipyrine, as well as two co-crystals of a derivative 
of 4-aminoantipyrine were also synthesized. The complexes discussed show that careful 
application of synthon theory, choice of solvent and consideration of the pKa difference between 
4-aminoantipyrine and the co-former are required to successfully co-crystallize this reactive 
molecule. In summary, the co-former must be chosen so that its functional group forms a robust 
heterosynthon with the reactive molecule. The presence of polar solvents or large pKa differences 
between 4-aminoantipyrine and its potential co-former favors salt formation, whereas a non-
polar solvent and a small pKa difference is required for the co-crystallization of 4-
aminoantipyrine. 
 
 
 
 
 
 
 
KEYWORDS:   
4-Aminoantipyrine, Co-crystal, Supramolecular synthesis, Crystal engineering, Solvent, pKa, 
Synthon 
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Introduction 
How does one co-crystallize a highly reactive molecule? 4-Aminoantipyrine (4AAP) is an active 
pharmaceutical ingredient with powerful anti-inflammatory, antipyretic and analgesic properties. 
Its amino functional group is highly reactive and it will react readily with ketones and aldehydes 
at room temperature. Due to its chemical reactivity it has been widely used as a nitrogen 
scavenger species against hydroxyl radicals.
1
 Although 4AAP has many recognized therapeutic 
benefits, the use of 4AAP has been associated with agranulocytosis.
2
 In order to reduce adverse 
effects in cases of drugs with considerable side effects, a number of derivatives using the 4AAP 
backbone have been made.
3
 In addition, the pharmaceutical industry often turns to the synthesis 
of salts and co-crystals, where the different physical properties of the co-crystals may enhance 
the bioavailability of the drug.
4
 To date, 251 derivatives of 4AAP have been reported in the 
Cambridge Structural Database,
5
 where the modifying adduct has attached to the amino nitrogen 
atom. Yet, despite the drive to synthesize salts and co-crystals of pharmaceuticals such as 4AAP, 
only five molecular salts of 4AAP have been reported,
6-11
 of which two are simple salts with 
halide counter-ions.
6,7
 No co-crystal of 4AAP has ever been reported. The scarcity of salts of 
4AAP and the complete absence of any co-crystals of the species are presumably due to the fact 
that it reacts covalently with the potential co-former rather than co-crystallizing on a 
supramolecular basis. 
How then does one go about co-crystallizing 4AAP? Firstly, in “Knowledge-based approaches to 
co-crystal design”,12 Wood stresses the importance of choosing a suitable synthon. 4AAP 
possesses amine and carbonyl functional groups which can undergo hydrogen bonding. Both 
amine and carbonyl functional groups form robust heterosynthons with carboxylic acids, and so 
carboxylic acids were therefore chosen as the co-formers in all our attempts at co-crystallization. 
Secondly, solvent choice is critical in determining whether a salt or co-crystal will be formed. A 
polar solvent stabilizes ionic species through charge-charge or charge-heteroatom interactions, 
whereas non-polar solvents inhibit the formation of charged species since they cannot interact 
with the ions.
13
 Thirdly, details of the effect of pKa on co-crystal formation has recently come 
into the spotlight. Childs et al. states that the absolute separation of the pKa values of a molecule 
and its potential co-former plays a critical role in determining whether the supramolecular 
synthesis of two such molecules will result in a salt or in a co-crystal.
14,15
 More recently, 
Lemmerer et al. presented empirical evidence to suggest that an absolute ∆pKa separation of less 
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than 3 ([∆pKa] = [pKa(protonated base) – pKa(acid)]) will greatly enhance the formation of a co-
crystal rather than a salt (the “Rule of Three”).16 Our strategy therefore was to attempt co-
crystallizations of carboxylic acids with 4AAP, and to take into account the calculated pKa 
values of the co-formers, as well as considerations of the polarity of the solvent. pKa values were 
calculated using ACD/Labs Software V11.02.
17
 Co-crystallizations were first attempted with a 
derivative of 4AAP (namely 4-aminoantipyrine-N-acetamide), of which there are several 
reported co-crystals, in an attempt to find suitable solvents and co-formers, as a proof of concept 
exercise. 
The crystal structure of 4AAP has been reported by Li et al.
18
 and by Mnguni et al.
19
 (Figure 1a). 
4AAP has a pKa of 4.07 ± 0.65 (based solely on the calculated pKa for the species in water 
solution). Its exocyclic nitrogen atom is readily protonated and forms a chloride salt in the 
presence of hydrochloric acid and a bromide salt when refluxed in an aqueous dibromomethane 
solution (Figure 1b & c).
6,7
 The crystal structure of these two salts have been reported by 
Chitradevi and Yang respectively.
6,7
 Murtaza et al. prepared a three-component salt (Figure 2a) 
by acidifying the 4AAP with an aqueous solution of hydrochloric acid, and then refluxing with 
thiourea (pKa 14.91 ± 0.29) in ethanol ([∆pKa] = 10.84).
8
 A molecular salt of 4AAP and 2,2’-
dithiobenzoic acid was synthesized first by Huo and then Fazil et al.
9,10
 and was crystallized 
from ethanol and from a 50% ethanol/water mixture respectively (Figure 2b). Huo commented 
that the components were selected as building blocks for creating a co-crystal, but proton transfer 
was observed in the ethanol medium. The calculated pKa of 2,2’-dithiobenzoic acid is 3.02  ± 
0.36 which is much closer to the 4.07 pKa of 4AAP (with ([∆pKa] = 1.05) and therefore more 
likely to co-crystallize than co- formers with larger pKa separations. However, the polar solvent 
(ethanol) lends itself to salt formation as the polar solvent stabilizes the ionic species through 
charge-charge and charge-heteroatom interactions. Finally, a salt of 4AAP with salicylic acid 
(pKa 3.01 ± 0.10) was prepared in aqueous solution by Chitradevi et al. ([∆pKa] = 1.06)
11
 (Figure 
2c).  
In this report, we describe co-crystals and salts of 4AAP and its derivative 4-aminoantipyrine-N-
acetamide using salicylic acid, 3-nitrophathalic acid, 1-hydroxy-2-naphthanoic acid and 2-
aminobenzoic acid (Figure 3).  
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Figure 1: The structure of 4-aminoantipyrine and its reported simple salts: 
(a) 4-aminoantipyrine (SIKBAR), (LOYXEE) 
(b) aminoantipyrine-4-aminium chloride (HUKTIS) 
(c) aminoantipyrine-4-aminium bromide monohydrate (PAXSOY) 
 
 
Figure 2: Previously synthesized salts of 4-aminoantipyrine. 
(a) aminoantipyrine-4-aminium thiourea chloride (EVOLIL) 
(b) aminoantipyrine-4-aminium 2,2’-dithiodibenzoate (PUGHEF), (PUGHEF01) 
(c) aminoantipyrine-4-aminium salicylate (DUHYOV) 
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Figure 3: Co-crystals and salts of 4-aminoantipyrine and its derivative 4-aminoantipyrine-N-
acetamide reported in this paper. Compound I, crystallized from methanol, is a two-component 
co-crystal of 4-aminoantipyrine-N-acetamide and salicylic acid. Compound II, crystallized from 
1,2-dichloroethane, results in a three-component co-crystal consisting of 4-aminoantipyrine-N-
acetamide, salicylic acid and 1,2-dichloroethane. Salts of aminoantipyrine-4-aminium with 3-
nitrophthalate (III) and 1-hydroxy-2-naphthoate (IV) respectively. Co-crystal of 4-
aminoantipyrine and 2-aminobenzoic acid (V). 
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Experimental Methods 
Synthesis 
 
(4-aminoantipyrine-N-acetamide)·(salicylic acid) (I): 0.1080 g of 4-aminoantipyrine (0.5314 
mmol) and 0.0963 g of acetylsalicylic acid (0.535 mmol) were added into a sample vial. The 
solids were dissolved in AP-grade methanol (3 mL), stirred for 1 hour at 40°C, and were left to 
stand at room temperature open to the atmosphere. Colorless plates were afforded after 3 days.  
 
(4-aminoantipyrine-N-acetamide)·(salicylic acid)·(1,2-dichloroethane) (II): 0.0749 g of 4-
aminoantipyrine (0.369 mmol) and 0.0658 g of acetylsalicylic acid (0.365 mmol) were added 
into a sample vial. The solids were dissolved in 1,2-dichloroethane (3 mL), stirred for 30 minutes 
at 40°C, and were left to stand at room temperature open to the atmosphere. Colorless needles 
were afforded after 7 days.  
 
(aminoantipyrine-4-aminium)·(3-nitrophthalate) (III): 0.0753 g of 4-aminoantipyrine (0.371 
mmol) and 0.0802 g of 3-nitrophthalic acid (0.380 mmol) were added into a sample vial. The 
solids were stirred in 1,2-dichloroethane (3 mL) and methanol was added dropwise until all the 
solids had dissolved. The mixture was stirred for 30 minutes at 40°C, and was left to stand at 
room temperature open to the atmosphere. The resulting solid was re-dissolved in chloroform, 
and ethanol was added dropwise until all solid had re-dissolved. The mixture was then stirred for 
24 hours and was left to stand at room temperature open to the atmosphere.  Colorless plates 
were afforded after 2 days.  
 
(aminoantipyrine-4-aminium 1-hydroxy-2-naphthoate) (IV): 0.0987 g of 4-aminoantipyrine 
(0.486 mmol) and 0.0883 g of 1-hydroxy-2-naphthoic acid (0.469 mmol) were added into a 
sample vial. The solids were dissolved in AP-grade methanol (3 mL), stirred for 1 hour at 40°C, 
and were left to stand at room temperature open to the atmosphere. Colorless cubes were 
afforded after 3 days.  
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(4-aminoantipyrine)·(2-aminobenzoic acid) (V): 0.0996 g of 4-aminoantipyrine (0.490 mmol) 
and 0.0673 g of 2-aminobenzoic acid (0.491 mmol) were added into a sample vial. The solids 
were stirred in 1,2-dichloroethane (3 mL) and methanol was added dropwise until all the solids 
had dissolved. The mixture was stirred for 2 hours at 40°C, and was left to stand at room 
temperature open to the atmosphere. The resulting solid was re-dissolved in pure chloroform, 
was stirred for 24 hours, and was left to stand at room temperature open to the atmosphere.  
Colorless blocks were afforded after 2 days.  
 
 
 
Crystal Data and X-ray Structure Analysis.  
Intensity data for the five crystal structures were collected on a Bruker APEX II CCD area 
detector diffractometer with graphite monochromated Mo-Kα radiation (50 kV, 30 mA) at 173K. 
The collection method involved ω-scans with a 0.5° width. SAINT+ version 6.02.6 software was 
used for data reduction and SADABS was used to make empirical absorption corrections.
20
 The 
crystal structures were solved using direct methods on SHELXS-97.
21
 Non-hydrogen atoms were 
first refined isotropically, followed by anisotropic refinement by full matrix least-squares 
calculations based on F
2
 using SHELXL-2017.
21
 C-bound H atoms were located in the difference 
electron density map, then positioned geometrically and were allowed to ride on their respective 
parent atoms, with thermal displacement parameters 1.2 times that of the parent C atom. Where 
possible, the coordinates and isotropic displacement parameters of the N-bound and O-bound H 
atoms involved in hydrogen bonding interactions were allowed to refine freely. Diagrams and 
publication material were generated using WinGX,
22
 ORTEP-3,
22
 PLATON
23
 and MERCURY
24
. 
The crystallographic data of each crystal is summarized in Table 1 and the hydrogen bonding 
geometries in Table 2. 
  
193 
 
 
Table 1 Crystallographic data for compounds 1-5 
 I II III IV V 
Formula (C13H15N3O2)· 
(C7H6O3) 
(C13H15N3O2)· 
(C7H6O3)·0.5(C2H4Cl2) 
(C11H14N3O)· 
(C8H4NO6) 
(C11H14N3O)· 
(C11H7O3) 
(C11H13N3O)· 
(C7H7NO2) 
Mr 383.40 432.87 414.37 391.42 340.38 
Temperature/K 173(2) 173(2) 173(2) 173(2) 173(2) 
Wavelength/Å 0.71073 0.71073 0.71073 0.71073 0.71073 
Crystal size/mm3 0.52×0.16×0.15 0.60×0.13×0.10 0.24×0.19×0.10 0.64×0.58×0.54 0.38×0.30×0.23 
Crystal system Triclinic Triclinic Orthorhombic Monoclinic Orthorhombic 
Space group P1 P1 P212121 P21/c Pbca 
a/Å 6.7874(2) 6.5113(5) 7.1537(4) 7.9866(4) 7.5880(10) 
b/Å 11.1280(3) 10.9128(7) 7.5193(4) 12.7996(6) 17.448(2) 
c/Å 12.8934(3) 15.4411(11) 34.0871(16) 18.8706(8) 25.067(3) 
α/° 76.025(1) 89.988(4) 90 90 90 
β/° 88.881(1) 83.665(4) 90 98.753(3) 90 
γ/° 86.196(1) 75.049(4) 90 90 90 
V/Å3 942.93(4) 1053.12(13) 1833.57(17) 1906.59(15) 3318.7(7) 
Z 2 2 4 4 8 
ρ (calcd)/Mg m-3 1.350 1.365 1.501 1.364 1.362 
μ/mm-1 0.099 0.219 0.117 0.095 0.095 
F(000) 404 454 864 824 1440 
ϴ Range for data collection/° 1.63 to 28.00 1.93 to 25.50 2.39 to 28.00 1.93 to 28.00 1.62 to 27.99 
Reflections collected 20961 12450 10125 41500 33204 
No. of unique data [R(int)] 4536 [0.0466] 3910 [0.0704] 4379 [0.0862] 4601 [0.1320] 3989 [0.0447] 
   No. data with I ≥ 2σ(I) 3471 2641 2236 2354 3211 
Final R(I ≥ 2σ(I)) 0.0402 0.0483 0.0637 0.0587 0.0361 
Final wR2 (all data) 0.1114 0.1316 0.1624 0.1626 0.0995 
CCDC deposition number 1586521 1586520 1586519 1586523 1586522 
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Table 2 Hydrogen bonding details of compounds 1-5 
 
a
-x + 1, -y + 2, -z + 1. 
b
-x + 2,-y + 1, -z. 
c
-x + 2, y + 1/2, -z + 3/2. 
d
x, y + 1, z. 
e
-x + 1, y + 1/2, -z 
+ 3/2. 
f
-x + 2,y - 1/2, -z + 3/2. 
g
-x + 1, -y, -z + 1. 
h
-x + 2, -y, -z + 1. 
i
x + 1, y, z.
. j
-x + 2, -y + 1, -z 
+ 1. 
k
-x + 1, -y + 1, -z + 1.  
 d(D─H)/Å d(H···A)/Å d(D···A)/Å ∠(D─H···A)/° 
I     
N3─H3···O1 0.91(2) 1.90(2) 2.8119(15) 177(2)a 
O3─H3A···O2 0.95(2) 1.67(2) 2.6144(14) 172(2) 
O5─H5···O4 0.94(3) 1.71(3) 2.5799(16) 152(2) 
II     
N3─H3···O1 0.95(2) 1.83(2) 2.783(2) 177(2)b 
O3─H3A···O2 1.04(3) 1.57(4) 2.583(2) 165(3) 
O5─H5···O4 0.93(3) 1.73(4) 2.573(3) 148(3) 
III     
N3─H3A···O7 0.91 2.03 2.913(5) 162 
N3─H3B···O2 0.91 2.22 2.867(6) 128c 
N3─H3B···O3 0.91 2.16 2.808(5) 127d 
N3─H3C···O7 0.91 1.98 2.881(5) 168e 
O2─H2···O6 0.84 1.67 2.507(5) 172f 
IV     
N3─H3A···O3 0.91 1.89 2.771(3) 163g 
N3─H3B···O1 0.91 1.88 2.694(2) 148h 
N3─H3C···O3 0.91 1.78 2.661(3) 162 
N3─H3C···O4 0.91 2.65 3.367(3) 136 
O2─H2···O4 0.97(4) 1.60(4) 2.502(3) 153(4) 
V     
N3─H3A···N4 0.93(2) 2.66(2) 3.349(2) 131(2)i 
N3─H3B···O3 0.89(2) 2.21(2) 2.9567(16) 141(2)j 
N4─H4A···O3 0.893(19) 2.004(19) 2.6873(18) 132(2) 
N4─H4B···N3 0.88(2) 2.461(19) 3.2747(19) 154(2)k 
O2─H2···O1 0.94(2) 1.69(2) 2.6303(13) 177(2) 
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 Results 
 
Compounds I and II display similar hydrogen bonding patterns with compound I being a co-
crystal of 4-aminoantipyrine-N-acetamide and salicylic acid, and compound II containing an 
additional solvent molecule in the supramolecular structure (Figure 4). Both compounds I and II 
crystallize in the P  space group. Each 4-aminoantipyrine-N-acetamide molecule is hydrogen 
bonded to a second 4-aminoantipyrine-N-acetamide molecule through two N3―H3···O1 
hydrogen bonds forming a dimer with 0D packing dimensionality (Figure 5). This packing 
results in a  2
2 10   ring between the two 4-aminoantipyrine-N-acetamide molecules. There is a 
centre of inversion in the centre of the  2
2 10  ring (at unit cell coordinates ½,½,0). In addition to 
dimerizing, each 4-aminoantipyrine-N-acetamide is hydrogen bonded to a salicylic acid acid 
molecule through a O2―H3A···O3 carboxylic acid/carbonyl heterosynthon. The phenol group 
on the salicylic acid molecule is not involved in intermolecular hydrogen bonding, but rather, it 
undergoes intramolecular hydrogen bonding (  1
1 6  in graph-set notation) through a 
O5―H5···O4 hydrogen bond which is typical of salicylic acid.25 Compound I was crystallized 
from methanol and no solvent is present in the supramolecular structure. Compound II was 
crystallized from 1,2-dichloroethane, and this solvent is found between the  molecules in a 1 : 1 : 
0.5 ratio of 4-aminoantipyrine-N-acetamide : salicylic acid : 1,2-dichloroethane. No hydrogen 
bonds or short contacts are present between the solvent and the co-crystal components. 
               
 
Figure 4: Asymmetric units and numbering scheme of compounds I and II. 
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   (I)                  (II) 
 
Figure 5: Hydrogen bonding diagrams of compounds I and II. 
 
Compounds III and IV are salts formed via charge-assisted hydrogen bonding between the 
acidic proton (H3A) of the aminium group of a aminoantipyrine-4-aminium cation and an 
oxygen atom of the carboxylate anion of 3-nitrophthalate (via O7) and 1-hydroxy-2-naphthoate 
(via O3) respectively (Figure 6). The asymmetric unit of (III) consists of the cation and anion in 
a 1:1 ratio and crystallizes in the P212121 space group. The packing of structure III consists of 
two-dimensional (2D) ribbons, with translational symmetry via a twofold screw axis along the 
crystallographic a-axis, stabilized by π-stacking. There is an extensive hydrogen bonded network 
involving one 8-membered, two 11-membered and one 13-membered rings (Figure 7). The 8-
membered ring, of type   
    , involves one aminoantipyrine-4-aminium cation and two 3-
nitrophthalate anions. The aminium cation provides two of the H-bond donors, and the third one 
comes from the carboxylic acid group of one of the 3-nitrophthalate molecules. The 13-
membered ring is of the type   
      and involves two aminoantipyrine-4-aminium cations and 
two 3-nitrophthalate anions. There are four H-bond donors, two from each aminium group. An 
oxygen from each deprotonated carboxylate anion, as well as the carbonyl oxygen of a fully 
protonated carboxylic acid group of a 3-nitrophthalate molecule, provide the three H-bond 
acceptors. There are two R(11) rings in the packing of III. The   
      ring involves three 
molecules, namely one aminoantipyrine-4-aminium cation and two 3-nitrophthalate anions. H3B 
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is bifurcated and hydrogen bonds to O2 and O3 of two adjacent 3-nitrophthalate anions. The 
third hydrogen bond is formed between H2 on the carboxylic acid group of a 3-nitrophthalate 
molecule to an oxygen of the carboxylate group (O6) of an adjacent 3-nitrophthalate anion. On 
the other hand, the   
      ring involves four molecules, where one of the aminoantipyrine-4-
aminium hydrogen atoms (on the aminium functional group) is hydrogen bonded (bifurcated) to 
an oxygen (O7) of a carboxylate group of one of the 3-nitrophthalate anions and the carbonyl 
oxygen of a fully protonated carboxylic acid group of the other 3-nitrophthalate molecule. In the 
second aminoantipyrine-4-aminium, two of the aminium hydrogens are hydrogen bonded, each 
to a carboxylate oxygen of the two neighbouring 3-nitrophthalate molecules.  
 
Compound IV crystallizes in the P21/c space group and packs in two-dimensional ribbons along 
the crystallographic a-axis (Figure 8). The hydrogen bonding network along the ribbon consists 
of alternating   
      and   
     rings with all three aminium protons of each of the 
aminoantipyrine-4-aminium cations acting as hydrogen bond donors. There is a centre of 
inversion in the centre of each of the   
      and   
     rings. In the   
      ring, the carbonyl 
oxygen (O1) of two aminoantipyrine-4-aminium molecules therefore acts as the acceptor, 
whereas in the   
    ring, the acceptors are the oxygen atoms (O3) of two opposite carboxylate 
groups. In the packing, there is a glide plane perpendicular to [010] with glide component [00½]. 
For compound III, it may be expected that a co-crystal would result rather than a salt because the 
difference between the pKa values of the 4-aminoantipyrine and 3-nitrophthalate are quite small 
(4.07 ± 0.65 and 3.02 ± 0.30 respectively, with [∆pKa] = 1.05). However, because a polar solvent 
(a mixture of ethanol and chloroform) was present, the ethanol stabilized the ionic species 
through charge-charge interactions, and a salt resulted. Likewise, compound IV was expected to 
be a salt rather than a co-crystal because the polar solvent methanol was used for crystallization. 
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Figure 6: Asymmetric units and numbering scheme of compounds III and IV. 
 
 
    
   R3
3(8)      R3
3(11)   
                    
   R4
3(13)    R2
3(11)   
 
Figure 7: Hydrogen bonding diagrams of compound III showing the extensive hydrogen 
bonding network. The blue lines (solid and dotted) show the outline of the rings. 
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Figure 8:  Hydrogen bonding diagram of compound IV. 
 
 
 
To gain further insight into the usefulness of various solvents for the crystallization of 4AAP and 
4-aminoantipyrine-N-acetamide, the pure powders of 4AAP and 4-aminoantipyrine-N-acetamide 
were dissolved in eight different solvents and allowed to crystallize out at room temperature 
using the slow evaporation method and the results were recorded (Table 3). For 4AAP, 1,2-
dichloroethane was found to be an ideal solvent as it formed a high yield of large crystals. 
Crystallization from chloroform was also successful. For 4-aminoantipyrine-N-acetamide, 1,2-
dichloroethane was likewise found to be the solvent of choice as it also resulted in a high yield of 
large crystals. Dichloromethane, ethyl acetate and 1-propanol are also suitable solvents for 
crystallizing 4-aminoantipyrine-N-acetamide, should a moderately polar or polar solvent be 
required. 
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Table 3 Result at attempts to crystallize 4AAP and acetyl 4AAP from various solvents. 
 4-Aminoantipyrine 4-aminoantipyrine-N-acetamide 
Methanol A gel was formed. An amorphous mass resulted. 
Ethanol 
A gel was formed. A few fine 
crystals formed on the glass above 
the gel. 
Few crystals were formed. 
Isopropanol 
4AAP was only partially soluble but 
dissolved on heating. An oil was 
formed. 
Few crystals were formed. 
Chloroform Crystals were formed. An amorphous mass resulted. 
1,2-Dichloroethane Large crystals were formed. Large crystals were formed. 
Dichloromethane An amorphous mass resulted. Crystals were formed. 
1-Propanol 
An oil was formed. A few very fine 
crystals formed on the glass above 
the gel. 
Crystals were formed. 
Ethyl Acetate 
Reacted with the 4AAP to form 
acetyl-4AAP 
Crystals were formed. 
 
 
In considering the choice of heterosynthon for V, the co-former was chosen to be a carboxylic 
acid with a similar pKa value to that of 4-aminoantipyrine. Hemamalini et al. successfully co-
crystallized a series of aminobenzoic acids (including 2-aminobenzoic acid) with 
aminopyridines.
26
 The carboxylic acid functional group on the 2-aminobenzoic acid can form a 
robust heterosynthon with either the amine or carbonyl functional groups of 4AAP, and has a 
pKa of 4.94 ± 0.10, which is reasonably similar to the 4AAP pKa value of 4.07 ± 0.65, with 
[∆pKa] = 0.87, and was therefore considered a suitable co-former. For solvent choice, the non-
polar 1,2-dichloromethane had been successfully used for the synthesis of II and III, as well as 
for the crystallization of pure 4AAP (Table 3) and was therefore chosen as the solvent for V.  
However, as the 2-aminobenzoic acid was not completely soluble in the 1,2-dichloromethane, 
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methanol was slowly added dropwise to the solution until all of the reagents had dissolved. Then, 
as the presence of methanol was undesirable, all the solvent was evaporated and the resulting 
solid mass was re-dissolved and recrystallized in pure chloroform, which had also been found to 
be a good non-polar solvent for the crystallization of 4AAP (Table 3). Compound V is finally a 
1:1 co-crystal of 4AAP. In the asymmetric unit, the carboxylic acid proton (H2) of 2-
aminobenzoic acid is hydrogen bonded to the carbonyl oxygen (O1) of 4AAP (Figure 9). 
Intramolecular stabilization of the 2-aminobenzoic acid molecule occurs via a six membered 
  
     ring with the amine proton (H4) as the donor and the carbonyl oxygen (O3) of the 
carboxylic acid group as the acceptor. V Packs in a one-dimensional ribbon along the a-axis.  
 
      
 
Figure 9: The asymmetric unit of the co-crystal V and a view of the packing. 
 
 
Conclusion 
 
Two 4-aminoantipyrine-N-acetamide co-crystals, two 4-aminium-4-aminoantipyrine salts and 
one 4-aminoantipyrine co-crystal were synthesized. The highly reactive 4-aminoantipyrine was 
co-crystallized with 2-aminobenzoic acid, and is the first reported co-crystal of the active 
pharmaceutical ingredient, 4-aminoantipyrine. The success of the co-crystallization of the 
reactive 4-aminoantipyrine is due to the strict application of three criteria: (1) the co-former was 
chosen so that its functional group formed a known robust heterosynthon with the reactive 
molecule; (2) the co-former was chosen to have a pKa value similar to that of the 4-
aminoantipyrine and, (3) a non-polar solvent was chosen to inhibit the formation of charged 
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species. Where polar solvents were used or where the pKa value was substantially different to 4-
aminoantipyrine, the crystallizations resulted in salts.  
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Chapter 8:  Crystal Engineering of 4-aminoantipyrine  
 
8.1 Introduction 
 
4-Aminoantipyrine was covalently modified to form a series of Schiff bases. This chapter details 
the synthesis of the crystals and a structural study a series of 4-aminoantipyrine derivatives. 
 Details of the publication status of the paper precede the paper. 
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8.2 A structural study of nine 4-aminoantipyrine derivatives 
 
 
Title of paper: A structural study of nine 4-aminoantipyrine derivatives 
Journal: Will be submitted to Acta Crystallographica C: Structural Chemistry 
Reference:   
Status: Submission pending. To be submitted by end March 2018. 
Date Received:  
Date Revised:   
Date Published:   
 
Synopsis of Paper 
In this paper, nine crystalline derivatives of 4-aminoantipyrine that have been covalently 
modified are synthesized and structurally characterized. 
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Table 8.1: List of compounds reported in chapter 8.2  
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ABSTRACT:   
Nine derivatives of 4-amino-1,5-dimethyl-2-phenyl-2,3-dihydro-1H-pyrazol-3-one (4-
aminoantipyrine), C11H13N3O,  have been synthesized and structurally characterized. The 
derivatives were synthesized from the reactions of various ketones, aldehydes, alcohols and 
carboxylic acids, producing: 1,5-dimethyl-4-(4-oxocyclohexa-2,5-dienylideneamino)-2-phenyl-
1H-pyrazol-3(2H)-one, C17H15N3O, (I), 4-(benzylideneamino)-1,5-dimethyl-2-phenyl-1H-
pyrazol-3(2H)-one, C18H17N3O, (II), 4-(3-hydroxy-4-methoxybenzylideneamino)-1,5-dimethyl-
2-phenyl-1H-pyrazol-3(2H)-one, C19H19N3O3, (III), N-(1,5-dimethyl-3-oxo-2-phenyl-2,3-
dihydro-1H-pyrazol-4-yl)-2-phenylacetamide, C19H19N3O2, (IV), N-(1,5-dimethyl-3-oxo-2-
phenyl-2,3-dihydro-1H-pyrazol-4-yl)-3-phenylpropanamide, C20H21N3O2, (V), 4-(bis(2-
hydroxyphenyl)methyleneamino)-1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one, C24H21N3O3, 
(VI), 1,5-dimethyl-4-(2-oxoacenaphthylen-1(2H)-ylideneamino)-2-phenyl-1H-pyrazol-3(2H)-
one, C23H17N3O2, (VII), 2,5-bis(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-
ylamino)cyclohexa-2,5-diene-1,4-dione, C28H26N6O4, (VIII), and 4,4'-(1,3-dihydroxypropane-
1,3-diyl)bis(azanediyl)bis(1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one) dihydrate, 
C25H29N6O6,  (IX). The reaction of 4-aminoantipyrine with ketones and aldehydes yielded 
imines, whereas its reaction with an alcohol yielded an enamine. The reaction of 4-
aminoantipyrine with carboxylic acids yielded two amides and one enamine. These reactions of 
the amine functional group of 4-aminoantipyrine with carboxylic acid functional groups is 
unusual, as two of them occurred at room temperature and one at 40°C, whereas these reactions 
are usually only expected to take place at over 100°C. 
 
 
 
 
 
 
KEYWORDS:   
4-Aminoantipyrine, crystal engineering, imines, enamines, amides 
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Introduction 
 
4-Aminoantipyrine (4AAP) is an API with powerful antipyretic (fever reducing) properties 
(Acheson, 1960), and is considered a prophylactic against oxidative stress (Teng et al., 2011a). 
The crystal structure of 4AAP has been reported by Li et al. (Li et al., 2013) and by Mnguni et al 
(Mnguni and Lemmerer, 2015). Two of its derivatives, aminoantipyrine and 4-(N,N-dimethyl)-
aminoantipyrine, have been used as analgesic and anti-inflammatory drugs since the late 19
th
 
century. Their concurrent use with aspirin is particularly beneficial as they have been shown to 
prevent or attenuate the anti-platelet effects of aspirin (Hohlfeld et al., 2008). However, despite 
the many documented therapeutic benefits, these pyrazolones have been associated with 
agranulocytosis and their use has been largely discontinued (Teng et al., 2011b). This has 
sparked a drive to produce covalently modified derivatives of 4AAP (Deshmukh et al., 2015). 
Deshmukh commented that due to the significant benefits of 4AAP derivatives, and their 
interactions with DNA, the precise nature and structures of these Schiff bases is of “remarkable 
importance”. The desired modification of 4AAP to prepare pharmaceutically significant 
derivatives is by the covalent addition of adducts to the 4-amino functional group shown in 
Figure 1. Mnguni et al. recently reported that in 4AAP that has been covalently modified to 
form Schiff bases to form enamines, six-membered intermolecular N−H···O hydrogen bonding 
is favoured, with imines having C−H···O bonds. Mnguni notes that of 146 structures in the 
Cambridge Structural Database (CSD, Version 5.34) (Groom and Allen, 2014) of modified 
isoniazid that crystallize with an imine backbone, all 136 non-solvated or hydrated structures 
have an intramolecular C−H···O bond. All structures having an enamine backbone contain 
intramolecular N−H···O hydrogen bonding (Mnguni and Lemmerer, 2015). This report contains 
a structural study of 4-aminoantipyrine molecules that have been covalently modified to form 
Schiff bases. 
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N
N
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O
    
N
N
N
O
R1
R2  
Figure 1: Structure of 4AAP and its derivatives. The desired modification of 4AAP is by the 
covalent addition of adducts (R1 and/or R2) to the 4-amino functional group. 
 
 
 
Experimental Methods 
1,5-dimethyl-4-(4-oxocyclohexa-2,5-dienylideneamino)-2-phenyl-1H-pyrazol-3(2H)-one, I 
0.0631 g of 4-aminoantipyrine (0.311 mmol) and 0.0343 g of 1,4-benzoquinone (0.317 mmol) 
were added into a sample vial. The solids were dissolved in 3 mL of 1,2-dichloroethane, stirred 
for 30 minutes at room temperature, and were left to stand very slightly opened to the 
atmosphere. Red plates were afforded after 2 days.  
 
4-(benzylideneamino)-1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one, II 
0.0998 g of 4-aminoantipyrine (0.491 mmol) and 1.0 mL of benzaldehyde were added into a 
sample vial. 3 mL of 1,2-dichloroethane was added, the solution stirred for 30 minutes at room 
temperature, and left to stand very slightly opened to the atmosphere. White needles were 
afforded after 3 days.  
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4-(3-hydroxy-4-methoxybenzylideneamino)-1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one, 
III 
0.1025g of 4-aminoantipyrine (0.5043 mmol) and 0.0805 g of 3-hydroxy-4-
methoxybenzaldehyde (0.529 mmol) were added into a sample vial. The solids were dissolved in 
10 mL of a 1:1 1,2-dichloroethane : acetonitrile mixture, and stirred for 60 minutes at room 
temperature. Dimethylformamide (DMF) was added dropwise until all the solids had dissolved. 
The solution was then left to stand opened to the atmosphere. Colourless blocks were afforded 
after 60 days.  
 
N-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-2-phenylacetamide, IV 
0.0821 g of 4-aminoantipyrine (0.404 mmol) and 0.0577 g of phenylethanoic acid (0.424 mmol) 
were added into a sample vial. The solids were dissolved in 3 mL of 1,2-dichloroethane, stirred 
for 30 minutes at room temperature, and were left to stand very slightly opened to the 
atmosphere. The resultant solid mass was re-dissolved in chloroform and again left to stand very 
slightly opened to the atmosphere. Yellow blocks were afforded after 24 hours.  
 
N-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-3-phenylpropanamide, V 
0.0978 g of 4-aminoantipyrine (0.481 mmol) and 0.0727 g of phenylpropanoic acid (0.484 
mmol) were added into a sample vial. The solids were dissolved in 3 mL of methanol, stirred for 
30 minutes at 40°C, and were left to stand very slightly opened to the atmosphere. Colourless 
plates were afforded after 3 days.  
 
4-(bis(2-hydroxyphenyl)methyleneamino)-1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one, VI 
0.0733 g of 4-aminoantipyrine (0.361 mmol) and 0.0782 g of 2,2’-dihydroxybenzophenone 
(0.365 mmol) were added into a sample vial. The solids were dissolved in 5 mL of a 1:1 mixture 
of 1,2-dichloroethane : methanol, stirred for 30 minutes was left to stand opened to the 
atmosphere. 3 mL of chloroform and 3mL of ethanol was added to re-dissolve the resultant solid 
mass after all the solvent had evaporated, and the solution was again left to stand very slightly 
opened to the atmosphere. Yellow blocks were afforded after 2 days.  
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1,5-dimethyl-4-(2-oxoacenaphthylen-1(2H)-ylideneamino)-2-phenyl-1H-pyrazol-3(2H)-one, 
VII 
0.0672 g of 4-aminoantipyrine (0.331 mmol) and 0.0611 g of acenaphthylene-1,2-dione (0.335 
mmol) were added into a sample vial. The solids were dissolved in 5 mL of a 1:1 mixture of 1,2-
dichloroethane : methanol, and stirred for 60 minutes. 6 drops of dimethylformamide (DMF) 
were added to ensure that the solid was fully dissolved. The solution was then left to stand very 
slightly opened to the atmosphere. Orange blocks were afforded after 14 days.  
 
2,5-bis(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-ylamino)cyclohexa-2,5-
diene-1,4-dione, VIII 
0.0832 g of 4-aminoantipyrine (0.409 mmol) and 0.0611 g of 2,5-dihydroxy-1,4-benzoquinone 
(0.408 mmol) were added into a sample vial. The solids were dissolved in 20 mL of a mixture of 
equal parts of 1,2-dichloroethane, methanol, chloroform, and toluene, and stirred for 120 
minutes. 6 drops of dimethylformamide (DMF) were added to ensure that the solid was fully 
dissolved. The solution was then left to stand very slightly opened to the atmosphere. Red plates 
were afforded after 14 days. (The unusual mixture of solvents is due to the fact that initially the 
reagents would not dissolve in 5 mL of 1,2-dichloroethane. Therefore, 5 mL of each of the other 
solvents were added one by one until the reagents started dissolving.) 
 
4,4’-(1,3-dihydroxypropane-1,3-diyl)bis(azanediyl)bis(1,5-dimethyl-2-phenyl-1H-pyrazol-
3(2H)-one) dihydrate, IX 
0.0742 g of 4-aminoantipyrine (0.365 mmol) and 0.0391 g of malonic acid (0.376 mmol) were 
added into a sample vial. The solids were dissolved in 3 mL of a 1:1 mixture of 1,2-
dichloroethane : methanol, stirred for 30 minutes at room temperature, and were left to stand 
very slightly opened to the atmosphere. The resultant solid mass was re-dissolved in chloroform 
and again left to stand very slightly opened to the atmosphere. Colourless blocks were afforded 
after 3 days.  
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Crystal Data and X-ray Structure Analysis.  
Intensity data for the nine crystal structures were collected on a Bruker APEX II CCD area 
detector diffractometer with graphite monochromated Mo-Kα radiation (50 kV, 30 mA) at 173K. 
The collection method involved ω-scans with a 0.5° width. SAINT+ version 6.02.6 software was 
used for data reduction and SADABS was used to make empirical absorption corrections (Bruker, 
2004). The crystal structures were solved using direct methods on SHELXS-97 (Sheldrick, 2015). 
Non-hydrogen atoms were first refined isotropically, followed by anisotropic refinement by full 
matrix least-squares calculations based on F
2
 using SHELXL-2017 (Sheldrick, 2015). C-bound H 
atoms were located in the difference electron density map, then positioned geometrically and 
were allowed to ride on their respective parent atoms, with thermal displacement parameters 1.2 
times that of the parent C atom. Diagrams and publication material were generated using WinGX 
(Farrugia, 2012), ORTEP-3 (Farrugia, 2012), PLATON (Spek, 2009) and MERCURY (Macrae, C. 
F. et al., 2008). The crystallographic data of each crystal is summarized in Table 1, the hydrogen 
bonding geometries in Table 2, and a table of bond lengths for bonds involving N1 in Table 3. 
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Table 1 Crystallographic data for compounds 1-9 
 I II III IV V 
Formula C17H15N3O C18H17N3O C19H19N3O3 C19H19N3O2 C20H21N3O2 
Mr 293.32 
 
291.34 
 
337.37 
 
321.37 
 
335.40 
 
Temperature/K 173(2) 173(2) 173(2) 173(2) 173(2) 
Wavelength/Å 0.71073 0.71073 0.71073 0.71073 0.71073 
Crystal size/mm3 0.078×0.151×0.282 0.134×0.198×0.387 0.122×0.302×0.529 0.032×0.291×0.393 0.116×0.190×0.668 
Crystal system Monoclinic Monoclinic Monoclinic Triclinic Orthorhombic 
Space group P21/c P21/c P21/c P1 Pca21 
a/Å 8.2850(5) 12.9148(4) 7.0345(2) 10.1188(9) 15.6407(5) 
b/Å 23.9870(14) 6.8245(2) 26.0987(6) 10.4488(9) 6.8754(2) 
c/Å 7.2890(4) 17.0268(5) 9.0665(2) 17.8713(15) 32.4198(13) 
α/° 90 90 90 100.768(4) 90 
β/° 98.162(4) 90.112(2) 98.3950(10) 92.597(4) 90 
γ/° 90 90 90 116.833(4) 90 
V/Å3 1433.89(14) 1500.69(8) 1646.70(7) 1638.2(3) 3486.3(2) 
Z 4 4 4 4 8 
ρ (calcd)/Mg m-3 1.359 1.290 1.361 1.303 1.278 
μ/mm-1 0.092 0.082 0.094 0.086 0.084 
F(000) 616 616 712 680 1424 
ϴ Range for data 
collection/° 
1.698 to 25.475 1.577 to 25.498 1.560 to 27.993 2.846 to 27.999 2.513 to 26.320 
Reflections collected 15414 9987 26500 77304 14726 
No. of unique data 
[R(int)] 
2661 [0.0742] 2223 [0.0637] 3964 [0.0471] 7908 [0.0583] 7908 [0.0583] 
   No. data with I ≥ 2σ(I) 1577 1565 3234 6188 4236 
Final R(I ≥ 2σ(I)) 0.0504 0.0650 0.0451 0.0456 0.0545 
Final wR2 (all data) 0.1287 0.1975 0.1153 0.1063 0.1529 
CCDC deposition 
number 
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 VI VII VIII IX 
Formula C24H21N3O3 C23H17N3O2 C28H26N6O4 C25H29N6O6 
Mr 399.44 
 
367.39 
 
510.55 
 
509.54 
 
Temperature/K 173(2) 173(2) 173(2) 173(2) 
Wavelength/Å 0.71073 0.71073 0.71073 0.71073 
Crystal size/mm3 0.203×0.214×0.264 0.095×0.100×0.249 0.046×0.222×0.266 0.140×0.204×0.292 
Crystal system Monoclinic Triclinic Monoclinic Triclinic 
Space group P21 P1 P21/n P1 
a/Å 7.8217(4) 7.1299(2) 13.0398(4) 9.8423(6) 
b/Å 15.7139(8) 9.2954(3) 7.1786(2) 11.2923(7) 
c/Å 8.7602(4) 13.9034(4) 14.9824(5) 13.3810(8) 
α/° 90 75.985(2) 90 69.053(3) 
β/° 108.278(3) 84.244(2) 112.642(2) 73.926(4) 
γ/° 90 83.840(2) 90 68.979(3) 
V/Å3 1022.39(9) 886.22(5) 1294.37(7) 1277.49(14) 
Z 2 2 2 2 
ρ (calcd)/Mg m-3 1.298 1.377 1.310 1.325 
μ/mm-1 0.087 0.090 0.091 0.097 
F(000) 420 384 536 538 
ϴ Range for data 
collection/° 
2.448 to 27.997 2.267 to 25.500 1.764 to 27.993 1.654 to 27.999 
Reflections collected 8444 13937 13992 22991 
No. of unique data [R(int)] 4210 [0.0238] 3222 [0.0443] 3129 [0.0553] 6140 [0.0632] 
   No. data with I ≥ 2σ(I) 3888 2479 2084 3310 
Final R(I ≥ 2σ(I)) 0.0364 0.0378 0.0458 0.0757 
Final wR2 (all data) 0.0957 0.1094 0.1133 0.2364 
CCDC deposition number     
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Table 2 Hydrogen bonding details of compounds I-IX 
 d(D─H)/Å d(H···A)/Å d(D···A)/Å ∠(D─H···A)/° 
I     
 C4-H4C∙∙∙O1a 0.98 2.33 3.282(3) 164 
 C11-H11···N1b 0.95 2.63 3.576(3) 175 
 C14-H14···O2c 0.95 2.41 3.348(3) 170 
 C16-H16···O1d 0.95 2.51 3.384(3) 152 
 C17-H17···O1 0.95 2.11 2.961(3) 148 
I 
    
 C4-H4C···O1e 0.98 2.53 3.497(4) 168 
 C5-H5A···O1e 0.98 2.59 3.476(4) 151 
 C12-H12···O1 0.95 2.41 3.072(4) 127 
III     
 C4-H4C···O1f 0.98 2.34 3.3111(19) 172 
 C7-H7···O2g 0.95 2.53 3.2721(18) 135 
 C11-H11···N1h 0.95 2.69 3.6306(19) 172 
 C12-H12···O1 0.95 2.35 3.0401(18) 129 
 O2-H2···O1g 0.84 1.83 2.6570(15) 167 
IV     
C4-H4A···O2 0.98 2.51 3.1241(19) 120 
 C23-H23C···O4 0.98 2.58 3.0803(19) 112 
 C32-H32A···O4i 0.99 2.53 3.4177(17) 150 
 N1-H1···O3 0.88 1.95 2.8250(14) 173 
 N4-H4···O1 0.88 1.96 2.8093(14) 162 
V     
 C4-H4A···O1j 0.98 2.58 3.435(7) 146 
 C4-H4B···O2 0.98 2.40 3.066(7) 125 
 C5-H5A···O4 0.98 2.56 3.248(7) 127 
 C5-H5C···O1j 0.98 2.48 3.260(7) 137 
 N1-H1···O3k 0.88 2.00 2.833(7) 158 
 C24-H24A···O3j 0.98 2.55 3.396(7) 145 
 C24-H24B···O4 0.98 2.41 3.079(7) 125 
 C25-H25A···O2j 0.98 2.58 3.253(7) 126 
 C25-H25C···O3j 0.98 2.47 3.274(7) 139 
 N4-H4···O1l 0.88 2.01 2.850(7) 159 
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a
 x,y,z+1. 
b 
-x,-y+1,-z+2. 
c
 x,-y+3/2,z+1/2. 
d
 -x+1,-y+1,-z+1. 
e
 x,y+1,z. 
f
 x-1,y,z. 
g
 -x+1,-y+1,-z+1. 
h
 -x,-y+1,-z+2  
i
 -x+2,-y+2,-z+1. 
j
 x,y-1,z. 
k
 x-1/2,-y+2,z. 
l
 x+1/2,-y+2,z. 
m
 x,y,z-1. 
n
 x+1,y,z. 
o
 -x+1,-y+1,-z+1. 
p
 x,y+1,z.  
q
 x+1/2,-y+1/2,z+1/2. 
r
 x+1/2,-y-1/2,z+1/2. 
s
 -x+3/2,y+1/2,-z+1/2. 
t
 -x+1,-y+1,-z+1. 
u
 x-1,y,z. 
v
 -x,-y+2,-z+1.  
w
 -x+1,-y+2,-z. 
x
 -x,-y+1,-z+1.  
 
 
 
 
 
 
 
 
 
VI     
 O2-H2···N1 0.84 1.83 2.567(2) 146 
 O3-H3···O1m 0.84 1.89 2.727(2) 172 
VII     
 C4-H4C···O1n 0.98 2.41 3.378(2) 168 
 C5-H5C···O2o 0.98 2.43 3.397(2) 167 
VIII     
 C4-H4C···O1p 0.98 2.41 3.387(2) 172 
 C5-H5C···O2q 0.98 2.25 3.213(2) 168 
 C7-H7···O2r 0.95 2.59 3.262(2) 128 
 N1-H1···O1s 0.88 2.09 2.8645(18) 147 
IX     
 C5-H5C···O1Wt 0.98 2.50 3.475(5) 173 
 C17-H17A···O2u 0.98 2.55 3.502(5) 165 
 C23-H23···O2W 0.95 2.52 3.434(5) 161 
 C25-H25A···O3v 0.99 2.32 3.210(5) 149 
 C25-H25B···O1w 0.99 2.65 3.448(4) 138 
 N1-H1···O1w 0.90(3) 1.86(3) 2.764(3) 177(3) 
 N4-H4···O3v 0.99(5) 1.99(5) 2.938(4) 160(4) 
 O1W-H1W···O2 0.89 1.91 2.770(4) 162 
 O1W-H2W···O3 0.91 1.81 2.709(4) 170 
 O2W-H3W···O4x 0.85 2.13 2.914(6) 153 
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Table 3 Bond lengths for bonds 
involving N1  
Bond lengths 
[Å] 
I  
C2-N1  1.375(3) 
C12-N1  1.312(3) 
II  
C2-N1  1.381(4) 
C12-N1 1.290(4) 
III  
C2-N1 1.3937(18) 
C12-N1 1.2844(19) 
IV  
C2-N1 1.4070(16) 
C12-N1 1.3572(17) 
N1-H1  0.8800 
V  
C2-N1 1.407(8) 
C12-N1 1.363(8) 
N1-H1 0.8800 
VI  
C2-N1 1.421(3) 
C12-N1 1.290(3) 
VII  
C2-N1 1.386(2) 
C12-N1 1.2881(19) 
VIII  
C2-N1 1.4139(19) 
C12-N1 1.339(2) 
N1-H1 0.8800 
IX  
C2-N1 1.411(4) 
C12-N1 1.335(4) 
N1-H1 0.90(3) 
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Results 
 
The asymmetric units of structures I to IX are shown in Figure 2. 
      (I)          (II) 
 
(III)          (IV) 
 
   (V)          (VI) 
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   (VII)          (VIII) 
 
   (IX)    
Figure 2: Asymmetric units of structures I-IX. 
 
The reaction of the ketone group of 1,4-benzoquinone with the amine group of 4AAP produced 
the imine I. Structure I crystallizes in the P21/c space group and contains one molecule of 1,5-
dimethyl-4-(4-oxocyclohexa-2,5-dienylideneamino)-2-phenyl-1H-pyrazol-3(2H)-one. The 
molecules in crystal I form discreet zero-dimensional (0D) entities that are not hydrogen bonded 
to any other molecules. The crystal structure is held together entirely through multiple weak 
C−H···O and C−H···N interactions. The C−H···O interactions occur between both the carbonyl 
oxygen on the benzoquinine moiety and the antipyrine carbonyl oxygen with hydrogen atoms on 
the benzoquinone ring of neighbouring molecules as shown in Figure 3. The C−H···N 
interaction is between the amine nitrogen atom and the benzene ring of the antipyrine moiety. 
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Figure 3: Packing diagram of I showing the multiple weak C−H···O and C−H···N interactions. 
 
The reaction of the aldehyde group of benzaldehyde with the amine group of 4AAP produced the 
imine II. Structure II crystallizes in the P21/c space group and contains one molecule of 4-
(benzylideneamino)-1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one. As with crystal I, crystal II 
does not have regular hydrogen bonding, but packs via weak C−H···O and C−H···π interactions. 
The carbonyl oxygen atom of the antipyrine ring interacts with the H18 atom of the 
benzaldehyde aromatic ring via a C−H···O interaction and the methyl hydrogen atom H4B 
undergoes a C−H···π interaction with the π-system on the antipryring ring shown in Figure 4a. 
This results in a visually pleasing 1D tape along the b-axis with the aromatic rings directed 
towards the edges of the tape as shown in Figure 4b. 
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(a) 
 
 
 
(b) 
Figure 4: Packing diagram of II showing (a) C−H···O and C−H··· π interactions and (b) the 1D 
ribbon formed along the b-axis. 
 
The reaction of the aldehyde group of 3-hydroxy-4-methoxybenzaldehyde with the amine group 
of 4AAP produced the imine III. Structure III crystallizes in the P21/c space group and contains 
one molecule of 4-(3-hydroxy-4-methoxybenzylideneamino)-1,5-dimethyl-2-phenyl-1H-pyrazol-
3(2H)-one. The 3-hydroxy group on the benzaldehyde adduct provides a hydrogen bond donor 
(H2) to the carbonyl acceptor (O1) of a neighbouring molecule to form a dimer via two sets of 
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C−H···O heterosynthons with graph set notation  2
2 20  (Bernstein et al., 1995)) This results in a 
packing pattern consisting of 0D entities as shown in Figure 5. 
 
Figure 5: Packing diagram of III showing the dimers and the R2
2 20  ring formed by two 
C−H···O heterosynthons. 
 
The reaction of the carboxylic acid group of phenylethanoic acid with the amine group of 4AAP 
produced the amide IV. Structure IV crystallizes in the P  space group and contains two 
molecules of N-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-2-phenylacetamide. 
The two molecules in the asymmetric unit form a dimer via two N−H···O heterosynthons formed 
between the carbonyl oxygen aceptor atoms and the amine hydrogen donor atoms, resulting in 10 
membered ring, with graph-set notation   
     . The reaction of the amine group with a 
carboxylic acid group at room temperature is unusual, because at room temperature one would 
expect the basic amine to deprotonate the carboxylic acid to form an unreactive carboxylate. 
However, at high temperatures (above 100°C), dehydration can occur with the loss of a water 
molecule, and the nitrogen lone pair attacks the resulting carbocation forming an amide. 
However, in the case of IV, the dehydration reaction occurred at room temperature. This unusual 
dehydration reaction was also observed at room temperature in crystal IX described below, and 
at 40°C in crystal V. The hydrogen bonded dimers form a 0D packing pattern as shown in 
Figure 6. 
 
The reaction of the carboxylic acid group of phenylpropanoic acid with the amine group of 
4AAP produced the amide V. Structure V crystallizes in the Pca21 space group and contains two 
molecules of N-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-3-
phenylpropanamide. Structure V packs in one dimensional (1D) tubes along the b-axis (Figure 
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6b) which are held together by a  2
2 10  ring formed via two N−H···O heterosynthons, where 
the amine hydrogen atom of each molecule in the asymmetric unit provides the hydrogen bond 
donor to the carbonyl acceptor atom of the other molecule in the asymmetric unit. 
 
       (a) 
 
       (b) 
Figure 6: Packing diagram of (a) IV showing the dimers and the  2
2 20  ring formed by two 
C−H···O heterosynthons (b) Crystal V showing the “square tubing” packing pattern along the b-
axis. 
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The reaction of the ketone group of 2,2’-dihydroxybenzophenone with the amine group of 4AAP 
produced the imine VI. Structure VI crystallizes in the P21 space group and contains one 
molecule of 4-(bis(2-hydroxyphenyl)methyleneamino)-1,5-dimethyl-2-phenyl-1H-pyrazol-
3(2H)-one. As expected from Etter’s rules of hydrogen bonding (Etter et al., 1990), one of the 
hydroxyl group donors (H2) forms a six-membered intramolecular hydrogen bonded ring (graph 
set notation S(6)) with the imine nitrogen atom (N1). The other hydroxyl group forms a regular 
C−H···O heterosynthon with the carbonyl oxygen acceptor atom of an adjacent molecule to form 
a  1
1 9  chain or ribbon along the c-axis (Figure 7a). The structure is further stabilized by π ···π 
stacking of the aromatic antipyrine ring of one molecule and one of the benzophenone rings of 
another molecule in a slightly tilted fashion, 4.063 Å apart along the a-axis with a distance of 
4.063 Å between the rings (Figure 7b). 
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 (a)  
 
 
            (b)  
 
Figure 7: Packing diagram of VI showing (a) the 1D chain or ribbon formed along the c-axis 
and (b) the π···π stacking of the aromatic antipyrine ring and one of the benzophenone rings 
along the a-axis. 
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The reaction of the ketone group of acenaphthylene-1,2-dione with the amine group of 4AAP 
produced the imine VII. Structure VII crystallizes in the P  space group and contains one 
molecule of 1,5-dimethyl-4-(2-oxoacenaphthylen-1(2H)-ylideneamino)-2-phenyl-1H-pyrazol-
3(2H)-one. The extensive π system of the acenaphthylene lends itself to π···π nteractions in the 
asymmetric unit, and indeed, the molecules of this crystal stack together with the acenaphthylene 
groups stacked on top of each other as shown in Figure 8a with the aromatic ring involved in 
π···π interactions having a distance of 3.269 Å apart . The packing is supported by C−H···O 
ands C−H··· π interactions. The carbonyl oxygen (O1) of the antipyrine moiety has a weak 
C−H···O interaction with the H8 hydrogen atom of the antipyrine aromatic ring and the 
acenaphthylene carbonyl oxygen (O2) has a weak C−H···O interaction with the H22 atom of the 
acenaphthylene group of an adjacent molecule. Lastly a C−H···π interaction is found between 
the H9 hydrogen atom of the antipyrine aromatic ring and the acenaphthylene π system as shown 
in Figure 8b. 
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        (a) 
 
       (b) 
 
Figure 8: Packing diagram of VII showing (a) the extensive π ···π stacking of the 
acenaphthylene groups and (b) the weak supporting C−H···O and C−H··· π interactions. 
 
The reaction of the two hydroxy groups of 2,5-dihydroxy-1,4-benzoquinone with the amine 
groups of two 4AAP molecules produced the enamine VIII. Structure VIII crystallizes in the 
P21/n space group and contains one molecule of 2,5-bis(1,5-dimethyl-3-oxo-2-phenyl-2,3-
dihydro-1H-pyrazol-4-ylamino)cyclohexa-2,5-diene-1,4-dione. The two amine groups provide 
hydrogen bond donors to the antipyrine carbonyl acceptor of two different molecules to form 
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two N−H···O heterosynthons. These hydrogen bonds form a  1
1 10  chain which zig-zags down 
the b-axis, resulting in 1D ribbons along that axis. 
 
 
 
  (a) 
 
          (b) 
Figure 9: (a) and (b): Two different views of the chain formed down the b-axis by the two 
N−H···O heterosynthons in crystal VIII. 
 
The reaction of the two carboxylic acid groups of malonic acid with the amine groups of two 
4AAP molecules produced the enamine IX, which is a dihydrate crystal. Structure IX 
crystallizes in the 1 space group and contains one molecule of 4,4’-(1,3-dihydroxypropane-1,3-
diyl)bis(azanediyl)bis(1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one) dihydrate and two water 
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molecules. Although the stoichiometry of the reactants was 1:1, both carboxylic acid groups of 
the malonic acid reacted with the amine groups of two separate 4AAP molecules. One of the 
water molecules forms a bridge by hydrogen bonding through its two H-atoms to the carbonyl 
oxygen atoms of O2 and O3 respectively. This bridge creates a  2
2 11  hydrogen bonded ring. 
There is a second water molecule in the asymmetric unit shown in Figure 2, but it was not 
possible to determine the position of the second hydrogen atom, and hence it is shown in the 
diagram as having only one hydrogen atom, which also explains the reason for the larger 
ellipsoid. On the opposite side of the molecule to the water molecules, two 4,4'-(1,3-
dihydroxypropane-1,3-diyl)bis(azanediyl)bis(1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one) 
molecules are joined to each other via two N−H···O heterosynthons, formed between the amine 
hydrogen atoms and the antipyrine carbonyl oxygen atoms. This reults in a  2
2 10  hydrogen 
bonded ring between the two molecules. The extensive hydrogen bonding results in a 3D 
packing network (Figure 10).  
 
Figure 10: The 3D network formed by the extensive hydrogen bonding of structure IX. 
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Conclusion 
Three reactions of 4-aminoantipyrine with ketones (Structures I, VI and VII) and two with 
aldehydes (II, III) yielded imines, whereas the reaction of 4AAP with an alcohol (VIII) resulted 
in an enamine. Two amides (IV, V) and one enamine (IX) resulted from the reaction of 4AAP 
with carboxylic acids. The reactions of the amine functional group of 4AAP with carboxylic acid 
functional groups is unusual, as two of them occurred at room temperature and one at 40°C, 
whereas these reactions are usually only expected to take place at over 100°C. Regular hydrogen 
bonding is absent in structures I and II, and the packing of these structures is solely via weak 
C−H···O, C−H···N, C−H···π interactions. The extensive π system of VII leads to packing that is 
primarily via π···π stacking  interactions with supporting weak C−H···O  interactions. 
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Chapter 9:  Conclusion 
 
9.1 Concluding remarks 
 
In this study, crystal and co-crystal engineering was applied to synthesize 49 novel crystals and 
co-crystals of covalently modified isoniazid and 4-aminoantipyrine. Isoniazid was modified by 
bulky modifiers, namely benzophenone and benzophenone derivatives, and crystallized in the 
absence and presence of co-formers. The effects of reaction and crystallization conditions on the 
supramolecular structure of isoniazid was studied and reported. Co-crystal design strategies were 
developed to synthesize the first reported co-crystal of 4-aminoantipyrine, and the 
supramolecular synthesis of covalently modified 4-aminoantipyrine was studied. Side reactions 
of benzophenone were observed and this study was expanded to determine the origin and 
crystallization processes of these benzophenone azines observed during crystallization. The work 
reported in this thesis contributes to the development of co-crystal design strategies and to the 
understanding of co-crystal and crystal structures of isoniazid, 4-aminoantipyrine, benzophenone 
and their derivatives as detailed below.  
A series of co-crystals of isoniazid that had been modified with benzophenone and 
benzophenone derivatives were synthesized and their supramolecular structures were studied. All 
co-crystals were synthesized with 2-hydroxybenzoic acid (salicylic acid) and control of 
dimensionality was achieved. As expected, the salicylic acid co-formers formed intramolecular 
rings, leaving only the carboxylic acid available for intermolecular hydrogen bonding with the 
pyridine group of the modified isoniazid molecule. It was found that the benzophenone modifiers 
sterically masked the amide functional groups from participating in any intermolecular 
interactions. This steric masking is predictable and consistent and provides a general method 
whereby an amide functional group can be sterically blocked from intermolecular interactions. 
Only one structure of isoniazid which has been modified with a benzophenone modifier has been 
reported where the amide hydrogen is not masked, due to the the small size and planar geometry 
of the m-hydroxybenzoic acid co-former. 
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Carrying on the theme of the covalent assisted supramolecular synthesis of isoniazid with bulky 
ligands, another series of co-crystals was synthesized to study the effect of reaction and 
crystallization conditions on their supramolecular synthesis. A change in reflux time of the 
reagents resulted in stoichiometric variation in the resulting co-crystals. The addition of excess 
reagents as an additive resulted in polymorphism. Addition or absence of an acid catalyst either 
promoted or prevented solvate formation. It was also reported that the addition of either one or 
two methyl groups to the benzophenone aromatic rings did not substantially alter the packing 
patterns of the crystal structures.  
As the formation of co-crystals may either enhance or inhibit bioavailability and solubility of the 
drugs, the covalent modification of isoniazid was repeated in the absence of co-formers. The 
absence of the carboxylic acid co-former provided synthetic challenges as the co-former 
previously acted as a catalyst and enhanced the covalent modification of the isoniazid. The 
covalent modification without the co-former was difficult and harsh reaction conditions were 
often required. The use of new catalysts and the development of new synthetic strategies such as 
refluxing under pressure at higher temperatures than regular reflux setups allow, through the use 
of high-pressure screw-top vials, was therefore incorporated into the synthetic methods. A full 
structural study was done and reported on the covalently modified isoniazid crystals. 
Benzophenone azines were observed as side products during the studies mentioned above, and 
the study was therefore expanded to determine the origin and mechanism of the formation of 
these benzophenone azines to provide a comprehensive and complete picture of all processes 
involved in the study. Covalently modified isoniazid intermediates were isolated and the crystal 
structures determined. These, when placed in direct sunlight, resulted in the formation of an 
isoniazid dimer and benzophenone azine in each case, confirming the presence of a 
photodimerization process. The benzophenone azines crystals were found to be held together 
through weak interactions and a structural study of the packing of these crystals was reported. 
This thesis also contains an extensive literature review of all the relevant work done on the 
covalent modification, crystallization and co-crystallization to date. The work done on isoniazid 
as detailed above provides a potentially effective method of synthesizing effective drugs against 
multi-drug-resistant strains of Mycobacterium tuberculosis. This thesis therefore provides a 
comprehensive picture for a researcher who might be interested in synthesizing crystalline drugs 
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against multi-drug resistant strains of Mycobacterium tuberculosis, as well as providing methods 
by which the supramolecular synthesis may be achieved, as well as an understanding of the 
structures of such crystals and co-crystals. 
The formation of a co-crystal of 4-aminoantipyrine has long evaded researchers. Co-crystal 
design strategies were developed to synthesize the first reported co-crystal of 4-aminoantipyrine. 
The relevant chapter in this thesis details several reported literature attempts at synthesizing this 
co-crystal and provides details of the successes and failures on the path to synthesizing this co-
crystal. Two novel salts of 4-aminoantipyrine and two co-crystals of covalently modified 4-
aminoantipyrine were also reported.  
As it has been reported in literature that the covalent modification of 4-aminoantipyrine is of 
significant pharmaceutical importance, a series of crystals of covalently modified 4-
aminoantipyrine were synthesized and a full structural study of these crystals was presented.  
 
9.2 Future work 
 
The work done on isoniazid as detailed above provides a potentially effective method of 
synthesizing effective drugs against multi-drug-resistant strains of Mycobacterium tuberculosis. 
However, biological assays should be performed to determine the effectiveness of the crystals 
and co-crystals presented in this thesis against multi-drug-resistant strains of TB. Methods 
should be developed to test the efficacy of co-crystals as compared with crystals of covalently 
modified isoniazid. 
With regard to future co-crystal engineering, this study was largely confined to the use of mono-
carboxylic acid co-formers such as 2-, 3- and 4-hydroxybenzoic acids. However it would be of 
interest to prepare series of modified isoniazid with dicarboxylic acids, where 2D planes and 3D 
networks would be favoured, and to study the structures generated with these co-formers. Liquid 
assisted grinding (LAG) was also reported in the literature review to have produced several 
polymorphs of isoniazid co-crystals, a phenomenon not often seen with solvent dissolution in 
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isoniazid co-crystals. It would therefore be instructive to determine how effective covalent 
assisted supramolecular synthesis would be using LAG. 
With regards to 4-aminoantipyrine, the reaction of the amine group with a carboxylic acid at 
ambient temperature is unusual, because at room temperature one would expect the basic amine 
to deprotonate the carboxylic acid to form an unreactive carboxylate, whereas at high 
temperatures (above 100°C), dehydration can occur with the loss of a water molecule, and the 
nitrogen lone pair attacks the resulting carbocation forming an amide. However, this unusual 
dehydration reaction was observed at room temperature in two crystals and at 40°C in a third 
crystal, and it would be of interest to determine whether 4AAP will react with other carboxylic 
acids at room temperature. The methods of supramolecular synthesis of 4AAP co-crystals should 
also be applied to develop series of 4AAP co-crystals, as such co-crystals have the potential to 
mitigate some of the harmful side effects of treatment with this drug. 
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“The beauty of crystals lies in the planeness of their faces.” 
~ Alfred Edwin Howard Tutton in “The Natural History of  rystals” 
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APPENDIX 1 
 
Note that the DSC traces in this Appendix were produced and analyzed by Prof. Lemmerer and 
the Pawley refinements in this Appendix were done by Dr. Roy Forbes as required by the 
referees for the publication “Covalent Assisted Supramolecular Synthesis: Masking of Amides in 
Co-Crystal Synthesis using Benzophenone Derivatives”.  
The powder diffraction patterns were originally collected and analyzed by myself, but I did not 
contribute to the Pawley refinements in this Appendix and these therefore do not form part of 
this thesis. The supplementary material for this published paper is placed here for completeness. 
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SI1. Melting Points for Co-Crystals 1-6b 
 
Table S1. Melting points for Co-Crystals as determined by a Mettler Toledo MP50 melting point system. Melting 
points for polymorphs 3a and 3b, and 6a and 6b were determind by DSC (below). 
Co-Crystal Melting Point 
(°C) 
Co-Crystal 1 145.8 
Co-Crystal 2 128.2 
Co-Crystal 3a 134.3 (See text) 
Co-Crystal 3b 151.7 (See text) 
Co-Crystal 4 128.2 
Co-Crystal 5 204.9 
Co-Crystal 6a 136.6 (See text) 
Co-Crystal 6b 163.2 
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SI2. Representative DSC traces for Co-Crystals 3a, 3b, 6a, 6b  
 
3a  
Figure S1: Representative DSC trace (exothermic is up) for Co-Crystal 3a.  
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3b 
 
Figure S2: Representative DSC trace (exothermic is up) for Co-Crystal 3b.  
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6a 
 
Figure S3: Representative DSC trace (exothermic is up) for Co-Crystal 6b. 
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6b 
 
Figure S4: Representative DSC trace (exothermic is up) for Co-Crystal 6b.  
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SI3. Powder X-ray diffraction patterns for Co-Crystals 1 - 6b 
 
Experimental diffraction patterns of Co-crystals 1 – 6b were collected on a Bruker D2 Phaser using Co 
Kα1/2 radiation (Kα1 =1.788960 and Kα2 = 1.789879 Å) and a Lynxeye PSD detector. Pawley refinements 
were carried out on all data using Bruker AXS TOPAS version 4.2.  
1: (N'-(diphenylmethylene)isonicotinohydrazide)·(salicylic acid) 
 
 
Figure S5: Pawley refinement of 1, recorded at room temperature; the red line represents the diffraction pattern 
calculated from the unit cell of 1, the blue line represents the experimental diffraction pattern of 1, the grey line 
represents the difference curve between the calculated and experimental diffraction patterns while the HKL 
reflections (blue lines) predicted for the crystal structure of 1 are shown above the X-axis. The grey spheres 
highlight the positions of unidentified reflections. 
 
The result of the Pawley refinement shown in Figure S5 suggests that the crystal structure of 1 is 
representative of the bulk sample. Minor unidentified reflections, most likely due to the presence of 
impurity phases were also observed. The difference between the lattice parameters calculated at room 
temperature and that of the crystal structure data collected at 173K are shown below in Table S2.  
 
Table S2: A comparison of the lattice parameters of the input crystal structure and that obtained from the Pawley 
refinement 
 Lattice Parameters 
a (Å) b (Å) c (Å) β (º) 
Crystal 
structure 
25.8071(6) 6.924(2) 12.2426(3) 103.501(10) 
Pawley 
refinement 
25.8856(53) 7.041(14) 12.2471(27) 103.358(11) 
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2: (N'-(bis(2-hydroxyphenyl)methylene)isonicotinohydrazide)·(salicylic acid) 
 
 
Figure S6: Pawley refinement of 2, recorded at room temperature; the red line represents the diffraction pattern 
calculated from the unit cell of 2, the blue line represents the experimental diffraction pattern of 2, the grey line 
represents the difference curve between the calculated and experimental diffraction patterns while the HKL 
reflections (blue lines) predicted for the crystal structure of 2 are shown above the X-axis. The grey spheres 
highlight the positions of unidentified reflections. 
 
The result of the Pawley refinement shown in Figure S6 suggests that the crystal structure of 2 is 
representative of the bulk of the sample though several unidentified reflections are observed. These 
reflections may be present as a result of impurities in the sample. Alternatively, the unidentified 
reflections may also be as a result of structural changes that occur on heating the sample from 173K to 
ambient temperature.  The difference between the lattice parameters calculated at room temperature and 
that of the crystal structure data obtained collected at 173K are shown below in Table S3.  
 
Table S3: A comparison of the lattice parameters of the input crystal structure and that obtained from the Pawley 
refinement 
 Lattice Parameters 
a (Å) b (Å) c (Å) α (º) β (º) γ (º) 
Crystal structure 6.6193(2) 12.3234(3) 14.418(3) 98.727(2) 98.596(2) 100.665(2) 
Pawley 
refinement 
6.5544(11) 12.3372(28) 14.523(31) 99.355(20) 99.111(12) 100.543(17) 
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3a: (N'-(di-p-tolylmethylene)isonicotinohydrazide)·(salicylic acid), Form I 
 
 
Figure S7: Pawley refinement of 3a, recorded at room temperature; the red line represents the diffraction pattern 
calculated from the unit cell of 3a, the blue line represents the experimental diffraction pattern of 3a, the grey line 
represents the difference curve between the calculated and experimental diffraction patterns while the HKL 
reflections (blue lines) predicted for the crystal structure of 3a are shown above the X-axis. The grey spheres 
highlight the positions of unidentified reflections. 
 
The result of the Pawley refinement shown in Figure S7 suggests that the crystal structure of 3a is 
representative of the bulk sample. Minor unidentified reflections were also observed. These reflections 
may be the result of the presence of impurity phases. The difference between the lattice parameters 
calculated at room temperature and that of the crystal structure data obtained collected at 173K are shown 
below in Table S4. 
 
Table S4: A comparison of the lattice parameters of the input crystal structure and that obtained from the Pawley 
refinement 
 Lattice Parameters 
a (Å) b (Å) c (Å) α (º) β (º) γ (º) 
Crystal 
structure 
9.9062(2) 12.0906(3) 12.4633(3) 113.5360(10) 113.0770(10) 96.2970(10) 
Pawley 
refinement 
9.8931(43) 12.1068(28) 12.4539(42) 113.648(17) 113.229(26) 96.387(27) 
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3b: (N'-(di-p-tolylmethylene)isonicotinohydrazide)·(salicylic acid), Form II 
 
 
Figure S8: Pawley refinement of 3b, recorded at room temperature; the red line represents the diffraction pattern 
calculated from the unit cell of 3b, the blue line represents the experimental diffraction pattern of 3b, the grey line 
represents the difference curve between the calculated and experimental diffraction patterns while the HKL 
reflections (blue lines) predicted for the crystal structure of 3b are shown above the X-axis. The grey spheres 
highlight the positions of unidentified reflections. 
 
The result of the Pawley refinement shown in Figure S8 suggests that the crystal structure of 3b is 
representative of the bulk sample. Minor unidentified reflections were also observed. These reflections 
may be due to the presence of impurity phases or maybe the result of structural changes that occur on 
heating the sample from 173K to ambient temperature. The difference between the lattice parameters 
calculated at room temperature and that of the crystal structure data obtained collected at 173K are shown 
below in Table S5. 
 
Table S5: A comparison of the lattice parameters of the input crystal structure and that obtained from the Pawley 
refinement 
 Lattice Parameters 
a (Å) b (Å) c (Å) α (º) β (º) γ (º) 
Crystal structure 8.2520(3) 11.2852(4) 12.9411(5) 77.516(2) 85.880(2) 82.910(2) 
Pawley 
refinement 
8.2499(24) 11.2635(33) 12.8957(42) 77.543(22) 86.084(24) 82.672(31) 
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4: ((E)-N'-(phenyl(p-tolyl)methylene)isonicotinohydrazide)·(salicylic acid) 
 
 
Figure S9: Pawley refinement of 4, recorded at room temperature; the red line represents the diffraction pattern 
calculated from the unit cell of 4, the blue line represents the experimental diffraction pattern of 4, the grey line 
represents the difference curve between the calculated and experimental diffraction patterns while the HKL 
reflections (blue lines) predicted for the crystal structure of 4 are shown above the X-axis. The grey spheres 
highlight the positions of unidentified reflections. 
 
The result of the Pawley refinement shown in Figure S9 suggests that the crystal structure of 4 is 
representative of the bulk sample. As described previously for co-crystals 3a and 3b, unidentified 
reflections were also observed. The difference between the lattice parameters calculated at room 
temperature and that of the crystal structure data obtained collected at 173K are shown below in Table S6. 
 
Table S6: A comparison of the lattice parameters of the input crystal structure and that obtained from the Pawley 
refinement 
 Lattice Parameters 
a (Å) b (Å) c (Å) α (º) β (º) γ (º) 
Crystal structure 7.0057(4) 11.5495(7) 15.6046(9) 87.598(4) 82.792(4) 72.850(3) 
Pawley 
refinement 
7.0266(34) 11.6277(29) 15.7048(55) 87.460(18) 82.774(44) 73.806(38) 
 
  
257 
 
5: ((E)-N'-((4-(dimethylamino)phenyl)(phenyl)methylene)isonicotinohydrazide)·(salicylic acid) 
 
 
Figure S10: Pawley refinement of 5, recorded at room temperature; the red line represents the diffraction pattern 
calculated from the unit cell of 5, the blue line represents the experimental diffraction pattern of 5, the grey line 
represents the difference curve between the calculated and experimental diffraction patterns while the HKL 
reflections (blue lines) predicted for the crystal structure of 5 are shown above the X-axis. The grey spheres 
highlight the positions of unidentified reflections. 
 
The result of the Pawley refinement shown in Figure S10 suggests that the unit cell of the crystal structure 
of 5 may be dissimilar to that obtained from the input crystal structure. The fit was improved by means of 
a lattice parameter search during the Pawley refinement. The difference between the lattice parameters 
calculated at room temperature and that of the crystal structure data obtained collected at 173K are shown 
below in Table S7. Furthermore, several minor unidentified reflections are observed. These reflections 
may be due to the presence of impurity phases or may be indicative of a structural change that occurs on 
heating the sample to ambient temperature. 
 
Table S7: A comparison of the lattice parameters of the input crystal structure and that obtained from the Pawley 
refinement 
 Lattice Parameters 
a (Å) b (Å) c (Å) β (º) 
Crystal 
structure 
25.010(2) 6.9708(7) 12.4779(11) 90.949(6) 
Pawley 
refinement 
29.918(20) 8.2867(44) 11.1485(45) 86.185(27) 
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6a: (E)-N'-((4-aminophenyl)(phenyl)methylene)isonicotinohydrazide)_(salicylic acid), Form I 
 
 
Figure S11: Pawley refinement of 6a, recorded at room temperature; the red line represents the diffraction pattern 
calculated from the unit cell of 6a, the blue line represents the experimental diffraction pattern of 6a, the grey line 
represents the difference curve between the calculated and experimental diffraction patterns while the HKL 
reflections (blue lines) predicted for the crystal structure of 6a are shown above the X-axis. The grey spheres 
highlight the positions of unidentified reflections. 
 
The result of the Pawley refinement shown in Figure S11 suggests that the unit cell of the crystal structure 
of 6a accounts for the majority of the reflections observed in the experimental powder diffraction data.  
Again, unidentified reflections are observed and these may be due to the presence of impurity phases or 
may be indicative of a structural change that may have occurred on heating the sample to ambient 
temperature. The difference between the lattice parameters calculated at room temperature and that of the 
crystal structure data obtained collected at 173K are shown below in Table S8.  
 
Table S8: A comparison of the lattice parameters of the input crystal structure and that obtained from the Pawley 
refinement 
 Lattice Parameters 
a (Å) b (Å) c (Å) α (º) β (º) γ (º) 
Crystal structure 9.2815(3) 11.7198(3) 12.2187(3) 94.4050(10) 110.971(2) 113.076(2) 
Pawley 
refinement 
9.2724(50) 11.7070(57) 12.1547(56) 94.175(39) 110.291(38) 113.908(34) 
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6b: (E)-N'-((4-aminophenyl)(phenyl)methylene)isonicotinohydrazide)_(salicylic acid), Form II 
 
 
Figure S12: Pawley refinement of 6b, recorded at room temperature; the red line represents the diffraction pattern 
calculated from the unit cell of 6b, the blue line represents the experimental diffraction pattern of 6b, the grey line 
represents the difference curve between the calculated and experimental diffraction patterns while the HKL 
reflections (blue lines) predicted for the crystal structure of 6b are shown above the X-axis.  
 
The result of the Pawley refinement shown in Figure S12 suggests that the crystal structure of 6b is 
representative of the bulk sample. The difference between the lattice parameters calculated at room 
temperature and that of the crystal structure data obtained collected at 173K are shown below in Table S6. 
 
Table S9: A comparison of the lattice parameters of the input crystal structure and that obtained from the Pawley 
refinement 
 Lattice Parameters 
a (Å) b (Å) c (Å) β (º) 
Crystal 
structure 
7.8452(3) 10.7034(4) 13.1775(5) 93.234(3) 
Pawley 
refinement 
7.8222(10) 10.8071(13) 13.4288(15) 93.9322(62) 
 
 
 
 
